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Abstract 
Clinical trials for treatment of acute ischaemic stroke require large numbers of patients 
and are expensive to conduct.  Treatment is typically administered within the first hours 
or days after stroke onset. Outcome is usually assessed by a single measure, the most 
common being the modified Rankin scale (mRS) at day 90. Any strategy that can reduce 
cost or deliver more reliable answers on safety and efficacy of the investigational 
treatment would be welcome for future exploratory testing of novel treatments. This 
thesis focused on the impact of applying different methods of design, inclusion and 
outcome measurement to limit sample size and strengthen analysis in clinical trials in 
acute stroke.  
Firstly, inclusion criteria were investigated to assess the impact on functional outcome. By 
assessing how the effect of thrombolysis changes over onset time to treatment (OTT) the 
relationship between OTT and age could be investigated. By looking across the entire 
range of OTT and assessing the interaction between the two covariates this provided 
complementary data to a previous VISTA analysis conducted by Mishra et al. It was found 
that across the full range of OTT, up to 3.5h, the treatment effect of thrombolysis in very 
elderly stroke patients (>80 years old) was comparable to that of their younger 
counterparts. The association of AF and modified Rankin Scale (mRS) at day 90 was then 
assessed.  Multiple logistic regression analysis adjusted for age and baseline National 
Institutes of Health Stroke Scale (NIHSS) showed that history of AF had no independent 
impact on stroke outcome. 
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Deferred selection of subjects for neurorestorative therapies from hyperacute (<6h) to 
24h was then explored using a simulation approach. The sample size required to detect a 
‘shift’ in mRS outcome equivalent to a 5% absolute difference in proportion achieving 
mRS 0-2 versus 3-6 was modelled, setting power at 80% and assuming adjustment for 
entry age and NIHSS. It was found that extending the time window for patient selection 
provides a measurement which has a stronger more predictive relationship with 
outcome. 
Trial inclusion was explored further by investigating selection for delayed treatment with 
thrombolysis. Prognostic scoring methods were proposed to identify a strategy for 
patient selection to be applied first to an existing trial dataset and then validated in the 
pooled RCT 4.5-6h data. ). Prognostic score limits were chosen to optimise the sample for 
a net treatment benefit significant at p=0.01 by Cochran Mantel Haenszel test and by 
ordinal logistic regression. More inclusive limits were also defined based on p=0.05 
criteria. After finalising prognostic score limits, for validation they were applied by an 
independent statistician to the pooled RCT data for 4.5-6h. The validation analysis based 
on ordinal outcomes failed to deliver a population in whom treatment >4.5h was safe and 
effective; analysis based on net benefit (mRS 0-1) showed significance. 
Secondly, different strategies for endpoint selection were considered. In the past some 
trialists have investigated the use of earlier endpoints on single trial datasets and taken 
advantage of the fact that numerous outcome scales are available to measure various 
domains of neurological and functional recovery. The use of an earlier neurological 
endpoint for detecting futility in a trial was considered with validation on external RCT 
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data.  Global endpoints, investigating different aspects of functional recovery at different 
time-points were then considered. 
Simulations were undertaken to assess the relationship between sample size and power 
for ordinal scales and the corresponding global outcomes. Day 7 NIHSS was found to be 
the most sensitive individual ordinal endpoint. Dichotomised analyses supported these 
results. However this needed validation in a randomised trial dataset for use in 
exploratory stroke trials. The validation study reinforced the results from the non-
randomised VISTA study.  The global test combination of NIHSS90 with NIHSS7 appeared 
to offer incremental sensitivity to treatment effect compared to the ordinal scales alone. 
The combination of mRS90 with NIHSS7 did not increase the sensitivity to treatment 
effect when compared to NIHSS alone, but offers a broader clinical measure without loss 
of statistical power.   
Finally, alternatives to the traditional RCT were considered. Abandoning the rigour of the 
blinded RCT carries substantial penalty in loss of reliability and should not be undertaken 
lightly.  
If a placebo control is deemed impractical or unethical, investigators often consider 
comparisons against historical controls. A within-VISTA exploration of case-control 
matching is presented. The reliability of different matching methods and covariate 
combinations were assessed using a simulation approach.  The results indicate that 
caution must be taken when using historical controls to generate a matched control 
group. Substantial further work matching to external data and validation to RCT data is 
needed. 
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Cluster randomised trials, which randomise patients by groups, are becoming a more 
widely used approach. When evaluating strategies to promote the transfer of research 
findings into clinical practice, i.e. in "Implementation Research", an RCT is impractical and 
a cluster randomised trial design is of advantage. Some elements in the design and 
sample size calculation of cluster randomised trials were considered. Intra cluster 
correlation coefficients (ICCs) were estimated from linear and generalised linear mixed 
models using maximum likelihood estimation for common measures used in stroke 
research. These estimates of relevant ICCs should assist in the design and planning of 
cluster randomised trials. 
In conclusion, this research has shown that there are several areas in the design of clinical 
trials of acute stroke that merit further investigation. Several strategies have been 
highlighted that could potentially reduce sample size whilst retaining optimal levels of 
statistical power. However other aspects such as patient selection and the nature of the 
intervention under study can affect trial cost and statistical power and need to be taken 
under consideration. 
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Chapter 1  
Introduction and background 
1.1. What is Stroke? 
1.1.1. Definition of Stroke 
The World Health Organisation (WHO) defines acute Stroke as “rapidly developing clinical 
signs of focal (or global) disturbance of cerebral function, with symptoms lasting 24 hours 
or longer leading to death, with no apparent cause other than of vascular origin.”1 This 
definition includes stroke due to cerebral infarction (ischaemic), resulting from an arterial 
or venous blockage, and haemorrhagic strokes, resulting from a bleed2. Applying this 
definition excludes transient ischaemic attack (TIA), defined to last less than 24 hours, 
and patients with haematoma, haemorrhage or infarction caused by infection or tumor3. 
Stroke is the result of disruption of blood supply to the brain, occluding the supply of 
oxygen and nutrients, causing damage to brain tissue4. Due to the anatomy of the blood 
supply to the brain, certain patterns of focal neurological symptoms such as loss of body 
function, weakness down one side, visual problems, dysphasia and dysarthria are similar 
from patient to patient5.  
1.1.2. Pathology of stroke 
Stroke can be due to an ischaemic or haemorrhagic disturbance of cerebral blood flow. 
Stroke can be classified into three groups; ischaemic, primary intracerebral haemorrhage 
(PICH) and certain instances of subarachnoid haemorrhage (SAH)6.  As ischaemic and 
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haemorrhagic strokes often present in a similar manner but the causes and treatment are 
different, CT or MRI imaging is required to reliably distinguish between the two2 5. 
An ischaemic stroke or cerebral infarction accounts for approximately 85% of strokes7-8 
and occurs due to a critical reduction of the blood supply to the brain5. Ischemia can be 
sub-divided into three different categories: thrombosis , embolism and decreased system 
perfusion9. The location, extent and shape of the infarct depends on the size of the 
blocked vessel, mechanism of the obstruction and the compensatory capacity of the 
vascular region10. Thrombosis is the cause of approximately 50% of ischaemic strokes5, 
leading to obstruction of the blood flow, often at sites of narrowing or partial occlusion of 
the blood vessels damaged by artheroma5. Embolic cerebral infarction is caused by 
material formed elsewhere in the vascular system lodging in an artery and causing a 
blockage to blood flow9.  Decreased systemic perfusion is due to low systemic arterial 
pressure causing diminished flow to the brain9.   
Two prominent classifications for ischaemic stroke come from the criteria used in the Trial 
of Org 10172 in Acute Stroke Treatment (TOAST)11 and the Oxfordshire Community Stroke 
Project classification (OCSP)12. The TOAST subtype classification system uses both clinical 
features, laboratory testing and CT/MRI imaging to categorise a stroke into one of five 
categories: large-artery atherosclerosis, cardio embolism, small artery occlusion (lacune), 
stroke of other determined aetiology and stroke of undetermined aetiology11. It can 
generally only be applied some days after hospitalisation. The OCSP classification system 
describes only four subtypes.  It is based on a purely clinical assessment13 with the 
subtypes defined as; total anterior circulation (TAC), partial anterior circulation (PAC), 
lacunar (LAC) and posterior circulation  (POC), a final letter can be added as S for 
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syndrome or I for infarct14. Other clinical scales can be useful but many are very detailed 
and hence time consuming to apply13. 
Intracerebral haemorrhage (ICH) reflects bleeding directly into the brain9. ICH accounts 
for approximately 10-15% of all strokes.8 10 15  It and is often caused by elevated blood 
pressure often referred to as hypertension damaging or weakening the blood vessels5 9. 
ICH can also be caused by lack of blood clotting factors, often due to prior anticoagulant 
medication such as Warfarin5. The degree of damage from ICH depends on the location, 
volume and pressure of the bleeding9. ICH is characterised by a severe prognosis, 
particularly in the short term and there is no specific targeted therapy available16-17.   
Subarachnoid haemorrhage (SAH) accounts for approximately 3% of all strokes18.  In 
subarachnoid haemorrhage (SAH), blood leaks out onto the surface of the brain and is 
dispersed into the subarachnoid spaces around the brain9.  Approximately 75% of SAH are 
caused by an aneurysm. SAH is a significant cause of morbidity and mortality worldwide19. 
However approximately 15% of patients presenting with SAH have no obvious source of 
bleeding. This is known as a nonaneurysmal SAH (NA-SAH).20 NA-SAH carries a more 
favourable prognosis than aneurysmal SAH20.  
1.1.3. Pathophysiology of stroke 
The brain is a metabolically active organ which uses approximately 25% of the body’s 
energy supply. The sole substrates for energy metabolism in the brain are glucose and 
oxygen; the brain requires approximately 100 mg of glucose and 500mL of oxygen each 
minute21. This means that the brain requires oxygenated blood containing adequate 
sugar. Cerebral blood flow is closely related to metabolic regulation but it is important for 
the survival of brain tissue that the flow rate remains reasonably constant despite the 
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blood pressure changing, this is controlled by a process known as autoregulation9. When 
an ischaemic stroke occurs, decreased or absent circulating blood deprives neurons of the 
necessary substrates, glucose and oxygen.  
Because cerebral blood flow is closely related to cerebral metabolism, autoregulation 
may compensate for relative ischemia by increasing the extraction of oxygen and glucose 
from the blood. However, when cerebral blood flow is severely diminished, cell 
membranes and functions are severely affected and neurons cannot survive for long. This 
can result in irreversible injury. The progression and extent of ischemic injury can be 
influenced by diverse factors such as rate of onset and duration of ischaemia, collateral 
circulation, health of the systemic circulation, haematological factors, temperature and 
glucose metabolism21.  While irreversible damage will occur in any deeply ischaemic area 
there may be an adjacent zone known as the penumbra in which blood flow is less 
severely reduced and where the glial and neuronal tissue survives for longer22-23. This can 
persist for longer than the acute phase of the stroke24.  
In contrast ICH causes damage to brain tissue by disrupting connecting pathways and 
causing localised pressure injury21 23. The pathophysiology of an ICH is an acute space 
occupying lesion compressing and disrupting the surrounding tissue.  This causes an 
increase in intracranial pressure and may lead to herniation; moving brain tissues, 
cerebrospinal fluid and blood vessels inside the skull10. 
1.1.4. Signs and symptoms 
Clinical features that arise depend on the normal function of the specific part of the brain 
that has lost blood supply.  Common symptoms and signs include weakness of one side of 
the body (hemiparesis), difficulty with swallowing (dysphagia), incoordination (ataxia), 
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difficulty understanding or expressing speech (dysphasia), slurred speech (dysarthria) and 
problems with vision such as loss of vision to one side affecting both eyes (hemianopia). 
Other symptoms such as confusion, weakness and blackouts are also common but are 
non-focal2. Pancioli et al conducted a telephone survey looking at public awareness of 
stroke risk factors and warning signs and risk factors of stroke. Only 57% of respondents 
could name one of the 5 established warning signs and only 68% of respondents could 
name at least one risk factor for stroke25. To increase public awareness of stroke in the 
UK, and encourage rapid medical intervention in acute stroke, the Stroke Association set 
up the FAST campaign26. 
The FAST campaign concentrates on three main symptoms Face, Arm and Speech: can the 
person smile? Has their face drooped? Can the person raise both arms? Can the person 
speak properly? The final letter denotes Time. This is a crucial factor as not only do brain 
cells die over time but for ischaemic stroke, treatment is most effective when given 
early27. In 2012 Robinson et al conducted a new survey to assess knowledge of symptoms 
and awareness of the FAST campaign. It was found that 70% of the population were 
aware of the FAST campaign and over 80% of respondents were aware of the individual 
signs28. 
1.1.5. Investigation 
The diagnosis of stroke is first made clinically based on the neurological symptoms. If the 
symptoms are focal, have a negative effect (i.e. loss of vision, loss of movement rather 
than positive such as pain) and develop suddenly rather than over a period of hours or 
days the likelihood of a stroke is high. Once a patient has been admitted to hospital, a 
detailed medical history is taken to assess for prior risk factors. Because acute therapies 
for stroke have a very narrow time window assessment of neurological impairment needs 
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to be performed quickly; the most evaluated scale is the National Institutes of Health 
Stroke Scale (NIHSS)4 which can be completed in 8 minutes29. 
The most widespread diagnostic tool used in the assessment of acute stroke is 
neuroimaging.  Brain imaging is essential to differentiate haemorrhagic from ischaemic 
strokes and also to exclude stroke mimics such as tumours. Imaging can help to select a 
patient most likely to benefit from treatment and exclude those with greater risk of 
complications. The most common and accessible imaging technique used is CT scanning. 
While a CT scan is sensitive at detecting ICH, its sensitivity to tissue damage in the acute 
period of ischaemic stroke is reasonably poor30. It gives a suboptimal view of the 
posterior fossa. However CT is widely available, practical, quick and easy to use31. 
Compared to CT, MRI can image the entire brain and detect microbleeds without 
radiation or iodinated contrast agents32. However many patients may be ineligible for 
MRI due to confusion or they may have a metallic foreign body such as a pacemaker.  
The SIGN guidelines for Scotland suggest that all patients with suspected stroke should 
have brain imaging upon presentation4.  A CT scan is recommended for most patients in 
the acute phase of stroke though MRI with diffusion weighted imaging and gradient echo 
sequences is recommended if available and applicable4. For minor strokes and TIA, MR is 
the imaging modality of choice. Scans are usually interpreted by a trained radiologist. 
1.2. Epidemiology of stroke 
1.2.1. Stroke surveillance  
Stroke is a non-communicable disease of increasing socioeconomic importance in ageing 
populations33.  While in recent years imaging techniques have been introduced for 
diagnosis, stroke can be defined clinically allowing past trends to be observed without 
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access to specific laboratory or imaging equipment34. Surveillance systems are said to be 
most appropriate when the disease or health concern is both a major public health 
problem and preventable or modifiable35.  Stroke meets many of the criteria warranting a 
surveillance system. Documenting the size of stroke burden in relation to other diseases 
provides a foundation for improvement of stroke prevention and treatment36.  
Surveillance allows trends to be observed within populations, showing epidemiological 
changes in stroke impact over time. The WHO global burden of disease project37 gives us 
reliable data measured across different WHO member states. Studies such as the WHO 
MONICA project1, the Global and Regional Burden of Stroke Study6 and the Global Stroke 
Initiative36 attempt to document the size of stroke burden in relation to other diseases.  
1.2.2. Incidence and prevalence of Stroke 
It has been reported that approximately 15 million stroke cases occur each year38. The 
most reliable epidemiological data come from population based studies. Incidence 
measures the number of strokes (new or recurrent) per unit of time (usually year)39. 
Stroke incidence and prevalence are highly associated with age. There is a continuous 
trend between increasing age and increasing stroke incidence2 33. This is illustrated in 
Figure 1-1 below. There is also an observed trend between socioeconomic status and 
stroke incidence; with an observed increase of 100% reported in lower-middle income 
countries over the past four decades40.  The WHO MONICA project found  geographical 
differences in stroke incidence41 but a review of several population based studies by 
Feigin et al only observed small differences in age-standardised stroke incidence33. These 
differences in reported incidence rates could be due to changes in medical care and 
exposure to risk factors42.  
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Figure 1-1:  Annual incidence by age per 1000 population in all types of stroke. 
reproduced from Feigin et al (2003)
33
.  
Feigin et al42 conducted a review of 56 population based studies and found a pooled 
estimate of age-adjusted incidence of first ever stroke for high income countries was 94 
per 100,000 population per year and for low to middle income countries 117 per 100,000 
population per year in the period 2000-2008. These estimates had decreased from 121 
and 164 per 100,000 population per year respectively in the period 1990-199942. With the 
recent improvements in surveillance of stroke these estimates will be more reliable than 
earlier estimates of incidence39, the categorisation for high income and low-middle 
income countries was taken from the world bank definitions 200443. The incidence of 
stroke in the United Kingdom has been calculated from the General Practice research 
database (GPRD) to have fallen from 148 per 100,000 person years to 104 per 100,000 
person years over the period 1999 to 200844. This decrease in stroke incidence over time 
is most often attributed to better treatment of risk factors45. 
The prevalence of stroke depends on incidence, mortality and mean duration of survival 
after stroke46. In 2002 the World health Organisation (WHO) estimated that there were 
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15.3 million strokes worldwide37. The centre for disease control (CDC) calculated the 
prevalence of stroke in the United States in 2006 to be 2.7% and 2010 to be 2.6%46.   UK-
specific prevalence according to the GPRD has increased from 0.64% to 0.72% in the 
period 1999 to 200844.  
1.2.3. Stroke related mortality and case fatality 
Stroke caused an estimated 5.7 million deaths in 200547, in 2011 stroke and other 
cerebrovascular diseases were the second leading cause of death worldwide causing an 
estimated 6.15 million  deaths48.  Johnston et al39  derived global mortality rates using 
data from the WHO global burden of disease project49 to range from 24.5 to 251 per 
100,000 population (0.024% to 0.251%) depending on the country. These estimates were 
based on data obtained from 192 WHO member states with reliable data and adjusted for 
age and sex. As can be seen in Figure 1-2 below Western Europe and North America are 
among those with the lowest and Eastern Europe and North Asia are amongst those with 
the highest stroke mortality rates.  
Stroke mortality varies widely from region to region as it is determined by many factors 
such as incidence, stroke sub-type, age and gender of the population studied2. With life 
expectancy increasing and populations in low-middle income countries ageing there has 
been an epidemiological shift resulting in stroke becoming a major health problem in  
such countries47.  Compared to people in high income countries, those from low-middle 
income countries experience a higher stroke mortality rate. Approximately 85% of all 
stroke deaths are registered from these regions47 50-51.  
Early case fatality, coded as death within 21 days to 1 month after event, from a 
population based study was found to be 17-30% for high income countries and 18-35% 
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for low-middle income countries for the period 2000-200842. UK specific early case-
fatality coded as death within 56 days of first stroke was found to be 15% from the 
GPRD44. From Figure 1-3 a decreasing trend in stroke mortality can be observed over a 
period of 10 years, the mortality rate for females appearing slightly higher than males in 
both higher (≥ 80) and lower (<80) age groups.  The information presented in both Figure 
1-2 and Figure 1-3 include early mortality rates for all stroke subtypes and are not specific 
to ischaemic stroke. 
 
Figure 1-2: Rates of age and sex-adjusted stroke mortality, reproduced from 
Johnston et al (2009) 
39
. 
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Figure 1-3: Proportion of patients who die within 56 days of first stroke by age 
group and gender. Reproduced from Lee et al (2011)
44
.  
1.2.4. The burden of stroke 
In addition to mortality, long term morbidity is also a growing issue leaving stroke 
survivors with moderate or severe disabilities who are then dependant on others to carry 
on with daily life52. Stroke is a leading cause of serious, long term disability53 causing a 
greater range of disability than any other acquired condition54. Approximately 40% of 
survivors are left with some degree of functional impairment55.  Worldwide over 5 million 
people are left permanently disabled after stroke; however stroke also causes emotional 
and intellectual problems with approximately 1 in 3 survivors suffering from depression27.   
Due to different surveillance approaches the comparison of disability rates over time and 
between populations is difficult.  Reports of incidence and prevalence come mainly from 
developed countries with strong epidemiological traditions34.  One of the first global 
assessments of burden was the global burden of disease study56 looking to understand 
the long term impact of chronic, morbid conditions35.  The unit of measurement used to 
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measure burden is the disability-adjusted life year (DALY), in which one DALY represents 
the loss of one year of healthy life49.  
The World Health Organisation burden of disease project (2004 update) found that 
worldwide cerebrovascular diseases contributed to 3.1% of total DALYs, placing stroke in 
6th place among the leading causes of burden of disease49. DALYs due to stroke vary 
among regions due to geographical differences in incidence, risk factors, access to 
healthcare and mortality rates39. Figure 1-4 shows how DALYs differ for 20 different WHO 
member states; similar to trends in mortality, high income countries such as UK and USA 
have a lower rate of DALY from stroke than lower-middle income countries such as 
Russia. Looking at Figure 1-4 similar geographic trends can be seen to those observed in 
mortality rates can be seen for DALYs. 
The true burden of stroke is often under-represented, possibly due to a lack of 
understanding of its nature and the misrepresentation that stroke is a disease only of the 
elderly.  Stroke is a major cause of dementia, depression and other secondary medical 
problems such as falls and fractures57.  Stroke has a major impact on everyday life from 
the more obvious physical effects and emotional wellbeing to family life, social skills and 
vitality27.  
Since stroke causes morbidity more often than mortality, patients require longer hospital 
stays followed by ongoing support57. However as well as human cost, stroke has a major 
economic burden worldwide. It was estimated in 2006/7 that the cost of stroke to the 
health and social care system was over £2.5 billion in the UK alone, over 80% of these 
costs for inpatient hospital care58. In the United States the total direct cost of stroke was 
estimated at $25.2 billion. In the 27 EU countries this figure was estimated to be €18.5 
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billion. These costs are nearly twice the cost for coronary heart disease 53. Stroke 
accounts for between 2 and 4% of total healthcare expenditure in developed countries59. 
The lengthy hospital stay of a small proportion of patients goes some way to explaining 
this disproportionate use of resources3. However the costs of stroke are more diverse 
than other conditions. These costs reflect the high rates of disability and dependence 
experienced by stroke survivors. Indirect costs, considering lost productivity due to 
morbidity and mortality, account for over 30% of the total cost of stroke51. 
Despite the enormous and growing burden of stroke, there is evidence that research into 
the condition does not receive the funding it deserves36. Spending on stroke research is 
low in comparison to the other two most common causes of death in the developed 
world, heart disease and cancer57.  Funding comes primarily from three sources: disease-
specific charities, disease-specific government agencies and the pharmaceutical 
industry60. In 2005 it was estimated that in the US alone cancer received approximately 
16 times the amount of funding received by stroke. Figure 1-5 shows condition-specific 
NIH funding over a 3 year period. These patterns are mirrored in the UK and across 
Europe60-61. 
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Figure 1-4: Age and sex-adjusted DALY loss attributed to stroke. Reproduced 
from Johnston et al (2009) 
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Figure 1-5: Research spending by the National institutes of health by 
condition. Reproduced from data provided in Broderick (2004)
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1.2.5. Trends over time, looking to the future 
The global population aged over 65 years of age was estimated to be over 600 million in 
200338 and is projected to be increasing by 9 million per year38.  Given that age is one of 
the most substantiated risk factors for stroke63 it follows that with the ageing population 
and improvements in life expectancy, stroke will affect an increasing number of people27 
45.  However there have been measures to counteract the increasing prevalence with 
major developments in identification and control of risk factors as well as the 
management of acute stroke45. 
The Framingham study observed a population free of prevalent strokes over a period of 
50 years. During the three periods of this study (1950-1977,1978-1989 and 1990-2004) 
age adjusted incidence reduced significantly from 0.076 to 0.053 in men and 0.062 to 
0.051 in women per 100,000 person years. Thirty day mortality significantly decreased in 
men over the three periods from 23% to 14% but barely changed in women, with rates of 
21% to 20%.  
Trends in stroke incidence and mortality vary widely among different populations, making 
predictions difficult40. Data from the WHO show an increased incidence of stroke during 
the period 1970-2008 in lower-middle income countries increasing from approximately 52 
to 117 per 100,000 person years which is a disproportionate increase when compared to 
high income countries. Figure 1-6 shows a comparison of these rates over four decades 
for low-middle income countries and high income countries. In many developed 
populations, death from stroke has fallen dramatically in the past 30 years27; however an 
inverse association has been observed between socioeconomic status and mortality. 
Figure 1-7 shows the changes over four decades in the mortality rates from stroke 
separated by income group. Much of the disparity may be due to the lack of reliable data 
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for developing countries64 rather than just the limited resources available for healthcare.  
These data suggest that for the impact of stroke to be reduced globally, prevention 
strategies targeted to lower socioeconomic groups need to be introduced. In particular 
more cost-effective measures are needed, promoting access to effective intervention and 
care40. 
 
Figure 1-6: Variation in incidence of stroke for lower-middle income countries 
(LMIC) and high income countries (HIC). Reproduced from data provided in 
Addo et al (2012)
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Figure 1-7: Variation in early case fatality of stroke for lower middle income 
countries and high income countries. Reproduced from data provided in Addo 
et al (2012)
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ischaemic attack are at high risk of recurrent stroke. The long-term stroke recurrence 
rates range from 4%-14% annually, with 2 year cumulative recurrence rate approximately 
14.1%.65. Recurrent stroke is most common within 30 days of the event, approximately 
30% of recurrent strokes occur within this time frame66. 
Several medical conditions are well known to contribute to the risk of stroke; the most 
consistent and powerful is high blood pressure or hypertension67.  The association 
between blood pressure and stroke incidence has been widely studied68-69. Diastolic 
blood pressure (DBP) is independently associated with the incidence of stroke, 
particularly at higher levels70-72.  There have been major efforts to reduce hypertension in 
the general population by improving knowledge of hypertension and the development of 
new anti-hypertensive medications73-74. Population wide reductions in blood pressure and 
mortality rates of stroke highlights the influence that the methods to reduce blood 
pressure have had73; however it is important that these methods are sustained75. 
Atrial Fibrillation (AF) increases the risk of stroke. The attributable risk of stroke for AF 
increases from 1.5% to 23.5% with increasing age from 50 to >7976. Atrial Fibrillation 
reduces cardiac output and in turn reduces cerebral blood flow exerting a significant 
impact on the risk of stroke independently of other cardiac risk factors76. There have been 
strategies in place for the management of AF and the reduction in the rate of stroke in 
those with AF using anticoagulant therapies such as warfarin77. Warfarin reduces the risk 
of stroke in patients with AF. Though anticoagulation remains the established approach, it 
is suboptimal in many cases. New antiarrhythmic and antithrombotic agents have now 
been approved78 and will have an increasing role in the future79. 
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Hypertension often coexists with diabetes80-81. Several studies have confirmed diabetes to 
be an independent risk factor for ischaemic stroke.    In non-diabetic patients impaired 
glucose tolerance was found to be an independent risk factor of stroke, almost doubling 
the risk and nearly tripling it in those with diabetes82. 
1.3.2. Lifestyle risk factors 
There are many risk factors for stroke can be attributed to lifestyle; it has been shown 
that a healthy lifestyle is more effective in lowering cardiovascular disease than any one 
single factor83. The main factors that are considered to contribute to a high risk lifestyle 
are smoking, exercise, diet, body mass index (BMI) and alcohol consumption83. In a large 
cohort of women it was found that controlling these risk factors was associated with a 
substantial decrease in the risk of stroke, even after adjustment for other risk factors such 
as diabetes, cholesterol and hypertension, with a hazard ratio of 0.45 compared to those 
with a high-risk lifestyle84. 
INTERSTROKE is a case-control study designed to look at the association of traditional and 
emerging risk factors with stroke85. Hypertension, smoking, obesity, diet and physical 
inactivity accounted for 80% of the global risk of all stroke85.  
Guidelines for the primary prevention of ischaemic stroke published by the American 
Heart Association and American Stroke Association summarised existing evidence on risk 
factors for stroke. From epidemiological and retrospective cohort studies it was found 
that diets rich in fruit and vegetables with reduced sodium and potassium, regular 
exercise, reduction in weight, smoking cessation and low to moderate alcohol 
consumption all reduce the risk of stroke86. Many of these lifestyle factors are associated 
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with a reduced risk of other factors such as high blood pressure and diabetes, further 
reducing the risk of stroke.  
1.3.3. Race as a risk factor 
There is some evidence to suggest that there is a racial disparity in stroke incidence for 
those living in western countries2. The Reasons for GEographic And Racial Differences in 
Stroke (REGARDS) study sought to investigate the disparities in stroke incidence and 
mortality between racial groups87. The incident stroke risk was 2.9 times greater in blacks 
than whites, remaining around two-fold higher after adjusting for other risk and 
socioeconomic factors88.  
The age adjusted stroke incidence rates for those aged 45 to 84 were 660 per 100,000 
population in black men and 360 in white men, 490 in black women and 230 in white 
women. These rates have not changed significantly over time; however the case fatality 
rate is similar in both racial groups. The age adjusted incidence of first ischaemic stroke 
per 100,000 was 88 in whites, 191 in blacks and 149 in Hispanics, taken from the Northern 
Manhattan Stroke Study53.  
It is thought that risk factor prevalence and control differs between racial groups, 
contributing heavily to the inequality in stroke incidence89. From the REGARDS study, race 
differences were found to be large for blood pressure, diabetes and use of 
antihypertensive therapy.  Hypertension is more prevalent and more difficult to control in 
blacks and often presents at an earlier age90. Diabetes is also more prevalent and rates of 
diabetes are increasing faster in blacks than whites89. Data from the Northern Manhattan 
Stroke Study found that the prevalence of stroke risk factors varied widely by race 
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particularly when considering diabetes and hypertension the prevalence and risk was 
higher in both blacks and Hispanics than in whites91.  
1.4. Acute treatment 
For the purposes of this thesis the primary focus will be acute ischaemic stroke. 
1.4.1. Thrombolysis 
1.4.1.1. What is thrombolytic therapy 
One of the biggest advances in the last few decades has been the use of thrombolytic 
therapy in the early stages of ischaemic stroke. The interest for its use arose from the use 
of thrombolytic agents in myocardial infarction and an increased understanding of stroke 
mechanisms 10 92.  Thrombolytic agents can be used to help dissolve any recent thrombus 
quickly, restoring blood flow to the affected area92.  Recombinant tissue plasminogen 
activator (rt-PA) is the only thrombolytic treatment licensed for stroke use in Europe. It 
has been shown to increase the odds of survival without dependency93.  
1.4.1.2. Is it safe and effective? 
The use of intravenous thrombolytic therapy for acute stroke was approved by the U.S 
Food and drug administration (FDA) in 199694. Wardlaw et al conducted a Cochrane 
review of thrombolysis for acute ischaemic stroke95, including 26 trials.  Thrombolysis 
gave a net reduction in the proportion of patients dead or dependant. The benefits of 
intravenous thrombolysis are greatest when given between 0 and 3 hours of stroke onset 
as shown in the National Institute of Neurological Disorders and Stroke (NINDS) rt-PA 
trial96. The odds of achieving more favourable outcome for those treated with 
thrombolysis were 1.7, with treated patients 30% more likely to have minimal or no 
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disability96. It has since been shown in the third European Cooperative acute stroke study 
(ECASS III) that treatment between 3 and 4.5 hours is also safe and effective, with odds of 
favourable outcome of 1.32.  
As the goal of thrombolytic therapy is to dissolve a thrombus, the most common 
complication that occurs is bleeding97. The principal adverse event from treatment with 
thrombolysis for stroke is symptomatic Intracerebral haemorrhage (SICH) 98. From the 
NINDS trial the rate of SICH is approximately 6%96 in stroke patients treated with 
thrombolysis. However different definitions are used to define SICH so this estimate 
varies99.  Other side effects include extracranial haemorrhage, infection, recurrent stroke 
and anaphylaxis. Specific trials will be discussed in section 1.6.2. 
1.4.1.3. Guidelines for use 
The European Stroke Organisation (ESO) published guidelines for treatment of ischaemic 
stroke in 2008100 and updated in 2009 to include treatment with thrombolysis between 3 
and 4.5h101. These guidelines suggest patients eligible for treatment should follow certain 
characteristics. These include: Diagnosis of ischaemic stroke presenting less than 4.5 h 
after onset, showing no minor or rapidly improving symptoms and no symptoms 
indicative of SAH. No recent head trauma, major surgery, arterial puncture, previous 
stroke or myocardial infarction (MI).  Patients outwith the ages of 18 and 80 may be 
treated but it is outside current European guidelines.  Patient must have normal blood 
pressure, have taken no oral anticoagulant and have no evidence of active bleeding or 
acute trauma. Platelet count should be greater than 100,000mm3, blood glucose greater 
than 2.7mmol/L and if heparin has been recently administered aPTT must be normal. 
Finally the CT scan does not show a multilobar infarction and the patient or family 
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members understand both the benefits and the risks of thrombolytic therapy. Guidelines 
for the United States, published by the American Heart Association, follow similar 
restrictions but licensing only allows for treatment below 3h94 102.  
1.4.2. Aspirin 
1.4.2.1. Is it safe and effective? 
The small benefit associated with prolonged use of aspirin in the prevention of 
cardiovascular events has been well documented103. The use of aspirin for the treatment 
of acute stroke was assessed in two large multicentre trials, the International Stroke Trial 
(IST)104 and the Chinese Acute Stroke Trial (CAST). The use of aspirin in conjunction with 
thrombolysis might increase the risk of bleeding and so it is only recommended to be 
given to patients in the acute phase of stroke who are ineligible for thrombolysis105. 
1.4.2.2. Guidelines for use 
Aspirin is the only oral antiplatelet agent that has been evaluated for the treatment of 
acute ischaemic stroke94. While the benefits of aspirin after acute stroke are small, the 
intervention is available to the majority of patients10 and is recommended as part of 
management after acute stroke94. 
1.4.3. Mechanical embolus removal and other endovascular approaches 
1.4.3.1. Is it safe and effective? 
The Mechanical Embolectomy Removal in Cerebral Ischaemia (MERCI) trial106 showed 
that clot extraction after large vessel intracranial occlusion was successful in 53.7% of 
those treated with the device alone. In those treated with a combination of the device 
and intra arterial (IA) thrombolysis recanalisation was achieved in 69.5% of patients 
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treated.  However there is a risk of SICH, in approximately 9.8% of those given the device 
SICH was observed. Clinically significant procedural complications occurred in 5.5% of 
patients and the device related serious adverse event rate was 2.4%106. Other mechanical 
embolectomy trials include the Penumbra System107, the Interventional Management of 
Stroke (IMS) trial108 and the MR RESCUE trial109. Both the IMS and MR RESCUE trials found 
that embolectomy was not superior to standard treatment with intravenous 
thrombolysis108 110. Other endovascular approaches have been investigated such as intra-
arterial thrombolysis with pro-urokinase in the PROACT I and II trials111-112 and urokinase 
in the MELT study113. Some smaller studies have also been conducted114-115. The benefits 
and drawbacks of intra-arterial thrombolysis are discussed further in several systematic 
reviews95 116-121.   
1.4.3.2. Guidelines for use 
Both the MERCI retriever device and the Penumbra system are approved for use in the US 
and Europe122. These are two of the few devices approved for clot extraction from an 
occluded artery94.  Other endovascular approaches such as intra-arterial thrombolysis 
have also been approved for use in current practice94. However, a recent study by the 
SYNTHESIS expansion investigators found that endovascular therapy is not superior to 
intravenous thrombolysis123.  Mechanical thrombectomy provides a therapeutic option 
for those who are ineligible for or unresponsive to IV thrombolysis. In carefully selected 
patients the device is recognised as a reasonable intervention.  However since all studies 
for the devices have been single-arm, the effectiveness of the device for improving 
outcomes after stroke is unclear. Further studies including randomised clinical trials are 
needed to fully validate these findings94 122 124.  
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1.5. Outcome measurement 
1.5.1. Functional outcome measures 
There are several dimensions to post stroke recovery: neurological deficit, functional 
disability, quality of life and physical impairment.  There is no single outcome measure 
that describes or predicts all of these dimensions. This has led to scales being used 
inconsistently among trials125. Assessing the influence of a treatment for acute stroke 
requires valid, reliable and responsive outcome measures126. Accurate assessment of 
patient outcomes is particularly important for clinical trials as the effect of an 
intervention is being sought whether positive or negative. There are a wide range of 
functional outcome measures available. A recent review by Quinn et al found that 47 
different outcome measures were described in 126 trials published in the years 2001-
2006127. This heterogeneity in the use of scales presents a problem in the comparison of 
studies.  
1.5.1.1. Most prominent outcome measures used 
Quinn et al found that the three most prominent outcome measures used were the 
modified Rankin Scale (mRS), the Barthel Index (BI) and the National Institutes of Health 
Stroke Scale (NIHSS). The mRS was primary endpoint in 26.2% of trials, the BI in 7.9% and 
the NIHSS in 11.9%. The majority of trials recorded at least two outcomes and so each of 
these scales was used as secondary outcome in several studies128. Each of these three 
scales measure a different domain of disability. 
The mRS, shown to be the most prevalent of all outcome scales, is a tool to assess 
functional independence after stroke.  The scale is graded based on a short 
(approximately 5 minute) interview of the patient or caregivers. The scale is scored on an 
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ordinal basis into one of seven categories with 0 indicating no symptoms at all and 6 
records death. The nature of the mRS leads to difficulty in distinction between grades so 
there is often a high rate of interobserver variability129-130. This variability is one of the 
main weaknesses of the mRS as it can lead to misclassification of the outcome 
measure130. Formal training and certification is available and recommended for use of the 
mRS, particularly for use in a clinical trial setting131.  The lack of specificity in the mRS is 
another  pitfall; it does not take into account factors such as cognition, language and 
emotional disability125.  
The NIHSS is a 15-item scale measuring neurological impairment. The individual items of 
the scale measure deficits affecting level of consciousness, motor function, ataxia, 
language, visual fields, dysarthria, sensory, extraocular movements, facial palsy and 
neglect125 132. The score ranges from 0 (no deficit) to 42 (maximal deficit). The scale is 
assessed based on a series of tasks graded by a trained observer. The NIHSS is widely 
used and has high interobserver reliability when performed by trained investigators133. 
Formal training and certification are available online and the latter is required for 
participation in clinical trials134. One of the main pitfalls of the NIHSS is that it is not 
indicative of a patient’s functional ability. The scale favours left hemisphere strokes i.e. 
such patients receive a higher score for a given volume of infarction135. 
The BI measures activities of daily living and mobility by assessing the patient’s ability to 
perform 10 basic tasks.  These tasks are feeding, chair/bed transfer, grooming, toilet, 
bathing, ambulation, stair climbing, dressing, bowel control and bladder control. These 
each attract a score of 0, 5 or 10 points that are summed to give a score ranging from 0 to 
100. Lower scores indicate greater dependency136. The BI is widely used in clinical trials 
and there is training and certification available online125 127. The intra and interobserver 
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reliability have been reported to be very high, along with internal consistency of the 
scale125 136.  While the BI looks at activities of daily living, many aspects of functional 
independence are not included which could have a significant bearing on independence 
such as language, emotional function and visual impairment. The scale also has a ‘ceiling 
effect’ where patients who may have several aspects of functional disability may perform 
well in all of the BI categories, with the patient receiving a high score but in reality being 
unable to function independently136. 
1.5.1.2. Time point of outcome measurement 
In most acute stroke trials the primary end point is measured at 90 days post stroke. 
Within the Virtual International Stroke Trials Archive (VISTA) 24 acute stroke trials had an 
outcome measurement at approximately 90 days (26,898 patients)132.   
1.5.1.3. Other methods of measurement 
There are several other scales that can be used to measure outcomes after stroke. Scales 
such as the Stroke Impact Scale (SIS) have been developed from the perspectives of the 
patient or caregiver. However as this scale is self-reporting it has limited use in aphasic 
patients. Use of a proxy is not always reliable. This has limited use of the SIS in a clinical 
trial setting with no trials to date using it as a primary outcome measure125 127. There are 
other neurological impairment scales used in clinical trials: the Scandinavian Stroke Scale 
(SSS), the Canadian Neurological Scale (CNS) and the Orgogozo neurological scale. Each of 
these scales has appeared as a primary outcome measure in fewer than 2% of stroke 
trials127.  
The Glasgow Outcome Scale (GOS) and the SF-36 were developed and validated for use in 
other conditions and have been adopted for use in stroke. The GOS is routinely used for 
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the assessment of brain injury and the SF-36 was developed as a general measure of 
quality of life. The GOS was used in approximately 6.3% of acute stroke trials and was a 
primary outcome measure  in 1.6%127, whereas the SF-36 was not reported in any acute 
trial though it has been used in trials looking at post-stroke care137. 
As no single scale adequately encompasses post-stroke outcome, the use of a single scale 
is not desirable. One method to generate a meaningful assessment of post stroke 
outcome is the combination of multiple scales, deriving what is known as a global test 
statistic.  A global test statistic allows the assessment of treatment effect across multiple 
scales simultaneously, improving power and providing evidence of treatment efficacy 
across multiple domains125. The NINDS rt-PA trial study group devised a global test 
encompassing the BI, the mRS, the GOS and the NIHSS138. The International Citicoline Trial 
in acute Stroke (ICTUS) trial used a combination of the BI, the mRS and the NIHSS.  
Analysis of endpoints will be discussed further in section 1.7.2. 
1.5.1.4.  What is recommended? 
As an ideal outcome measure is likely never to exist, the choice of outcome measure is 
entirely dependent upon what is expected from the intervention. The European 
Medicines Agency (EMA) Points to Consider document (2001) suggests that the primary 
efficacy endpoint should be defined according to the expected effect from the study drug. 
The document suggests that if a functional outcome measure such as the mRS is used as 
the primary efficacy variable, a second primary efficacy variable such as the NIHSS should 
look at neurological deficit in order to demonstrate efficacy across another domain139.   
The European Stroke Organisation working group on outcomes for acute trials support 
the mRS at 3 months or later as their preferred outcome, with the interview being 
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conducted by a certified rater140. They propose that the use of a second primary outcome 
measure showing a similar level of efficacy is unnecessary: if a second measure is used it 
should simply need to agree with the mRS in the direction of effect.  
1.5.2. Prognostic factors affecting outcome 
Several factors are predictive of functional outcome after stroke.  Initial stroke severity as 
measured by the NIHSS is the most important of these141-142. Another extremely 
influential factor for stroke outcome is age; it is well documented that advancing age is 
associated with poorer functional outcome.143 This may be mostly due to comorbidities. 
Older people are more likely to have other risk factors associated with stroke63 144. The 
Optimising the Analysis of Stroke Trials (OAST) collaboration found a significant 
relationship between baseline severity and functional outcome in 30 trials studied, and a 
relationship between age and functional outcome in 29 out of 30 trials studied.  
Several other factors influence functional outcome. Many of these factors are pre-existing 
risk factors for stroke and some are pre-existing medical conditions. Diabetes and 
ischaemic stroke often arise together. Admission glucose level is significantly associated 
with poor functional outcome after ischaemic stroke145-150. Hypertension is a risk factor 
for stroke and is more prevalent in the elderly151 so both increasing age and high blood 
pressure at admission have an additive effect on outcome152. The relationship between 
functional outcome and baseline blood pressure has been widely discussed153-155. The 
TAIST and IST trials found that both high and low blood pressure were independent 
predictors of poor functional outcomes after stroke156-157. Atrial Fibrillation (AF) is more 
prominent in older patients and is an independent predictor of severe stroke and poor 
outcome, particularly in the elderly76 158-159. These trends have been observed in both the 
Copenhagen stroke study and the NINDS rt-PA trial160-161. 
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1.6. Clinical trials in acute ischaemic stroke 
With the exception of the NINDS rt-PA stroke trial leading to the licensing of rt-PA and 
ECASS III leading to extension of the license, there have been limited advances in the 
development of new therapies for acute ischaemic stroke. The development of new 
therapies is difficult, costly and time consuming. Statistical analysis of trials will be 
discussed in section 1.7. 
1.6.1. Trial Design 
 Though the ultimate aim is to demonstrate efficacy and confirm acceptable tolerability 
and safety, this is usually achieved in stages. Trials leading up to acceptance of a 
treatment are arbitrarily defined as phase 1, 2 or 3. Post marketing studies are labelled as 
phase 4. A Phase I trial, usually conducted in a small group of perhaps healthy people, 
evaluates safety of the therapy, observing safe dose ranges and identifying any possible 
side effects. Phase II studies explore proof of concept, extending the size of the group and 
giving a preliminary indication therapeutic effect, although these trials are usually not 
sufficiently powered to determine definite efficacy. In Phase III trials, the drug is given to 
a large group of patients to confirm efficacy, confirm side effects and perhaps compare 
the treatment to other commonly used approaches. Often, regulatory authorities 
demand two phase 3 trials, each positive at a statistical threshold of p<0.05, to give a 
joint type I error rate of 0.0025. 
Well designed randomised control trials (RCTs) are the best way to evaluate a new 
treatment; treatment allocation should be randomly allocated and blinded to both 
patient and clinician.  There are many considerations that need to be made in the design 
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of clinical trials to ensure the results are valid and robust.  Considerations that need to be 
made for a phase III trial include162: 
 Dose selection based on the phase I/II studies 
 Time window for initiation of drug 
 Patient selection 
 Outcome measure: Single primary endpoint or use of a global assessment 
 Severity of stroke population to be studied 
 Length of follow up 
 Use of surrogate endpoints to support efficacy 
 Pre-specification of analysis plan 
If the intervention is invasive and it is considered unethical to recruit placebo patients to 
the study, a single-arm is sometimes conducted. Efficacy is analysed by comparing each 
patient’s outcome to their condition at baseline, before the intervention. Outcome 
measures used differ from standard efficacy measures used in RCTs. An example of this is 
the MERCI trial106 where rate of recanalisation is the primary efficacy measure. 
Cluster randomised trials are trials in which groups of individuals are randomised at group 
level to receive different interventions. Cluster trials are becoming increasingly popular in 
epidemiological research.  The units of randomisation are often trial-specific such as study 
centre, city, country etc. This method of trial design reduces statistical efficiency but 
there are also several attractive features of this design such as reduced risk of 
experimental contamination and increased administrative efficiency. 
Observational studies are another alternative to RCTs. The objective in observational 
studies is to include all incident cases. These studies may observe the effect of an 
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intervention as standard of care and compare it to effects in patients who did not receive 
the intervention but were otherwise treated similarly.  One benefit of observational 
studies is that potential participants will not have the concerns associated with treatment 
allocation. The aim is to observe the effect of the intervention given as standard of care, 
without blinded or randomised recruitment. Observational studies may overestimate 
treatment effect but this is a topic of much debate163. In stroke research observational 
studies have more often been used for investigations into rehabilitation164. 
1.6.2. Thrombolysis trials 
In the late 20th and early 21st century there has been a large increase in the number of 
clinical trials conducted in acute stroke, many of these assessing thrombolytic agents165. 
According to a review by Wardlaw et al (2009) there have been 26 trials investigating 
thrombolytic agents in patients with acute ischaemic stroke, including a total of 7152 
patients95. Thrombolytic agents investigated in these trials were rt-PA, streptokinase, 
urokinase, recombinant pro-urokinase and desmoteplase. The Meta analysis performed 
in this review found that treatment with any thrombolytic therapy reduced the 
proportion of death or dependency odds ratio (OR) 0.81 95% Confidence Interval (CI) 
(0.73-0.90) but increased the risk of SICH OR 3.49 95% CI (2.81-4.33).  
The only licensed treatment for i.v. thrombolysis is rt-PA treated within 4.5h post stroke. 
Two placebo controlled trials have shown efficacy; NINDS part II giving treatment within 
3h96 and European Cooperative Acute Stroke Study (ECASS) III, giving treatment between 
3 and 4.5h post stroke98. Six individual trials showed no efficacy of rt-PA based on the 
primary outcome of interest; NINDS part I96, ECASS I and II166-167, ATLANTIS part A168 and 
part B169 and the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET)170.  
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Conversely the NINDS part I study showed efficacy when looking at day 90 mRS compared 
to the primary endpoint; 4 point improvement in NIHSS at 24h96. Lees et al171 performed 
a pooled analysis including all of the rt-PA trial data from the ECASS, ATLANTIS, EPITHET 
and NINDS trials, concluding that patients selected using CT could benefit from rt-PA up 
to 4.5h. They found insufficient evidence of efficacy for treatment given post 4.5h.  Table 
1-1 shows the odds of favourable outcome based on dichotomising mRS 0-2 vs. 3-6 from 
each of the significant studies mentioned above. 
The third International Stroke Trial (IST-3) study group recently completed a large, 
international, multicentre trial investigating the use of IV rt-PA in a wider range of 
patients than clinical guidelines allow172.  The current European Union (EU) guidelines 
only allow treatment for patients up to 80 years of age, with no real evidence from 
current thrombolysis trials to substantiate this as only a small number of patients >80 
were recruited to the original studies95 173-174.  Many clinicians disregarded this restriction, 
instead following ESO clinical guidelines175-176. US clinicians faced no such restriction94. 
The IST results were non-significant when analysed based on the primary efficacy 
endpoint of OHS 0-2 at 6 months. A significant effect of rt-PA was found when looking at 
the secondary endpoint (OHS 0-1 at 6 months). Due to the difference in protocol from 
other thrombolysis trials, comparison to other studies is difficult and inadvisable177. 
Regarding age, the findings of this trial suggest that treatment with rt-PA in the >80 age 
group was at least as effective as in the younger age group, substantiating previous 
findings from a non-randomised analysis using VISTA and comparing SITS registry data to 
VISTA63 178.  
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Table 1-1: Results from each of the iv thrombolysis trials showing significant 
functional outcome (mRS 0-1) after treatment with rt-PA along with the 
pooled analysis by Lees et al
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. * denotes adjusted analysis 
Trial 
(Treatment 
window) 
OR (95% CI) for 
favourable outcome 
mRS at 3 months 
NINDS II 
(0-3h) 
1.7 (1.1-2.6) 
p=0.019 
ECASS III* 
(3-4.5h) 
1.42 (1.02-1.98) 
p=0.04 
NINDS I 
(0-3h) 
2.3 (1.4-3.6) 
<0.001 
Pooled analysis* 
(0-1.5h) 
2.55(1.44-4.52) 
p=0.0013 
Pooled analysis* 
(1.5-3h) 
1.64(1.12-2.40) 
p=0.0116 
Pooled analysis* 
(3-4.5h) 
1.34(1.06-1.68) 
p=0.0135 
The Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST) was a 
Europe wide multi-centre observational study investigating whether the use of IV 
thrombolysis within 3h of ischaemic stroke was as safe in clinical practice, outside of a 
randomised trial179. The SITS-MOST study looked only at thrombolysed patients and 
compared them to the corresponding treated patients from the pooled thrombolysis 
trials treated within 3h of onset180. Complete recovery as measured by mRS (0-2) at 3 
months was observed in 38.9% of patients in SITS-MOST compared to 42.3% in the 
pooled RCTs179-180 .  Retrospectively, an adjusted analysis was performed on the SITS-
MOST data and found that favourable outcome at 3 months was 50.4% in SITS-MOST 
compared to 50.1% in RCTs, supporting the conclusions from RCTs and pooled analyses 
that IV rt-PA within 3h is safe in routine clinical use181. 
1.6.3. Neuroprotectant trials 
In the 20th century there were at least 178 clinical trials in acute stroke, 88 of these 
involving neuroprotectant agents alone165.  The approval of thrombolytic therapy for 
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acute stroke prompted further interest in the development of neuroprotective therapies 
in stroke.    Despite the promising results from thrombolysis trials, this trend has not 
followed in the investigation of neuroprotection strategies.  Trials of neuroprotectant 
agents conducted in the late 20th century such as Glycine antagonist in neuroprotection 
(GAIN) Americas182 and International183, Lubeluzole184, Selfotel185, Aptiganel186, 
Tirilazad187 Intravenous Magnesium Efficacy in Stroke (IMAGES)188,  and Enlimomab189 all 
showed no efficacy and the reasons for this have been widely considered190-192.   
Studies conducted more recently such as Repinotan modified randomised exposure 
controlled trial (mRECT)193and the NXY-059 (SAINT I and II)194-196 studies have also failed 
to show efficacy. Citicoline had shown efficacy in a pooled analysis of individual patient 
data from clinical trials197 OR = 1.33 (95% CI, 1.10 to 1.62; P=0.0034) though only one trial 
within this meta-analysis showed efficacy on its primary outcome measures198-199. A 
randomised, multi-centre, double blinded, sequential placebo controlled study in 
citicoline in the treatment of acute ischaemic stroke was recently completed, known as 
the ICTUS trial. The aim of this trial was to confirm efficacy of citicoline in a large 
randomised trial200. The trial was discontinued after enrolment of 2298 patients showing 
no efficacy on the primary global endpoint. 
Table 1-2 below lists all the trials mentioned above along with each of their primary end 
points, significance levels for treatment effect and whether the trial reached completion 
or was discontinued. 
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Table 1-2 Primary endpoint, significance levels   and results of the failed 
neuroprotectant agents mentioned above 
Trial Primary efficacy endpoint P-Value Completed or 
discontinued 
GAIN Americas182 3 month BI, trichotomised  
0-55, 60-90, 95-100  
0.79 Complete, no benefit 
GAIN 
International183 
3 month BI, trichotomised  
0-55, 60-90, 95-100 
0.8 Complete, no benefit 
Lubelozole184 3 month BI, trichotomised  
0-70, 70-100, 
dead/vegetative 
0.162 Complete, no benefit 
selfotel185 3 month BI, dichotomised  
≥ 60 
0.490 Discontinued due to 
mortality imbalances, no 
benefit 
 
Aptiganel186 3 month mRS 0.44-low 
dose 
0.12-high 
dose 
Discontinued due to 
mortality imbalances, no 
benefit 
Tirilazad187 3 month GOS and BI, 
dichotomised 
>0.05 both 
outcomes 
Discontinuted, no benefit 
Enlimomab189 3 month mRS 0.04 
favouring 
placebo 
Completed, no benefit 
IMAGES188 Global endpoint common 
odds of death/ disability 
0.59 Completed, no benefit 
mRECT193 3 month BI, dichotomised  
≥ 85 
0.149 Complete, no benefit 
SAINT I194 3 month mRS (0 to 5) 
ordinal 
0.038 Completed, benefit shown 
on primary outcome. 
Second study proposed 
SAINT II196 3 month mRS ordinal 0.33 Completed, no benefit 
ICTUS200 Global test BI, mRS and 
NIHSS 
0.364 Discontinued, no benefit 
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1.6.4. Databases and registries 
Due to the data monitoring practices implemented in clinical trials, the trials have the 
opportunity to provide a rich, reliable source of complete patient data to aid in the 
planning of future trials. The data for many of these trials are kept by pharmaceutical 
companies or stored in academic archives for years after trial publication; some trials 
such as NINDS and the original IST trial have made the data available to the public in an 
anonymised form after a number of years post trial201-202.   
The importance of the data contained within a trial resource is often underestimated. 
Combining several trials into a single resource or database allows new hypotheses to be 
tested without the cost associated with research and development of a new 
intervention203.  The Virtual International Stroke Trials Archive (VISTA) is a large 
international database collating data contained in 29 RCTs in acute stroke, containing 
reliable data on over 28,000 patients. This database alone has resulted in over 40 
publications many of which have implications for the management of stroke patients in 
the acute setting and the design of future trials203-204. 
Stroke databases or registries are established to gather information for scientific 
research, to acquire epidemiological data to inform healthcare planning and to evaluate 
and improve the quality of care205. Studies based on such registries have led to advances 
in medicine and enhanced the understanding of the history of disease206. Several of these 
prospective registries have been implemented in different countries worldwide such as; 
the registry of the Canadian Stroke Network206, the Performance, Effectiveness and Cost 
of Treatment episodes in stroke (PERFECT) study in Finland205, the South London stroke 
registry in the UK207, the Harvard cooperative stroke registry8 and the German Stroke 
databank208.  Each of these registries is centred on one geographic region. The 
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opportunity for further research comes from multinational registries such as the stroke 
data bank209. 
One of the most widely used international registries is The multinational Safe 
Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register 
(SITS-ISTR). SITS-ISTR is an international, web-based, interactive registry of stroke patients 
treated with thrombolysis, including those that did not meet the criteria for SITS-MOST, 
as discussed in section 1.6.2. SITS-ISTR is an ongoing registry and enables participating 
centres to compare treatment results and encourages collaborative research176 179.  Since 
the inception of the registry a total of 29 publications have been accepted utilising the 
data, many of which investigate the safety of thrombolytic therapy and make 
recommendations on its use210. 
1.6.5. Inclusion criteria in stroke trials 
It is widely accepted that a rigorously designed randomised control trial is necessary to 
evaluate the efficacy of new therapies in acute stroke; however study design and 
recruitment rate can adversely affect the cost and duration of such studies165 211. The 
efficiency with which subjects are recruited into trials is largely influenced by the 
stringency of the entry criteria. A meta-analysis performed by Elkins et al found that trial 
entry and organisational criteria considered in their analysis accounted for approximately 
40% of the variability in subject recruitment efficiency across the included studies211. 
Several trials in the past have chosen inclusion criteria to facilitate the inclusion of as wide 
a rage of patients as possible, excluding only those with very good and very weak 
prognoses. Although it is desirable to show efficacy in all patient subgroups by including 
as wide a range of patient groups as possible, the nature of stroke itself may have led to 
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this being a failed strategy. The ECASS III trial showed the benefit of a more stringent 
approach to patient inclusion in comparison to other extended time window trials in 
thrombolysis such as ATLANTIS. The NINDS study group reassessed their data by 
restricting their patient group to follow the more  restrictive ECASS III criteria and found 
that restricting inclusion further did not alter the treatment effect of rt-PA less than 3 
hours212. It is a matter of debate that the heterogeneity of stroke makes it unlikely that 
any one intervention will show efficacy in all patients, suggesting the inclusion criteria 
should suit the intervention191. 
The inclusion criteria applied to a trial are entirely dependent on the intervention being 
studied. For interventions such as thrombolysis, the time window for patient enrolment 
remains one of the most important factors for inclusion. Once the mechanism of action of 
the drug is known, enrolling patients as soon as possible after stroke onset can maximise 
the chances of detecting treatment benefit162. 
 An appropriate patient population also needs to be selected to avoid inadvertently 
causing harm, for example thrombolysis trials such as ECASS III98 excluded ages < 18 and 
>80.  Another consideration in the patient population is the baseline severity (NIHSS): 
mild strokes <6 and severe strokes >25 are often excluded as patients with moderate 
deficit increase the likelihood of detecting a clinical benefit162. 
A very important consideration that has been brought into trial eligibility is the use of 
imaging to differentiate subtypes of stroke191.  The Stroke Therapy Academic Industry 
Roundtable (STAIR) group support the development and implementation of techniques 
for patient selection based on imaging-based penumbral identification. The main issue of 
using imaging for routine use in selecting patients is the limited imaging capability of 
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some trial centres and the variability in methodology, processing and interpretation of 
images across centres, potentially limiting applicability of study results in routine clinical 
practice213.   
1.6.6. Improvements in stroke trial design what have we learned? 
Following the disappointing success of neuroprotectant trials, there has been a great deal 
of discussion and collaboration regarding trial design and implementation of clinical trials 
in acute stroke.  The STAIR committee recommend considering a selective approach to 
patient inclusion taking into consideration the mechanism of the drug, as well as proper 
management of medical complications and standardised management of likely side 
effects of the drug. Choice of an optimal end point measure and the time-point of this 
measurement are also very important considerations to be made162 213. 
Grotta discusses the need to better translate the conditions under which animal models 
have been successful into trials conducted in human studies, suggesting that trials which 
have adhered to this have been the only positive trials to date214.  Standardisation of 
factors such as stroke severity, a shortened time to treatment, the combination of 
neuroprotection with reperfusion strategies, sufficient dose and potency should all be 
considered when selecting and testing a potential neuroprotective agent. Lees215 suggests 
further considerations to be made are the selection of neuroprotective agent, improving 
patient selection and more optimal selection of endpoints. Many of these considerations 
are also discussed by Dorman et al216. 
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1.7. Statistical analysis in stroke trials 
Specific analytic techniques incorporated within this thesis will be discussed in more 
detail in later chapters. A brief discussion of statistical analysis in stroke trials is given 
below. 
1.7.1. Baseline factors 
For clinical trials in acute stroke substantial baseline data are collected. Many of these 
baseline factors have an influence on outcome as discussed in section 1.5.2. In a double 
blinded RCT key baseline factors such as age, baseline severity, diabetes etc should be 
balanced between groups. In contrast imbalances in baseline factors between groups 
would be expected when conducting an observational study.  
Covariates play an important role in the analysis of clinical trials.  For analysis of outcome 
by treatment group some influential baseline factors may be treated as covariates for 
adjustment or subgroup analysis performed to assess if treatment effect depends upon 
certain patient characteristics. The choice of covariates is an important consideration in 
trial design.  The two main methods proposed are: adjusting for covariates that are 
imbalanced across treatment groups, adjusting for covariates correlated with outcome 
and covariates that follow both rules.   As the decision on which covariates to include is 
required to be made at the design stage of a trial, reliable covariates need to be identified 
from relationships observed in previous studies. This makes accounting for unexpected 
imbalances in a clinical trial setting difficult as there is a pre-specified analysis plan 
already in place which cannot be changed. 
Adjusting solely for imbalanced covariates can give an over-inflated estimate of the p-
value so truly significant differences may be missed. This method also fails to adjust for 
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covariates associated with outcome such as age or baseline NIHSS if they are balanced 
between treatment groups217. As mentioned previously, this method is not desirable in 
clinical trials as it either requires a post hoc decision or the decision needs to be based on 
previous studies which may have a different distribution of patient demographics218. 
Senn219 showed that non-significant covariate imbalance can still matter if the covariate is 
strongly related to outcome.  Adjustment for these factors achieves a more precise 
estimate of treatment effect and a more valid measurement of significance220.  
Covariate adjusted analysis is more complicated than a simple unadjusted analysis and 
can be difficult for readers to understand, however adjustment  using factors associated 
with outcome achieves more reliable results218. As it is now commonplace in stroke trials 
to perform adjusted analysis, steps should be taken to ensure correct variable selection is 
made. These selections should be based on both clinical knowledge and the wealth of 
data available in databases such as VISTA. 
1.7.2. Outcome measures 
Measures of functional outcome such as the mRS and the BI are non-parametric in nature 
and can pose analytical difficulties. Typically, most published stroke trials have 
dichotomised these scales into good/bad outcome and discarded the remaining 
information. There is some inconsistency in the dichotomisation of these scales: for 
example in the ECASS II and III studies mRS 0-1 was the primary endpoint98 167 and in the 
ATLANTIS study mRS 0-2 was used as a secondary endpoint169. Table 1-2 above shows the 
variability in the dichotomisations and trichotomisations of the Barthel index in studies of 
different neuroprotectants. This inconsistency makes comparison between studies 
difficult without access to the raw data.  
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Over the past decade, analysis of completed trials and theoretical work has generated 
discussion into the analysis of end points in acute stroke trials221.  While dichotomised 
scales make analysis of the endpoint easier to perform and interpret, it results in the loss 
of information.  For example consider a treated patient achieving mRS day 90 of 3 and 
compare them to an equivalent placebo patient achieving mRS day 90 of 5. While a 
clinically important difference, it would not be detected in a dichotomised analysis id the 
mRS was dichotomised at 0-2. An alternative to dichotomised analysis is an ordinal 
approach such as proportional odds logistic regression and the Cochran Mantel Haenszel. 
These approaches have gained favour in recent years after the use of ordinal mRS in the 
analysis of the SAINT I and II trials195. The mRS grades 5 and 6 were combined in SAINT I 
but the full ordinal scale was used in SAINT II.  The advantage of these tests is that they 
take into account the ordinal nature of the given scale rather than just cut at a specific 
point so results reflect all health state transitions in the analysis.  
When considering scales such as the NIHSS which are semi-continuous the nonparametric 
nature of the data becomes problematic. In some cases the NIHSS is dichotomised into 
specific categories.  For example, in the NINDS study, favourable outcome was defined as 
NIHSS ≤ 1. In the ECASS III study favourable outcome on the NIHSS was defined as ≤ 1 or  
>8 point improvement from baseline. This results in a loss of information, an alternative 
option used in several retrospective analyses63 222 is to convert the NIHSS into an ordinal 
measure using pre-defined cut points. This results in the loss of less information than 
dichotomisation.  
From previous trials there have been many lessons learned regarding the analysis of 
outcome measures in acute stroke, generating a great deal of discussion from academic 
collaborations.  The Optimising the Analysis of Stroke Trials (OAST) collaboration have 
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suggested ongoing and future trials utilise the full ordinal nature of the data when 
considering the analysis of the primary outcome223. The ESO working group recommend 
the mRS as the primary outcome measure and discuss different analytic techniques140. 
The STAIR committee discuss the advantages and disadvantages of analysis techniques for 
all outcome measures224. 
1.7.3. Power and sample size 
Sample size calculation is an essential component in the design of a clinical trial. The 
object of this calculation is to find a sample size adequate for the study to detect a real 
treatment effect as statistically significant225. As per study protocol; the required study 
sample size must be determined before recruitment starts226. Studies with too many or 
too few patients are economically and ethically unjustified. Key components in sample 
size calculation include the intended power, significance level, the expected event rate in 
the control group and the expected treatment effect227. 
In acute stroke the consistent failure of many RCT’s is often attributed to sub-optimal trial 
design, with many acute stroke trials failing to report a sample size calculation at all.  
Trials that did report sample size calculations often assumed unrealistic event rates and 
intervention effects or used inappropriate primary outcomes, resulting in an 
underpowered study227. However this may be unfair as it is difficult to predict event rates 
or intervention effects beforehand for a new therapy.  Analysis of the primary outcome 
plays an important role in the sample size calculation. It has been shown that trials 
designed to use an ordinal analysis will, on average, be smaller than using a dichotomous 
outcome223. 
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The CONSORT statement228 gives a checklist of essential items to be included in reports of 
RCT’s.  It suggests that in a trial report the authors should indicate how sample size was 
determined and if a power calculation was used, the outcome this was based upon. It also 
makes suggestions on how to discuss errors made in the calculations that have been 
realised retrospectively.  Since its inception the reporting of sample size calculations in 
acute stroke trials has improved227. 
1.8. Aims 
The aim of this work was to employ various analytic techniques to a vast range of 
historical data allowing us to suggest more optimal methods for consideration in the 
design of clinical trials in acute stroke. Chapter two discusses some of the methodology 
used throughout the thesis. Chapter three aims to explore some simple prognostic factors 
often considered for trial inclusion and their relationship with outcome. These include 
age, onset to treatment time (OTT), the interaction between the two and atrial fibrillation 
(AF).   In chapter four, the merits of using a later baseline measurement of NIHSS for trial 
inclusion is examined. A hyper-acute measurement and 24 hour measurement are 
compared under simulated trial conditions and will be assessed using different outcome 
measures in terms of statistical power and required sample size. Chapter five aims to 
utilise a previously published prognostic score to investigate the selection of a subgroup 
of subjects in whom thrombolysis is safe and effective above 4.5 hours. Suitable 
boundaries of this score were found using a dataset with patients treated at < 3.5h but 
sampled to match the published outcome distribution of those treated > 4.5h. These 
prognostic boundaries were then validated on external randomised data with patients 
treated > 4.5h. 
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Chapter 6 considers the reduction in sample size achieved by utilising an earlier endpoint 
in exploratory stroke trials. This was tested on non-randomised historical data using a 
simulation approach and the results validated on RCT data. In chapter 7 we explored 
whether a combination of endpoints incorporating both early and late measurements of 
outcome could enhance statistical power. A simple incremental combination as well as 
the global test statistic were utilised here in simulations similar to those employed in 
chapter 6.  In chapter 8 an evaluation of different propensity score matching techniques is 
given. This chapter aims to highlight the benefits and flaws of using a matched control 
group instead of a fully randomised control population. Finally chapter 9 aims to use 
historical data to provide reliable estimates of intracluster correlation coefficients (ICCs) 
for specific outcome measures for sample size calculations for future cluster randomised 
trials in acute stroke.  
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Chapter 2  
Data and Methods 
2.1. The VISTA database 
2.1.1. What is VISTA 
The VISTA database is a large collection of stroke data, including data from several pivotal 
trials in acute stroke. Eligibility criteria are applied to individual datasets before they are 
allowed entry into VISTA. These criteria have been put in place to facilitate the 
compatibility of data from multiple sources and include specific details regarding 
documentation of the study, relevant baseline and outcome assessments and monitoring 
procedures in place to validate the data. More detail regarding these criteria are outlined 
in the paper by Ali et al204.  
VISTA contains in excess of 28,000 patients with a general aim to promote research into 
stroke care and clinical trial design.  The premise of using trial data to make inferences 
about future trials is not new; several studies have investigated aetiology, risk factors and 
subgroup differences in stroke outcome on individual trial datasets146 214 229-235. The 
benefit of utilising databases such as VISTA as a resource for novel analysis is the wealth 
of data contained within. As VISTA is comprised of trial data, baseline demographics, 
treatment definitions and outcome measures are carefully recorded. Time points are 
more reliable in this type of data due to individual trial data monitoring practices and pre-
defined statistical protocols. This gives us a large and diverse study population for use in 
the analysis of different aspects related to stroke.  
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To maintain the anonymity of subjects within and the integrity of the VISTA database 
stringent guidelines have been put in place detailing handling of confidential patient 
information, ethics, representation and publication236.  While VISTA aims to facilitate the 
planning of future randomised trials in stroke, it does not permit the re-analysis of 
treatment effect in any individual trial. This is primarily to encourage those who hold the 
data to contribute to VISTA without the risk of any original trial results being challenged.  
Individual trial meta-analysis is also not permitted. 
A steering committee was created containing principal investigators from all contributed 
trials. Any project proposal applying for the use of VISTA is reviewed by all members of 
the steering committee, allowing them to accept or reject based on scientific merit, give 
comments or opinions and providing the opportunity for collaboration. This review 
system ensures that only proposals above a certain standard progress through to the 
analysis stage and avoids any conflicts or direct competition of projects within VISTA.  A 
similar review system is also in place for any manuscripts to be submitted for publication 
with the steering committee members giving comments and opinions on the publication 
which must be addressed before submission to a journal.  
Since its inception VISTA has led to a number of publications and has identified several 
areas for improvement in current practice. This success has led to the extension of VISTA 
to other forms of stroke research such as ICH, imaging and rehab203. For the purposes of 
this thesis VISTA refers to VISTA-acute only as none of the other arms of VISTA have been 
utilised.   
Databases such as VISTA allow retrospective analysis on a larger cohort of patients than 
any individual trial dataset.  The distribution of baseline and outcome variables contained 
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within VISTA has been described previously237.  Topics previously studied and published 
within VISTA include the difference in outcomes between countries, adverse events post 
stroke238-239,  healthcare cost240, the influence of different baseline factors on outcome63 
141 241-243, the use of home time as an outcome measure244-245 and the effect of different 
attributes of medical history on outcome post stroke246.  Some analyses have investigated 
imaging247-249 but the imaging data within VISTA acute limited the scope of these 
analyses. With the creation of VISTA Imaging203 individual scans are becoming more 
readily available for novel analysis. 
2.1.2. Caveats associated with VISTA  
While there are many benefits associated with the use of a resource such as VISTA there 
are some caveats that need to be considered.  
Certain restrictions are applied to VISTA datasets before they are released for an 
individual project; these are mainly for the protection of those who contributed the data. 
The data are anonymised with respect to both individual patient and trial. VISTA does not 
sanction re-analysis of any individual trial that will test treatment effects.  Due to these 
restrictions, data compiled from the VISTA database are non-randomised between 
treatment groups. For example: if we wish to investigate the effect of thrombolysis on 
outcome we cannot use patients from trials in which thrombolysis was the drug of 
interest. This leaves us with patients who were treated with thrombolysis as standard of 
care in trials with other investigational drugs. A comparison of the baseline factors of this 
group with a non-thrombolysed group of VISTA patients would likely show the two groups 
to be unbalanced. This means that the data are not representative of a randomised trial 
and must be taken into consideration when discussing results of an analysis. 
 50 
As VISTA contains a collection of clinical trial data, inclusion criteria have been applied to 
the patients before entry. Each trial has different inclusion criteria based on the 
intervention being tested. This may lead to certain subgroups of patients being under-
represented within the database. For example in order to avoid treating patients in whom 
the stroke was very mild or very severe there are usually upper and lower boundaries of 
baseline NIHSS applied to the patients before inclusion into a trial. Similarly there is often 
an upper and lower age restriction in trials, for example the ECASS I and II trials had a 
lower age limit of 18 and an upper age limit of 80 years98 166. 
Finally, caution must be taken when making recommendations based on historical data, 
with the development of new treatments and the expansion of stroke units data would 
be expected to evolve over time. However, VISTA acute contains data from patients 
entering into a trial during the years 1989 to 2006. With data readily available on 
thrombolysis given as standard of care as well as thrombolysis trials, VISTA is considered 
to represent current trends in acute stroke. These caveats must be taken into 
consideration when making inferences following an analysis. 
2.1.3. What do we use it for? 
Various VISTA data compilations have been used for the projects contained in this thesis. 
Each project was approved by the VISTA steering committee. Each dataset contains a 
unique selection of patients combined for the project purpose, data descriptions are 
given within the relevant chapter. Given the restrictions placed upon VISTA projects, the 
data given were non-randomised and so not representative of a true trial population. In 
some cases, where possible, methods were validated on external RCT data.  
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VISTA data has been used here to explore trial design in acute stroke, in particular to 
investigate how inclusion criteria and outcomes influence sample size.  This has been 
achieved using various analytical approaches including regression, simulation and 
propensity score matching methods.  
2.2. Simple statistical techniques 
2.2.1. Displaying data graphically 
With the inherent non-parametric nature associated with stroke data it is important to 
ensure the data are displayed correctly. When looking at continuous or discrete variables 
such as age and NIHSS within stroke data, the distribution is generally skewed to favour 
higher ages and lower values of NIHSS.  As the data are generally non-normal in nature 
they are best displayed using either histograms or box plots. In medical literature dot 
plots are often used in place of these when there is a small sample size. Due to the large 
sample given in VISTA datasets these were not utilised here.  Figure 2-1 shows a 
histogram and a box plot for NIHSS at day 90 taken from a sample of VISTA data. As can 
be seen in the plots the data are positively skewed i.e. the majority of the data are 
centred on lower values and tail off toward the higher values. Data displayed in this way 
are easy to interpret and the non normal nature of the data is clear.  
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Figure 2-1: Histogram and box plot illustrating the distribution of NIHSS at day 
90 
For ordinal data such as the mRS these plots are uninformative and can lead to wrongful 
interpretations of the data. A method of displaying ordinal data such as the mRS which 
have a select number of categories is to use bar charts. A method predominantly used in 
stroke research is a horizontal bar chart for each treatment group with vertical lines in 
between categories for each grade of the mRS. This is informally known as a ‘Grotta bar’ 
and example is given in Figure 2-2. The numbers given in each box represent the 
percentage of subjects from each treatment group within each mRS grade. 
 53 
 
Figure 2-2: Bar chart or ‘Grotta bar’ illustrating the distribution of mRS 
between treatment groups 
The graphical representation of data gives a good introduction to any analysis and its 
importance is often underrated.  
2.2.2. Tests of association 
2.2.2.1. Correlation coefficients and coefficient of determination (R2) 
Correlation coefficients are used to measure the strength of the association between two 
continuous variables. Correlation coefficients range from -1 to 1 where a perfect linear 
relationship with a positive slope would give a correlation coefficient of 1. If both 
variables have a high value the correlation coefficient is positive. A perfect linear 
relationship with a negative slope would give a correlation coefficient of -1. If one 
variable has a high value whilst the other has a low value the correlation coefficient is 
negative. A correlation coefficient of 0 indicates no linear relationship between the two 
variables. When calculating a correlation coefficient in statistical packages a p-value is 
given, this p-value assesses the hypotheses: 
H0: Population correlation coefficient (r) = 0 
H1: Population correlation coefficient (r) ≠ 0 
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There are at least two types of correlation coefficient that can be calculated. The Pearson 
correlation coefficient250 is used under the assumption that the variables are jointly 
normally distributed so may be suitable for continuous variables such as age and weight.   
When considering discrete or ordinal variables, particularly those with a limited number 
of groups such as the mRS the Pearson correlation coefficient may underestimate the 
value of the association. In such cases a non-parametric measure can be used called the 
Spearman-Rank correlation coefficient. This assigns a rank to instances of each variable 
and gives a better indication of the relationship between the two variables when the 
relationship is non-linear251.  
SAS gives the option to calculate a partial correlation, adjusting the correlation coefficient 
for other covariates. This attempts to determine the degree of association between two 
variables that would exist if all of the influences from the adjusting variables were 
removed. Given this; the partial correlation coefficient represents the correlation 
between two variables after removing the common variance with other predictors from 
both variables 252.  
The coefficient of determination, commonly referred to as R2 is a value between 0 and 1 
and, in general, is often used to indicate the goodness of fit of a regression model.  It 
quantifies the proportion of variation in the outcome that can be explained by the 
regression equation250.  When looking only at the relationship between two variables R2 
can be crudely calculated by simply squaring the correlation coefficient. As the absolute 
value of the correlation increases, R2 increases regardless of the sign of the correlation. 
When considering other variables in the equation this becomes slightly more complex 
although squaring a partial correlation coefficient does give a crude estimate of R2.  When 
conducting a linear regression with a continuous outcome most statistical packages will 
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give the adjusted R2 value representing the percentage of variation in the outcome 
explained by the predictors. 
When looking at logistic regressions predicting ordinal and binary outcomes there is no 
alternative to the ordinary R2 so something called a pseudo R2 must be calculated253-254. 
These are called pseudo R2 as they look like ordinary R2. When calculated within SAS 
these measurements can be interpreted in the same manner255.  
2.2.3. Comparison between groups 
In many of the projects contained within this thesis the initial stage of the project 
involved performing univariate analyses, investigating whether differences exist in a 
variable between groups. Different tests are used for continuous and categorical 
variables. SAS version 9.2/9.3 and R were used for all statistical analyses. 
2.2.3.1. Tests for continuous variables 
When considering a continuous variable first the nature of the variable must be taken 
into consideration. If the variable is normally distributed within each group, for example 
age, then a 2-sample t-test256 can be performed. This assesses the difference in the 
population mean between the two groups. Using the example of age as the continuous 
variable and rt-PA as the grouping variable we obtain a p-value assessing the hypothesis: 
H0: In the wider population there is no difference in mean age between treatment groups 
H1: In the wider population there is a difference in mean age between treatment groups 
If the p-value is lower than the accepted significance level of 0.05 then a significant 
difference in age exists between the two treatment groups. A 95% confidence interval is 
also given quantifying this difference. Other than normality there are two more 
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assumptions associated with this test, the observations are independent and the two 
groups have equal variances.  
If the variable is not normally distributed within one or both groups then either a 
transformation could be considered such as the log or square root transformation or a 
non-parametric test can be performed. Due to the non-parametric nature of stroke data 
transformation of the data generally makes very little difference. In this case a Mann 
Whitney U257 test can be performed to compare the distribution of the two groups. This 
test does not assume normality, allowing for the non-parametric nature of data such as 
NIHSS score. This test works by ranking the observations from low to high, disregarding 
their group. This gives a p-value assessing the hypothesis:  
H0: In the wider population, the underlying distribution of NIHSS is the same in both 
treatment groups 
H1: In the wider population, the underlying distribution of NIHSS is different in both 
treatment groups 
If the p-value is lower than the accepted significance level of 0.05 then a significant 
difference in NIHSS exists between the two groups. From this test a 95% confidence 
interval can be generated quantifying the difference in median NIHSS between the two 
groups. The assumptions required for this test are that the data are at least ordinal and 
the observations are independent. 
2.2.3.2. Tests for categorical variables 
When comparing a categorical variable between two groups there are two tests that can 
be used. If the categorical variable is binary, a test of two proportions can be used258.  The 
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test of two proportions compares the proportion of ‘events’ in each group, for example 
history of hypertension the ‘event’ would be ‘Yes’.  With P1 denoting the proportion of 
events in the treatment group and P2 denotes the proportion of events in the control 
group; the test gives a p-value assessing the hypothesis: 
H0: In the wider population, P1=P2 
H1: In the wider population, P1≠P2 
If the p-value is lower than the accepted significance level of 0.05 then a significant 
difference exists between the proportions of those with history of hypertension between 
the two groups. 
More widely used, particularly in medical literature, is the pearson chi-square (χ2)258 test 
of association. This test is used to assess the relationship between two categorical 
variables each with 2 or more groups. The χ2 test treats each variable as nominal i.e. there 
is no order to the categories and gives a p-value assessing the hypothesis: 
H0: In the wider population, there is no evidence of an association between the two 
variables 
H1: In the wider population, there is evidence of an association between the two variables 
This test assumes that the expected cell counts have a value of 5 or higher, if this 
assumption is not met Fishers exact test can be used.  
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2.3. Analysis of outcome measures 
2.3.1. Analysing ordinal and binary outcome measures 
The primary outcome in most clinical trials in acute stroke is the mRS. As mentioned 
above there is some debate as to how this should be analysed so we will discuss treating 
it as both a binary and an ordinal measure. 
When outcome is treated as a binary measure, usually denoted good outcome=1 and 
poor outcome=0, binary logistic regression can be used to analyse outcome. When 
treated as an ordinal measure scales such as the mRS can be analysed using ordinal 
logistic regression. The significance can then be assessed using the Cochran Mantel 
Haenszel (CMH) test. Logistic regression allows us to quantify the predictive value of an 
explanatory variable on a response variable.  Using regression methods allows for 
adjusted analysis, accounting for other covariates. 
2.3.1.1. Binary logistic regression 
Binary responses are often used in stroke research by dichotomising the outcome scale to 
create an outcome measure with two categories.  Such a response is analysed using the 
binary logistic regression model259. This calculates the probability of an event Y=1, given 
the values of the predictors X. The model is in the form: 
                       
Where   is the weighted sum of the predictors; given below. 
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The regression parameters β are estimated using the maximum likelihood method and 
the log odds of an event occurring are given by the inverse of the logistic function P. 
       
 
     
  
This can be explained as the log(odds that outcome     occurs) also known as 
          . The model assumes that, for every predictor   , 
                    
Assuming all other predictors are held constant, the parameter    is the change in the log 
odds per unit change in   . The odds ratio (OR) giving the odds that     when    is 
increased by one unit can then be calculated by    . 
2.3.1.2. Ordinal logistic regression with the proportional odds model 
In stroke research the proportional odds model has gained popularity in recent years for 
analysis of outcomes such as the mRS260. The benefit of ordinal response models is that 
they do not assume equal spacing between levels of outcome (i.e. outcome can be 0,1,2 
or 0,100,1000 the difference between each level is irrelevant). The ordinal models rank 
the values of outcome and order these ranks. For the purposes of this thesis we will 
consider only the proportional odds model259. 
For a response variable Y with levels 0,1,2,…k: the proportional odds model is given as 
follows: 
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For a fixed m (where          ), the model becomes similar to a binary logistic model 
for the event    . Using a common vector of regression coefficients β connecting the 
probabilities for varying   the proportional odds model allows for parsimonious 
modelling of the distribution of Y. For any predictor   the odds ratio for     is given by 
   , whatever the cut-off  . This single odds ratio is assumed to apply to all events. 
One of the main drawbacks of using this model in stroke research is the ordinality 
assumption is often violated. This is a basic assumption of all commonly used ordinal 
regression models. It states that the response variable behaves in an ordinal fashion with 
respect to all predictors. This can also be explained as the effect of each predictor being 
consistent across all levels of outcome259. Due to the nature of the mRS this assumption is 
often not met. There is some debate in the literature as to the importance of the 
hypothesis test for this assumption224 260-261.  
2.3.1.3. Cochran Mantel Haenszel (CMH) test 
In order to get a more conservative estimate of significance given the violation of the 
ordinality assumption; the CMH test262 was used for ordinal outcomes. The CMH test 
measures the strength of the association between treatment and outcome, after 
stratifying on the observed covariates. This accounts for confounders in the analysis. The 
significance level reported is the probability that the response is independent of the 
explanatory variable, after adjusting for control variables. The hypothesis being tested is: 
H0: After adjusting for covariates the response is independent of treatment 
H1: After adjusting for covariates the response is dependent on treatment 
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2.4. Simulation techniques 
Simulation techniques were used throughout this thesis as a method to estimate power 
and required sample size. A multiple re-sampling approach was applied with slightly 
different methods employed depending on the given analysis; specific details are given 
within each chapter. Here a general overview of the method is given. 
For each simulation a relevant dataset or ‘trial’ needed to be generated, any baseline 
restriction desired e.g. baseline NIHSS restricted 4-20 was applied beforehand. Each 
simulation used a different seed for sampling; this allows future replication of results and 
ensures the random samples taken for each simulation are different.  A selected number 
of patients (n) were sampled, with replacement, from all of the available control data to 
generate a placebo group and similarly form all available treated patients to generate a 
treatment group. This gives a simulated trial for analysis. Using R statistical programming 
language, a specified number of trials (in general between 1,000 and 10,000 were 
simulated from the given VISTA dataset. 
For each of these simulated trials analysis was performed using both ordinal and binary 
outcome measures as endpoints.  Logistic regression was performed to assess the effect 
of (simulated) treatment on outcome adjusted for the baseline used for inclusion in the 
trial and age, either binary or ordinal logistic regression were used depending on the 
outcome measure. The significance level for the simulated treatment effect along with OR 
for treatment and the distribution of mRS within each group (treatment and placebo) 
were recorded. Unadjusted analysis was also performed on each trial for exploratory 
purposes. 
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Power was obtained by calculating the proportion of times the treatment effect was 
found significant over the 10,000 trials. This can be expressed as 1-β where β is the 
probability of a type II error (false negative).  This method is outlined in the flowchart 
given in Figure 2-3. 
  
In order to look at the relationship between power and sample size an iterative approach 
was taken.  The sample size (n) was gradually reduced from a starting point (say 1000 per 
Treatment group 
size n  
All subjects 
given relevant restriction 
 
 
Randomly select n patients 
from all available data with 
control patients 
 
Randomly select n patients 
from all available data with 
treated patients 
 
 
Simulated trial size 2n 
 
Analysis of trial 
p-value (p) obtained from 
adjusted analysis 
Repeat 
10,000 times, 
generating 
10,000 trials 
Power calculated as the 
proportion of times a significant 
result is found or 1- β. 
Placebo group 
size n  
Figure 2-3: Outline of simulation method 
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treatment group) in decrements of 10 and the simulations described above were 
performed for every given sample size.  The sample size was reduced until power settled 
to 80%, and this allowed estimation of the required sample size under all data 
restrictions. 
2.5. Matching based on propensity scores 
2.5.1. Propensity scores 
An important problem in causal inference, particularly when using non-randomised data, 
is how to estimate treatment effects. Observational studies often provide the only 
available information to evaluate treatment effect.  It is often the case that there are a 
large number of control patients in the study population with a small number of treated 
patients. Matching from a different population based on covariates is a method often 
used to account for this imbalance263-265. Matching allows us to generate a control group 
similar to the treatment group based on baseline characteristics. 
Because matching exactly on the values of all covariates individually is difficult, 
particularly continuous covariates, alternative methods need to be pursued. Propensity 
score matching has gained popularity in recent years266, matching based on all covariates 
to substitute for the absence of experimental controls. 
The propensity score was introduced by Rosenbaum and Rubin267 and is defined as the 
probability of receiving treatment conditional on observed pre-treatment covariates268. 
Let the binary variable   denote treatment assignment taking the value 0 or 1, where 1 
denotes treatment. Let   represent a vector of pre-treatment covariates. The propensity 
score      for a subject is defined as the conditional probability of that subject being 
treated given their covariates,                . This reduces the dimensionality of 
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the matching process when several covariates are involved by naturally weighting all 
covariates and yielding an unbiased one-dimensional estimate for matching.  
Matching based on the propensity score balances the distributions of the observed 
covariates in the treated and control groups. Here the estimated propensity score is 
obtained by fitting a logistic regression model considering different combinations of pre-
treatment variables. Among subjects with a given propensity score, the covariate 
distribution   is on average the same among the treated and control populations.  
Packages such as SAS and R have in built functions for propensity score matching. 
2.5.2.  Methods of propensity score matching 
For the purposes of this thesis, propensity score matching was performed using the 
matchIt package269 available within the R statistical programming language. There are 
several methods of propensity score matching which involve matching each treated unit 
to a suitable control unit. The methods of matching included in this package are exact, 
nearest neighbour, optimal, full and genetic matching. These methods are described in 
some detail below. 
2.5.2.1. Exact matching 
This method matching on exact values across all covariates, pairing each treated subject 
with one control for whom all values are identical. As mentioned above, implementing 
this method can be difficult when there are several covariates, limiting the number of 
possible matches, often resulting in no match being found. 
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2.5.2.2. Nearest Neighbour Matching 
The desired number of matches, r can be defined here matching the r closest controls to 
each treatment subject.  This is also known as ‘greedy’ matching, where the closest match 
for each subject is found from all unmatched controls. This is performed without trying to 
minimise the global distance measure.  
2.5.2.3. Optimal matching 
Contrary to ‘greedy’ matching the optimal matching method matches the samples by 
minimising the distance across all matched pairs. While it is more computationally 
intensive, optimal matching is felt to be better at minimizing the global distance measure.  
It tends to provide better balance when there is a limited sample of control patients for 
matching. 
2.5.2.4. Full matching 
Rather than matching a single control to each case the full matching method creates 
matched ‘sets’. Each set consists of either one case unit with one or more matched 
control units or one control unit and one or more matched case units. This allows for a 
larger matched group than the other methods which have a fixed case to control ratio.   
Full matching minimises the weighted average of the estimated distance measure 
between each treated subject and each control subject within each subclass. 
2.5.2.5. Genetic matching 
This matching method uses a genetic search algorithm to apply weights to each covariate 
so that optimal balance can be achieved after matching is completed269. Genetic matching 
maximises the balance of observed baseline covariates across the matched treated and 
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control groups. Genetic matching has been shown to have more appealing properties 
than other matching methods, with better performance in terms of efficiency. However 
this increase in efficiency comes at the expense of computational time. 
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Chapter 3  
Simple factors for 
consideration in trial 
inclusion 
3.1. Introduction 
With the inherent variability in stroke patients270, several factors need to be considered 
for inclusion or exclusion when designing a clinical trial. Many of these factors strongly 
depend on the action of the drug under study. With neuroprotectant agents such as 
thrombolysis it is important to exclude the patients in whom the potential for harm could 
outweigh the benefit. For example patients in the ECASS III trial of thrombolysis271 had to 
be treated within 3 to 4.5h of symptom onset and were excluded if they had a baseline 
NIHSS score > 25, they were older than 80 or younger than 18, had either previous stroke 
or diabetes or oral anticoagulant treatment was given prior to stroke. It is important to 
consider different prognostic factors for trial inclusion and how they may affect outcome. 
The relationships between age, history of diabetes, previous stroke and the NIHSS at 
baseline and outcome have previously been studied within the VISTA database63 178 241 272. 
Within this chapter we investigated the interaction between onset time to treatment 
(OTT) and age and their combined effect on outcome and the relationship between Atrial 
Fibrillation (AF) and outcome. 
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3.2. Onset time to treatment and age 
3.2.1. Background 
Therapeutic benefit from thrombolysis in acute ischaemic stroke declines sharply as 
stroke onset to treatment delay (OTT) increases. The time window for safe initiation of 
thrombolysis closes around 4.5 hours from stroke onset171. Fears that elderly patients 
derive less benefit, encounter greater risk, or have a shorter therapeutic time window 
have limited the use of thrombolysis in this group of patients273. 
Investigations utilising both the VISTA database and the SITS registry have indicated that 
benefit from thrombolysis for acute ischaemic stroke does not deteriorate with advancing 
age63 178 273, but the association with OTT in the elderly had not been examined due to 
absence of information on treatment delay in controls. The third international stroke trial 
(IST 3)274, which has recently been published in combination with an updated meta-
analysis of summary data, described the association of therapeutic effects with treatment 
delay (≤3 versus 3-6 hours) using surrogate information on OTT275. The surrogate 
information used was time to randomisation. This provided an estimate of OTT 
comparable between treated subjects and open control275.  
We applied a similar approach among VISTA patients with reliable surrogate information 
on OTT to assess outcomes among thrombolysis treated patients versus untreated 
controls across a range of OTT according to age.  
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3.2.2. Methods 
3.2.2.1. Data source and patients 
We collected demographics, clinical data, and functional outcome measures from 
neuroprotectant trials in ischaemic stroke conducted from 1998 to 2008 and held within 
VISTA237. Data were anonymised in relation to patients and trials. We excluded trials that 
had tested effects of thrombolysis or of any drug now known to influence outcome after 
stroke, and patients who lacked relevant baseline or outcome information: baseline 
National Institutes of Health Stroke Score (NIHSS), age, thrombolysis administration as 
standard of care, and modified Rankin Scale (mRS) at day 90. Only non-thrombolysed 
patients (control) having a recorded OTT of the investigational drug as well as 
thrombolysed patients (treatment) having a recorded OTT of thrombolysis ≥1h and ≤3.5h 
were included. 
3.2.2.2. Statistical analysis 
A nonrandomised adjusted comparison of outcomes was conducted, differentiating 
between patients aged ≤80 and >80 years as well as between patients who received 
thrombolysis versus patients who did not. Analyses were adjusted for age and baseline 
NIHSS, which has previously been justified in detail141 241. As this was a subset of the data 
used by Mishra et al63 the results were expected to follow the same trend.  
Our primary outcome measure was the mRS at 90 days, analysed across the whole 
distribution of scores with the use of the Cochran Mantel Haenszel (CMH) test. Odds 
ratios (OR) and 95% confidence intervals (CI) were computed using ordinal logistic 
regression. Differences in rate of mortality were assessed using binary logistic regression. 
Unadjusted baseline comparisons were conducted using the 2 sample t-test, the Mann 
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Whitney U test, or the chi square test depending on the distribution and nature of the 
data.  
By treating OTT as continuous in a multiple logistic regression model, we established 
whether the effect of thrombolysis varies across OTT. The interaction between OTT and 
age along with the interaction between thrombolysis and age were investigated. 
Insignificant interactions were removed and the analysis repeated.  
Looking at the data independently for those above and below 80 years of age is sub-
optimal. The three-way interactions were repeated on the full data, treating age as a 
dichotomised variable (≤ 80 vs. > 80). This allowed us to see if the interaction between 
OTT and thrombolysis varied across the two sub groups of age. Finally the three-way 
interaction of age (continuous) variable, OTT and thrombolysis was modelled to 
investigate if age as a continuous variable influenced the interaction between OTT and 
thrombolysis. 
Plots were generated to illustrate the effect of thrombolysis on full scale mRS at day 90 as 
well as mortality at day 90 across the entire range of OTT. At each time-point the OR and 
95% CI for treatment effect was calculated using logistic regression adjusting for age, 
baseline NIHSS and the interaction between treatment and time. These plots were 
generated for different age ranges: ≤ 80 and > 80. Similar plots were generated for the 
entire population, adjusting for age as a continuous variable and baseline NIHSS.  
Analyses were undertaken using SAS 9.2 and R version 2.10.0.  
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3.2.3. Results 
3.2.3.1. Data and preliminary analysis 
We collected data from 3603 ischemic stroke patients of whom 2341 (65.0%) were 
thrombolysed within 3.5h of stroke onset. 597 (16.6%) patients were aged >80 of whom 
352 (60.0%) were thrombolysed. Detailed baseline characteristics are given in Table 3-1 
with p-values for between group comparisons included.  
Table 3-1: Baseline Demographics of patients split between age sub-
populations studied.  
 Control Thrombolysis P –value for difference All 
Sex (male)  % 
Aged ≤80 58.3% 59.9% 0.4068 59.4% 
Aged >80 39.6% 41.8% 0.5958 40.9% 
Age (years) mean (SD) 
Aged ≤80 67.0 (10.1) 65.2 (11.5) <.0001 65.8 (11.0) 
Aged >80 85.0 (3.6) 84.8 (3.5) 0.5472 84.9 (3.5) 
NIHSS baseline median (IQR) 
Aged ≤80 11 (7 13 (8) <.0001 13 (8) 
Aged >80 14 (10) 15 (9) 0.0643 14 (9) 
Diabetes % 
Aged ≤80 23.7% 19.2% 0.0036 20.7% 
Aged >80 18.4% 17.9% 0.8652 18.2% 
Glucose baseline (mg/dl) mean (SD) 
Aged ≤80 137.9 (56.7) 132.2 (51.4) 0.0084 134.1 (53.3) 
Aged >80 134.9 (48.4) 130.9 (46.3) 0.3421 132.5 (47.2) 
Hypertension % 
Aged ≤80 74.9% 67.9% 0.0002  70.1% 
Aged >80 78.2% 81.9% 0.2967 80.5% 
SBP baseline (mmHg) mean (SD) 
Aged ≤80 154.8 (27.1) 153.8 (24.8) 0.3581 154.2 (25.7) 
Aged >80 158.9 (24.6) 158.9 (27.1) 0.9898 158.9 (26.0) 
DBP baseline (mmHg) mean (SD) 
Aged ≤80 84.8 (15.9) 82.8 (16.0) 0.0021 83.5 (16.0) 
Aged >80 81.8 (16.2) 78.9 (17.1) 0.0549 80.2 (16.8) 
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3.2.3.2. Multiple logistic regression Analysis 
Irrespective of age, day 90 outcomes were more favourable among thrombolysed 
patients than comparators. Adjusted for baseline NIHSS and age, the OR for improved 
outcome with thrombolysis measured by the mRS was 1.31 in patients aged ≤80 (95% CI 
1.15-1.51, p<0.001; shown in Figure 3-1) and 1.46 in >80 year old patients (95% CI 1.08-
1.97, p=0.001; illustrated in Figure 3-2). This is a subset of the analysis performed by 
Mishra et al63, results given here are for illustrative purposes only. 
 
Figure 3-1: Distribution of mRS day 90 scores for each treatment group for 
those ≤ 80 years old 
 
Figure 3-2: Distribution of mRS day 90 scores for each treatment group for 
those > 80 years old 
When OTT was added into the ordinal logistic regression analysis, the interactions 
between OTT and other variables needed to be considered. We looked at the interaction 
between OTT and both age and thrombolysis as well as the interaction between age and 
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thrombolysis.  The corresponding p-values are given in Table 3-2. Further details of the 
fitted models are given in Appendix A. 
Table 3-2: Significance levels for all interactions in the ordinal logistic 
regression model. Outcome full scale mRS day 90 
 Interaction 
OTT and  
thrombolysis 
Interaction 
OTT and  
age 
Interaction 
age and  
thrombolysis 
Interaction OTT and 
thrombolysis after 
removing all other 
non-significant 
interactions 
Interaction OTT, age 
and thrombolysis after 
removing all non-
significant interactions 
All Data 0.0194 0.7098 0.0755 0.0159 Age continuous = 0.5292 
Age dichotomised= 0.2871 
≤80 0.0076 0.1376 0.5231 0.0130  
>80 0.4499 0.6874 0.0851 0.4499  
 
The interactions with age and both thrombolysis and OTT were non-significant in all 
models and were removed. The models were then re-fitted to investigate the interaction 
between OTT and thrombolysis after adjustment for age and baseline NIHSS. This was 
repeated for mortality and results are shown in Table 3-3, the same pattern was 
observed. Further details of the fitted models are given in Appendix A. 
Table 3-3: Significance levels for all interactions in the logistic regression 
model. Outcome mortality day 90 
 Interaction 
OTT and  
thrombolysis 
Interaction 
OTT and  
age 
Interaction 
age and  
thrombolysis 
Interaction OTT and 
thrombolysis after 
removing all other non-
significant interactions 
Interaction OTT, age and 
thrombolysis after removing 
all non-significant interactions 
All Data 0.0070 0.7998 0.3010 0.0060 Age continuous = 0.0833 
Age dichotomised= 0.2431 
≤80 0.0049 0.1471 0.9856 0.0073  
>80 0.2118 0.7475 0.1508 0.2667  
 
The relationship between mRS90 and treatment with thrombolysis over time for the 
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entire range of OTT is shown in Figure 3-3 (A and B) for each age restriction, OR show the 
odds of favourable outcome. This was repeated for mortality and is shown in Figure 3-3 (C 
and D) for each age group, OR represent ting the odds of mortality by day 90. 
Though in patients aged <80 thrombolysis showed decreasing favourable outcome with 
longer OTT (interaction mRS: p=0.0130; interaction mortality: p=0.0073), among patients 
aged >80 CIs were wider and there was no significant interaction (interaction mRS: 
p=0.4650; interaction mortality: p=0.2677).  
The primary interest lies in whether the interaction between OTT and thrombolysis varies 
across age subgroups ≤ 80 and > 80. The three-way interactions for dichotomised age, 
OTT and thrombolysis gave significance levels of 0.2871 and 0.2431 for mRS day 90 and 
mortality day 90 respectively. This interaction also lacked significance when age was 
treated as a continuous variable (Table 3-2 and Table 3-3).  
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Figure 3-3: Relation of stroke onset to start of treatment (OTT) with treatment 
effect assessed by day 90 modified Rankin Score (A, B) and by day 90 
mortality (C, D) after adjustment for baseline NIHSS and for age in patients 
aged ≤80 (A, C) and >80 (B, D). 
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The relationship between mRS90 and treatment with thrombolysis over time for all data 
is shown in Figure 3-4 (left), OR show the odds of favourable outcome after adjustment 
for age and baseline NIHSS. This was repeated for mortality and is shown in Figure 3-4 
(right), OR representing the odds of mortality by day 90.  
  
Figure 3-4: Relation of stroke onset to start of treatment (OTT) for all data 
with treatment effect assessed by day 90 modified Rankin Score (left) and by 
day 90 mortality (right) after adjustment for baseline NIHSS and age. 
 
3.2.4. Discussion 
We investigated the interaction between OTT and thrombolysis and the relationship to 
outcome in subgroups of patients aged ≤80 and >80.  While in the elderly a significant 
interaction of OTT with thrombolysis treatment benefit was not seen, the estimate of the 
relation is reassuringly comparable for the elderly to that confirmed in younger patients. 
IST-3 was planned to show the effectiveness of thrombolysis treatment in very elderly 
stroke patients276. The IST-3 investigators state that they lacked power to examine the 
relation between onset to treatment time and the effect of thrombolysis. With over 3000 
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patients, this may be due to heterogeneity of their sample rather than lack of numbers172. 
In an updated meta-analysis of summary data a significant treatment effect for 
thrombolysis is demonstrated in very elderly patients with initiation of treatment (OTT) 
within 3 hours after stroke onset, with no effect evident in data grouped across 3-6 
hours275. Our analysis has only been possible by using the same compromise for 
estimation of OTT in control patients as the updated Cochrane meta-analysis275; however, 
our data provide powerful additional evidence that IST-3 could not offer. 
The present analysis of non-randomised registry data, whether or not derived from trials, 
inevitably incorporates selection bias for thrombolytic treatment and other confounders, 
which have been previously discussed in detail241. 
Evidence from multiple sources is consistent. From this analysis we support the 
conclusion that thrombolysis is effective and safe in very elderly stroke patients until at 
least 3.5h after stroke onset. 
3.3. Atrial Fibrillation  
3.3.1. Introduction 
One in three patients treated by thrombolysis within 3h of ischaemic stroke onset 
achieves significant benefit277, raising the question whether a factor such as comorbidity 
would identify patients in whom treatment would confer no measurable advantage. Age, 
diabetes and prior stroke appear unlikely to influence treatment response but a 
comorbidity such as atrial fibrillation (AF) may be a candidate178.  
Atrial fibrillation (AF) is an independent risk factor for stroke and increases its incidence 
nearly fivefold76. The attributable risk of stroke for AF rises with age, from 1.5% for those 
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aged 50-59 years to 23.5% for those aged 80-89 years76. There are theoretical reasons for 
questioning whether thrombolysis will have a different effect among patients with AF 
versus sinus rhythm.  
On the one hand, patients with AF may have old emboli which after reaching intracranial 
vessels are unlikely to dissolve with thrombolysis278; on the other hand, they might have 
soft emboli formed at ruptured sites of membranous thrombi and that are at least in 
theory amenable to thrombolysis, whereas cholesterol emboli from carotid lesions, 
occlusion of small vessels from hypertensive disease and other non-embolic causes of 
stroke should be less responsive to treatment. In association with the factors that may 
influence clot dissolution, the timing of restoration of blood flow and the abruptness 
could also have an influence on the risk of haemorrhagic transformation, with or without 
thrombolysis. 
Thus, the question arises whether stroke patients with AF gain significant benefit from 
thrombolysis? 
The few studies that have been conducted on this subject showed that stroke patients 
with AF more frequently had poor outcome after treatment with thrombolysis when 
compared to those without AF278-281. However, they did not compare with a control group 
which has not been given thrombolysis. Among the randomized controlled trials 
examining efficacy of thrombolysis in stroke patients, results for the AF subgroup are 
described only for the ECASS III and NINDS trials. In the NINDS trial, disregarding 
treatment groups, AF was significantly associated with worse global outcome (OR for 
more favourable outcome 0.57, 95% CI 0.38-0.86) but there was no significant interaction 
with treatment and further data were not reported282. In the ECASS III trial, there was a 
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non significant trend among the subgroup of patients with AF (Thrombolysis n=53, 
Control n=55) that again favoured placebo over thrombolysis treatment (OR 0.68, 95% CI 
0.30-1.55)271. A small retrospective study compared stroke patients with AF who were 
(n=22) or were not (n=44) treated with thrombolysis. Here, by contrast, there were 
significantly improved odds of favourable outcome for patients with AF when treated 
with thrombolysis (OR 2.67, 95% CI 1.06-6.74)283.  
3.3.2. Methods 
3.3.2.1. Data source and patients 
We gathered demographics, clinical data and functional outcome measures from 
neuroprotection trials in ischaemic stroke conducted in the period 1998 to 2008. We 
obtained our data, anonymised in relation to patients and trials, from the Virtual 
International Stroke Trials Archive (VISTA)204. We excluded trials that had tested effects of 
thrombolysis or of any drug now known to influence outcome after stroke. We excluded 
patients who lacked relevant baseline and outcome information: baseline National 
Institutes of Health Stroke Score (NIHSS), age, history of AF, thrombolysis administration 
as standard of care, occurrence of adverse events (AE) as well as serious adverse events 
(SAE), and modified Rankin Scale (mRS) day 90. Death was recorded as mRS grade 6. 
Symptomatic recurrent strokes and symptomatic ICHs (SICH) were defined as any 
stroke/ICH with neurologic deterioration, as indicated by an NIHSS at 24 hours that was 
higher by 4 points or more than the value at baseline, or any stroke/ICH leading to death. 
Patients receiving oral anticoagulation at stroke onset or up to 3 days post-stroke were 
excluded.  
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3.3.2.2. Statistical analysis 
A nonrandomized adjusted comparison of outcomes was conducted, differentiating 
between patients with and without history of AF and between patients who received 
thrombolysis versus patients who did not. Analysis was adjusted for age and baseline 
NIHSS which has previously been justified in detail241 284. As VISTA is anonymised for trial 
source, the precise definition of AF could not be established, though few acute trials 
define this in any case. 
Our primary outcome measure was the distribution of mRS at 90 days using the full scale 
241. For comparison with prior trials and reports, dichotomized outcomes at 90 days (mRS 
0-1, mRS 0-2, NIHSS 0-1 and mortality) were reported.  
Unadjusted baseline comparisons were conducted using the 2 sample t-test, the Mann 
Whitney U test, the 2 proportions test or the chi squared test depending on the 
distribution and nature of the data. Correlations (r) were calculated using the Spearman 
rank correlation coefficient, which takes into account the ordinal nature of the mRS. The 
coefficient of determination (r2) was calculated from these correlations.  
Reported odds ratios (OR) express the odds of improved outcome in association with 
thrombolysis treatment or presence of AF respectively, adjusted for specified covariates. 
OR’s and 95% confidence intervals (95% CI) of ordinal outcome measures were computed 
using ordinal logistic regression and p-values computed using the Cochran Mantel 
Haenszel test. Dichotomised outcome measures were assessed using binary logistic 
regression.  
The significance of the interactions between AF and Thrombolysis; AF, age and 
thrombolysis; and age on mRS at day 90 were investigated. Plots of the effect of AF and 
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effect of thrombolysis (AF patients only) on full scale mRS day 90 against age were 
constructed to investigate the effect over age. 
Analyses were undertaken using SAS 9.2, and R version 2.10.0.  
3.3.3. Results 
3.3.3.1. Data and preliminary analysis 
We collated data from 7091 ischemic stroke patients of whom 3027 (42.7%) had been 
thrombolysed within 3h of stroke onset. 1631 (23.0%) patients had known history of AF at 
time of hospital admission of whom 639 (39.2%) were thrombolysed. Patients with AF 
were much older (mean 7.5 years) and had a higher baseline NIHSS (median 2 points). 
Age accounted for 8% (r=0.28) and baseline NIHSS for 24% (r=0.49) of the variation in 
mRS at day 90 (both p<0.001) and were included in all models (together r2 is 
approximately 29%). Detailed baseline characteristics are given in table 1 including p-
values for between treatment group comparisons and between AF group comparisons. 
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Table 3-4: Baseline characteristics for patients included in analysis. The 
difference between treatment groups was investigated for AF and Non-AF 
patients separately; p-values are given in the right hand column. Similarly the 
difference between AF and Non-AF patients was investigated for each 
treatment group separately; p-values given underneath each variable. 
 Control Thrombolysis P-Value for 
difference  
Sex (male); % 
AF 47.6% 47.3% 0.986 
Non AF 55.3% 58.2% 0.038 
P-Value <0.001 <0.001  
Age (years); mean (SD) 
AF 73.9 (9.7) 74.2 (9.5)/639 0.552 
Non AF 67.1 (12.2 65.7 
(12.5)/2388 
<0.001 
P-Value <0.001 <0.001  
NIHSS baseline; median (IQR) 
AF 14 (9) 15 (9) <0.001 
Non AF 11 (8) 13 (9) <0.001 
P <0.001 <0.001  
Diabetes; % 
AF 21.3% 18.5% 0.167 
Non AF 23.8% 17.8% <0.001 
P-Value 0.092 0.729  
Glucose baseline (mmol/l); mean (SD) 
AF 7.7 (2.9) 7.3 (2.6)/ 0.017 
Non AF 7.8 (3.6) 7.5 (3.1) 0.001 
P-Value 0.428 0.407  
Hypertension; % 
AF 75.5% 71.7% 0.094 
Non AF 67.5% 61.6% <0.001 
P-Value <0.001 <0.001  
SBP baseline (mmHg); mean (SD) 
AF 154.6 (26.4) 154.6 (26.6) 0.978 
Non AF 156.5 (26.9) 153.8 (25.4) <0.001 
P-Value 0.069 0.509  
DBP baseline (mmHg); mean (SD) 
AF 84.9 (16.7) 82.0 (17.9) 0.002 
Non AF 84.7 (15.8) 82.7 (15.7) <0.001 
P-Value 0.827 0.383  
Myocardial Infarction; % 
AF 10.6% 13.9% 0.053 
Non AF 11.5% 12.6% 0.248 
P-Value 0.457 0.366  
 
3.3.3.2. Analysis 
Irrespective of AF status, the mRS scores at day 90 had a more favourable distribution 
among thrombolysed patients than comparators as illustrated in Figure 3-5 and Figure 
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3-6. Adjusted for baseline NIHSS and age, the OR for improved outcome with 
thrombolysis was 1.44 in AF patients (95% CI 1.12-1.73, p<0.001) and 1.53 in non-AF 
patients (95% CI 1.39-1.69, p<0.001).  
 
Figure 3-5: Distribution of mRS day 90 for those with history of AF 
 
Figure 3-6: Distribution of mRS day 90 for those without history of AF 
Presence of AF had no influence on mRS at day 90 after adjusting for baseline NIHSS and 
age (OR 0.93, 95% CI 0.84-1.03, p= 0.409).  
Analyses with dichotomised outcomes are presented in Table 3-5. These are presented 
for each individual outcome as the OR for good outcome given history of AF within in 
each treatment group (given within the rows) and corresponding p-value. The OR for 
treatment effect for AF only patients is also given with the corresponding p-value in the 
final two columns of the table. 
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Table 3-5: Dichotomised outcomes 
 Control Thrombolysis OR (95% CI) P-Value 
mRS 0-1 at 90 days; n/N (%) 
AF 234/992 (23.6%) 156/639 (24.4%) 1.42 (1.08-1.85) 0.011 
Non AF 936/3072 (30.5%) 826/2388 (34.6%)   
OR (95% CI) 1.26 (1.04-1.52) 0.94 (0.75-1.82)   
P-Value 0.020 0.615   
mRS 0-2 at 90 days; n/N (%) 
AF 318/992 (32.1%) 211/639 (33.0%) 1.43 (1.11-1.83) 0.005 
Non AF 1348/3072 (43.9%) 1179/2388 (49.4%)   
OR (95% CI)  1.07 (0.89-1.28) 0.81 (0.66-1.00)   
P-Value 0.474 0.050   
NIHSS 0-1 at 90 days; n/N (%)  
AF 234/758 (30.9%) 163/491 (33.2%) 1.39 (1.07-1.82) 0.016 
Non AF 867/2598 (33.4%) 801/2051 (39.1%)   
OR (95% CI)  1.36 (1.12-1.66) 0.99 (0.79-1.24)   
P 0.002 0.922   
Mortality at 90 days; n/N (%) 
AF 230/992 (23.2%) 139/639 (21.8%) 0.78 (0.60-1.01) 0.055 
Non AF 461/3072 (15.0%) 325/2388 (13.6%)   
OR (95% CI)  1.08 (0.89-1.31) 1.07 (0.83-1.37)   
P-Value 0.443 0.607   
 
When analysing outcome on the full scale mRS day 90 no interaction was found between 
treatment with thrombolysis and age among those with history of AF (p=0.671). Figure 
3-7 (A) shows how the treatment effect of thrombolysis changes as age increases 
(adjusted for baseline NIHSS) for those with history of AF. 
The presence of AF was possibly associated with more favourable outcome among 
younger patients and less favourable above approximately 75 years, after adjusting for 
baseline NIHSS and treatment with thrombolysis (illustrated in Figure 3-7 (B)). The 
interaction between AF and age had borderline significance (p=0.010). 
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Figure 3-7: Odds of more favourable outcome across the full range of 90 day 
mRS for each year of age. This is presented (A) in patients with AF, contrasting 
outcomes in patients treated with thrombolysis versus not and (B) in all 
patients, contrasting outcomes for patients having AF versus normal rhythm. 
3.3.4. Discussion 
Despite being older and more severely affected, and thus at risk of poorer outcome than 
non-AF patients, stroke patients with AF had better outcome at 90 days when treated 
with thrombolysis than their untreated peers. No interaction between AF and 
thrombolysis treatment on outcome was found.  Our results were supported by the range 
of secondary dichotomised measures that we examined. 
However, it has to be stressed that this postulation just is valid for the group of AF 
patients as a whole. When looking at the interaction of age and AF on stroke outcome 
across the entire age range, our data indicate that AF seems to have a beneficial effect in 
young and a negative effect in elderly patients. This is in line with prior studies showing 
that age has an independent and additive effect on the hypercoagulable or prothombotic 
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state in AF285-286. Nevertheless, it remains unclear why in the present sample AF seemed 
to have a beneficial effect in younger stroke patients.  
It remains important to acknowledge that an analysis of non-randomised registry data, 
whether or not derived from trials, inevitably incorporates selection bias for thrombolytic 
treatment and other confounders. These have been previously discussed241. 
It is important to note that many subjects who present with medical history of AF at 
stroke onset may currently be on anticoagulants such as Warfarin. Current treatment 
with anticoagulants can increase the risk of a secondary bleed and in turn may influence 
the decision to thrombolyse. This could lead to the non-thrombolysis group within the AF 
population being those who are potentially at higher risk of complications.  Further work 
investigating the relationship between anticoagulant therapy and thrombolysis within the 
AF population is currently being conducted within VISTA.      
3.4. Conclusion 
In summary, these data lend support to the use of thrombolysis across all age groups of 
stroke patients with history of atrial fibrillation within approximately 3.5h after stroke 
onset. AF appears to be a marker of high age and baseline NIHSS rather than an 
independent risk factor for poor stroke outcome, and has no discernible impact on the 
effect of thrombolysis.  
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Chapter 4  
Effect on study sample size 
of an extended time window 
for initiation of neuro-
restorative therapy 
4.1. Background 
Functional outcome after acute stroke, such as modified Rankin Scale score after 90 days, 
is highly variable129-130.  This reflects diversity in location and extent of initial brain 
damage, variation in age and comorbidities that influence potential for recovery, 
imprecision of the tools available to assess clinical status, and the inherently 
unpredictable clinical course in the hyperacute period of stroke.  The first few hours after 
an ischaemic insult are characterized by substantial rates of complete recovery, but a few 
patients progress to coma or death. Certain measures of residual disability at 90 days 
such as Barthel Index reflect this as a bimodal distribution. Prognostic indicators of 
outcome available in the early hours after a stroke lack precision and reliability. 
In the absence of perfect predictions of outcome, acute stroke trials will have 
inadvertently included patients who have little prospect to benefit from investigational 
therapy. Moreover, the reliance on statistically less powerful dichotomisation analyses in 
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many instances further compromises trial power, compared to use of continuous 
variables.   
This combination of imprecise patient selection and weakened endpoint analysis inflates 
the sample sizes for stroke trials assessing early interventions. This renders proof-of-
concept, or “early phase” trials unattractively expensive, or unreliable if underpowered. 
In turn, this limits the opportunities to explore novel treatments and increases the risk 
that small but useful therapeutic advances are missed. 
Thrombolytic or neuroprotective agents administered to reduce the impact of ischaemic 
stroke must be given soon after the acute episode to prevent irreversible neuronal loss. 
However, a restorative treatment modality that can enhance recovery of surviving 
neurons may have applicability even if initiated after more severely compromised cells 
have already suffered irreversible damage or death. In contrast to neuroprotective 
strategies, restorative strategies may offer potential benefit if initiated later during the 
ischaemic cascade, for example 24-48 hrs after stroke onset. We aimed to investigate 
whether deferred selection of patients and outcome analysis that is adjusted using later, 
more reliable, estimates of prognostic factors would enhance trial efficiency, where the 
mechanism of treatment offers biological support for this strategy.  
4.2. Data source and patients 
We used the following individual patient data from the Virtual International Stroke Trials 
Archive (VISTA) for patients with ischaemic stroke enrolled in trials conducted between 
1998 and 2008 204: National Institutes of Health Stroke Scale (NIHSS) score within 6h of 
stroke onset and at 24h; modified Rankin Scale score recorded at 90 days; age; exposure 
to iv thrombolysis (or not) as standard of care. We accepted only patients who had no 
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investigational drug administered that has a confirmed influence on stroke outcome (i.e. 
non-significant trials testing neuroprotectants and only placebo patients from 
thrombolysis trials). We excluded patients missing baseline NIHSS, age or mRS day 90 
unless due to death, which was recorded as mRS grade 6 and NIHSS 42. 
4.3. Outcome measures 
The key efficacy endpoint of interest was the full range of the modified Rankin scale at 90 
days.  
4.4. Methods 
4.4.1. Statistical analysis 
We examined the relation between initial stroke severity and final outcome, contrasting 
predictions from NIHSS measured at <6h from stroke onset with those from the NIHSS 
collected after 24h. We sought to determine whether NIHSS scores from either time point 
provided more robust associations with 90 day mRS.    We did so by examining the 
coefficient of determination (r2) from basic correlations of NIHSS with mRS. The 
Spearman rank correlation coefficient was used to account for the ordinal nature of the 
mRS. Two different restrictions of NIHSS were used, 4-20 and 7-20. This allows 
investigation into a more restricted range for inclusion. 
Ordinal analysis of the mRS to investigate the relationship between each NIHSS time point 
and mRS at 90 days was performed using logistic regression with the proportional odds 
model, significance was measured using the Cochran Mantel Haenzsel test. Analysis was 
adjusted for age and treatment with thrombolysis.  
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This analysis was initially performed on the entire data including thrombolysed patients. 
However as the 24h NIHSS will already be subject to the initial tPA treatment effect, 
further analyses were performed investigating the two groups separately. Note that trial 
centres may have applied additional selection criteria within the first 3-4.5h from stroke 
onset before offering thrombolytic therapy.  
4.4.2. Simulation method 
The goal was to simulate a treatment effect using VISTA data that was approximately half 
that typically observed due to thrombolytic therapy administered within 91-180 minutes 
of stroke onset.  The distribution of mRS for this treatment time is shown in Figure 4-1. 
This treatment effect shows an improvement in mRS 0-2 of 10.8% with treatment and a 
decrease of 9.8% in mRS 3-6.  Half of this is an increase of approximately 5.4% in mRS 0-2 
and a decrease of 4.9% in mRS 3-6. 
 
Figure 4-1: Distribution of mRS for treatment with tPA 91-180 minutes 
We undertook simulations in a similar manner to those performed by Young et al234 287 to 
model the sample size required to detect an improvement in overall mRS distribution 
equivalent to a 5% absolute difference in proportion achieving mRS 0-2 versus 3-6, setting 
power at 80% and assuming adjustment for entry age and NIHSS. Baseline NIHSS criteria 
of 4-20 and 7-20 were each investigated.  
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Using R statistical programming language, 10,000 mock trials were simulated for each 
NIHSS entry range. For each trial, a selected number of patients (2*n) were sampled from 
all eligible data, without replacement. This generated control and treatment groups of 
size n with similar baseline distributions for age and NIHSS at entry. For the treatment 
group a treatment effect was generated. To avoid biasing the adjusted analyses, the 
treatment effect was simulated using 90 day mRS rather than baseline covariates. The 
method for generating a treatment effect is outlined in Figure 4-2 and described below.   
For each subject in the treatment group ti (i=1,....,n) another subject mi was matched  
with the probability of having 1 point lower mRS at 90 days (the probability selected here 
was 30%). The new treatment subject with simulated outcome is composed of the 
baseline variables from the subject ti and outcome variables from the matched subject mi, 
illustrated in Figure 4-2. 
For each simulated trial, analysis was performed using ordinal methods to take into 
account the full scale of the mRS. Logistic regression using the proportional odds model 
was performed to assess the effect of (simulated) treatment on outcome adjusted for 
entry NIHSS used for inclusion and age. The significance level for the simulated treatment 
effect along with OR for treatment and the distribution of mRS within each group 
(treatment and placebo) were recorded.  
Within each set of simulations, the sample size was gradually reduced until power settled 
to 80%, thus allowing estimation of the required sample size under each data restriction. 
Patients who had received acute thrombolytic treatment as standard care were 
considered independently. This treatment would likely influence the NIHSS score over the 
first 24h. 
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Figure 4-2: Flowchart outlining the method for generating a treatment effect 
within each of the simulated trials. 
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Figure 4-3: Flowchart outlining the method of trial simulation 
4.5. Results 
4.5.1. Preliminary analysis 
VISTA provided data on 7636 patients who met our criteria, with mean age 68 ± 12; <6h 
median NIHSS 12 (IQR 8-17); 24h NIHSS 9 (5-15); 3316 (43%) had been treated with 
thrombolysis.  Limiting the sample with each NIHSS restriction yields the altered samples 
given in  
 
New treatment group with 
simulated treatment effect 
generated as shown above 
Desired baseline restriction 
All subjects 
 
Randomly select n patients 
from available data 
Placebo group 
 
Randomly select n patients 
from available data 
Treatment group 
 
Simulated trial size 2n 
 
Analysis of trial 
p-value(p) obtained from 
adjusted analysis 
Repeat 
10,000 times, 
generating 
10,000 trials 
Power calculated as the 
proportion of times a significant 
result is found or 1- β. 
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Table 4-1 below. Note here that the sample contains both thrombolysed and non-
thrombolysed patients. 
 
Table 4-1: Descriptive statistics of each restriction. N denotes number of 
observations, N* denotes number of missing observations. 
Descriptive statistics for labelled NIHSS measurement 
NIHSS restriction  N N* Std dev Mean Median Max Min 
<6h NIH 4-20 6841 0 4.3 11.9 11.0 20 4 
24h NIH 4-20 4436 0 4.7 10.3 10.0 20.0 4.0 
<6h NIH 7-20 6137 0 4.0 12.6 12 20 7 
24h NIH 7-20 3200 0 4.0 12.4 12.0 20.0 7.0 
 
While using 24h NIHSS as opposed to NIHSS measured in the hyperacute phase (<6h) 
reduces the available sample it was postulated using this time-point would be more 
highly associated with outcome. This was investigated in Table 4-2 below. 
Table 4-2: Ordinal analysis result assessing the predictive ability of labelled 
baseline on mRS at 90 days adjusted for age and treatment with thrombolysis 
Baseline 
restriction of data 
Correlation (R
2
) 
Baseline measure 
with mRS 
OR  for NIH measure 
adjusted for age and rtPA 
Upper 95% CI 
for OR 
Lower 95% CI 
for OR 
<6h NIH 4-20 0.44(0.19) 1.23 1.22 1.25 
24h NIH 4-20 0.58(0.34) 1.31 1.29 1.33 
<6h NIH 7-20 0.40(0.16) 1.21 1.20 1.24 
24h NIH 7-20 0.48(0.23) 1.27 1.25 1.30 
 
In Table 4-2 it is clear that for both restrictions, 24h NIHSS is more highly correlated with 
outcome than the <6h hyperacute measurement. This suggests that 24h NIHSS is a more 
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predictive measurement to use for trial admission provided the treatment permits a later 
time window. When restricted within 4-20, 24h NIHSS correlated more closely than <6h 
with 90 day mRS.  With r2 values of 0.34 and 0.19 respectively, as shown in Table 4-2,  24h 
NIHSS explains 15% more of the absolute variation in 90 day mRS than <6h NIHSS. 
Narrowing the restriction of NIHSS reduces this difference to 7%.  
The odds ratios given in this table suggest that 24h NIHSS is a more powerful predictor for 
mRS at day 90 for both restrictions.  Each of the odds ratios reported represents the odds 
of tending toward worse outcome measured by mRS for every one point increase in 
NIHSS. These odds ratios suggest that 24h NIHSS restricted 4-20 is the most predictive of 
outcome at 90 days. 
Looking at Figure 4-4 and Figure 4-5 it is clear that selection of patients based on the 24h 
measurement provides a subgroup within which only a small proportion of patients are 
asymptomatic at 90 days. This is presumably because patients with early resolution over 
the period between 6 and 24 hours have been censored. 
The distributions of day 90 mRS for each time point are given in Figure 4-4 and Figure 4-5. 
These are shown for the restrictions 4-20 and 7-20 respectively. It is clear that selection of 
patients based on the 24h measurement provides a subgroup of patients within which 
there is only a small proportion who are asymptomatic at 90 days, presumably because 
patients with early resolution over the period 6-24 hours have been censored. 
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Figure 4-4: Distribution of mRS day 90 for 4-20 NIHSS restriction <6h and 24h 
NIHSS measurements 
 
Figure 4-5: Distribution of mRS day 90 for 7-20 NIHSS restriction <6h and 24h 
NIHSS measurements 
 
The data described above did not exclude those treated with thrombolysis. Results 
separated by treatment group are shown in Table 4-3 below. 
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Table 4-3: Ordinal analysis results assessing the predictive ability of labelled 
baseline on mRS at 90 days adjusted for age. Thrombolysed and non-
thrombolysed analysed separately 
Baseline restriction 
of data 
Correlation (R
2
) 
Baseline measure 
with mRS  
OR  for NIH measure 
adjusted for age  
Upper 95% CI 
for OR 
Lower 95% CI 
for OR 
<6h NIH 4-20 
Non_Throm 
0.48(0.23) 1.25 1.23 1.27 
<6h NIH 4-20 
Throm 
0.43(0.18) 1.21 1.19 1.24 
24h NIH 4-20 
Non_Throm 
0.60(0.36) 1.31 1.29 1.34 
24h NIH 4-20 
Throm 
0.57(0.32) 1.30 1.27 1.33 
<6h NIH 7-20 
Non_Throm 
0.44(0.19) 1.23 1.21 1.26 
<6h NIH 7-20 
Throm 
0.40(0.16) 1.21 1.19 1.23 
24h NIH 7-20 
Non_Throm 
0.50(0.25) 1.29 1.26 1.32 
24h NIH 7-20 
Throm 
0.47(0.22) 1.28 1.24 1.06 
 
Comparing the R2 values and odds ratios given in Table 4-3 the NIHSS measure taken in 
the hyperacute period is less associated with outcome at 90 days in thrombolysed 
subjects compared to non-thrombolysed. However when the time window is extended to 
24h the relationship with outcome matches for thrombolysed and non-thrombolysed 
patients.  
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4.5.2. Simulations 
4.5.2.1. Non-Thrombolysed only 
Simulations to assess necessary sample size determined that given a restriction of 4-20 a 
43% reduction was possible if selection was delayed until 24h (Table 4-4).   
Table 4-4: Simulation results 80% power 
Simulations to obtain 80% power based on adjusted analysis non thromblysed patients only 
Adjusted for reported  baseline and age 
Baseline 
restriction 
(Inclusion 
criteria) 
Trial size 
(assuming 
equal 
groups) 
Power 
(%) 
Adjusted OR for 
treatment 
effect 
Lower 
95% CI 
for OR 
Upper 
95% CI 
for OR 
Increase 
mRS 0-2 
(%) 
Decrease 
mRS 3-6  
(%) 
<6h NIHSS  
 4-20 
1280 80 1.319 1.311 1.327 6.1 5.1 
24h NIHSS  
4-20 
730 80 1.462 1.451 1.475 5.7 5.6 
<6h NIHSS 
 7-20 
1200 80 1.344 1.335 1.353 5.2 5.3 
24h NIHSS  
7-20 
600 80 1.528 1.513 1.542 7.0 7.0 
 
Based on generating the same treatment effect size: the sample reduces from 1280 (640 
per group) with selection <6h to 730 (365 per group) with selection at 24h, for a 5% 
absolute difference in proportion achieving mRS 0-2 and 80% power, illustrated in Figure 
4-6 and Figure 4-7. 
Given a restriction of 7-20 the reduction is increased to 50%. The simulated treatment 
effects are illustrated in Figure 4-8 and Figure 4-9.  
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Figure 4-6: Distribution of mRS day 90 for simulations using <6h NIHSS 4-20 
 
Figure 4-7: Distribution of mRS day 90 for simulations using 24 h NIHSS 4-20 
 
Figure 4-8: Distribution of mRS day 90 for simulations using <6h NIHSS 7-20 
 
Figure 4-9: Distribution of mRS day 90 for simulations using 24 h NIHSS 7-20 
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Table 4-5 shows the results to obtain 90% power; these follow the same trend as above. 
Table 4-5: Simulation results 90% power 
Simulations to obtain 90% power based on adjusted analysis non thromblysed patients only 
Adjusted for reported  baseline and age 
Baseline 
restriction 
(Inclusion 
criteria) 
Trial size 
(assuming 
equal 
groups) 
Power 
(%) 
Adjusted OR for 
treatment 
effect 
Lower 
95% CI 
for OR 
Upper 
95% CI 
for OR 
Increase 
mRS 0-2 
(%) 
Decrease 
mRS 3-6  
(%) 
<6h NIHSS  
 4-20 
1650 90 1.332 1.325 1.339 6.1 5.1 
24h NIHSS  
4-20 
930 90 1.460 1.449 1.470 5.7 5.6 
<6h NIHSS 
 7-20 
1600 90 1.340 1.333 1.347 5.2 5.3 
24h NIHSS  
7-20 
820 90 1.521 1.509 1.533 7.0 7.0 
 
If using NIHSS 4-20 as inclusion criterion, approximately 44% fewer subjects would be 
needed to obtain 90% power if the baseline measure was collected at 24h NIHSS instead 
of <6h. If using NIHSS 7-20 as inclusion criterion, this reduction increases to 49%. 
4.5.2.2. Thrombolysed only 
Among thrombolysed patients, the advantage in delayed selection was more apparent. 
Selection at <6h required a sample of 1720 (860 per group) whereas selection based on 
24h NIHSS required 660 (330 per group). Results are given in Table 4-6 below.  
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Table 4-6: Thrombolysed only simulation results to obtain 80% power 
Simulations to obtain 80% power based on adjusted analysis thrombolysed patients only 
Adjusted for reported  baseline and age 
Baseline 
restriction 
(Inclusion 
criteria) 
Trial size 
(assuming 
equal groups) 
Power 
(%) 
Adjusted OR 
for treatment 
effect 
Lower 
95% CI 
for OR 
Upper 
95% CI 
for OR 
Increase 
mRS 0-2 
(%) 
Decrease 
mRS 3-6  
(%) 
<6h NIHSS  
 4-20 
1720 80 1.271 1.264 1.278 4.8 4.9 
24h NIHSS  
4-20 
660 80 1.493 1.480 1.506 6.7 6.8 
<6h NIHSS 
 7-20 
1500 80 1.291 1.284 1.298 5.2 5.2 
24h NIHSS  
7-20 
600 80 1.538 1.524 1.551 8.1 7.8 
 
4.6. Discussion 
NIHSS recorded at 24h has a stronger relationship than hyperacute recordings with 
outcome at 90 days. The later baseline assessment explains 15% more of the absolute 
variability in outcome (an 80% relative advantage) among patients with baseline NIHSS 
scores of 4-20. This is supported by the adjusted odds ratios for initial NIHSS against final 
outcome. In contrast to earlier selection, ‘enrolment’ at 24h on the basis of an NIHSS 
range 4-20 delivers a population that includes few patients who become asymptomatic or 
die by 90 days: a higher proportion remain informative for trial purposes. 
Our simulations suggest that if delayed selection can be supported on biological grounds 
for the treatment modality under test, then sample size reductions of 43% may be viable. 
Furthermore, the data suggest that the main treatment effect of thrombolysis may largely 
occur within the first few hours after treatment and the required sample may be further 
reduced if thrombolysed cases form part of this population. Indeed, exclusion of 
thrombolysed patients would be counterproductive to such a trial, both in terms of the 
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lost sample and longer enrolment period and because these patients are at least as 
informative as the non-thrombolysed group. 
Overall, the analysis presented suggests that trial selection and analysis based on a 
delayed measurement of NIHSS selects a population in whom untreated outcome is more 
predictable and may allow trial samples to be reduced by 35-40%. We found statistical 
value in extending the window towards 24 hours. 
Extending the time window for patient selection provides a measurement which has a 
stronger more predictive relationship with outcome. This subsequently allows a larger 
population to benefit from treatment. Such extension of the time window must be 
balanced against any anticipated decay in biological effect of the treatment with 
increasing delay from stroke onset. However, with recent interest in neurorestorative 
treatments, as discussed by Steven Cramer288, any strategy that can limit the cost of proof 
of concept trials is desirable. Public access data show two such trials currently in phase II 
study; ISIS289 and extended release Niacin (Niaspan©)290.  
Our simulation approach derives strength from the large number of samples taken 
(10,000) and from the large, independent dataset used as source.  As the treatment effect 
here was simulated, we cannot make definite conclusions about the sample size, just 
recommendations. Ideally this would be tested on a population in whom there is a known 
treatment given after 24h with a comparative baseline population; however this appears 
impossible to validate due to the lack of applicable data available from current stroke 
trials. Since the adjusted and unadjusted analyses predicted comparable sample sizes, it 
appears that the statistical power advantage derives mainly from improved selection 
rather than improved covariate adjustment. 
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While trial selection and analysis based on a delayed measurement of NIHSS may allow 
trial samples to be reduced 35-40%, such an extension of the time window must be 
balanced against any anticipated decay in biological effect of the treatment with 
increasing delay from stroke onset.  
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Chapter 5  
Selection for Treatment 
Based on a Prognostic Score 
5.1. Background 
Treatment of patients with acute cerebral ischemia using intravenous thrombolysis is safe 
and effective if initiated within 3h96 or 4.5h98 of stroke onset.  There is evidence from RCT 
and pooled analysis of individual patient data to suggest that the conditions of use may 
be conservative and that additional patients treated within 6h may benefit171.  However, 
there is also evidence from the pooled data analysis to suggest that other patients may be 
harmed by initiation of treatment within OTT range 4.5-6h171.  Absolute mortality is 4.8% 
higher with thrombolysis treatment than placebo among patients treated at OTT within 
4.5-6 h (p=0.05), and favourable outcome is 1.8% better (P=Non-significant).  Thus, at 
these later OTT, it is unknown whether only a few patients are harmed and few benefit or 
whether a much larger group of patients benefit but harm offsets this benefit in a 
commensurately greater number.   
There is considerable interest in exploring enhanced methods of patient selection, in 
order to identify subgroups of patients who may derive benefit at later OTT without 
suffering harm.  Imaging approaches using mismatch of perfusion and diffusion weighted 
magnetic resonance scans, or CT perfusion scans, are under study.  So far, these have not 
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led to changes in routine clinical practice though trials are still underway or in planning 
stages.   
An alternative approach that has not been adequately explored, but which extends the 
principles underlying marketing authorisation for intravenous thrombolysis use in stroke 
in Europe, is to select patients for treatment based on their inherent prognosis.  Thus, 
since we are aware that symptomatic intracerebral haemorrhage (SICH) carries with it an 
elevated risk of death or severe disability, and since we know that exposure to 
intravenous thrombolysis enhances the odds of SICH by around 4-fold, we aim to avoid 
treating patients who have a high absolute risk of SICH without thrombolysis.  We do so 
because a four-fold increase in odds of a common event leads to a much higher absolute 
increase in risk than a fourfold increase in odds of an uncommon event.  For example, if 
the background rate of SICH is 1% and the odds ratio for SICH with thrombolysis 
treatment is 4, then the absolute SICH rate may be 4%, an absolute increase in risk of 3%.  
Alternatively, if the background rate of SICH were 2% then an odds ratio of 4 would 
elevate the absolute risk under thrombolysis to 7%, which is an absolute increase of 5%.   
These remain relatively small risks, but once we start dealing with common events such 
as death or disability, these influences of untreated prognosis can have a more profound 
effect on net treatment outcomes.  Thus, a population with an expected untreated 
mortality of 20%, exposed to a drug that increases odds of death by 50% (odds ratio 1.5), 
is likely to show mortality of 27% with treatment (an absolute excess of 7%).  If we can 
separate that population into two groups, one with expected mortality of 10% and one 
with expected mortality of 30%, then the absolute excess of deaths in these two groups 
should be under 5% in the former and 9% in the latter.  Couple that with matching effects 
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on independence, and we may be able to demonstrate a net beneficial effect that is not 
outweighed by the absolute excess of harm. 
We hypothesised that we could generate patient selection criteria for thrombolysis using 
a prognostic score based on simple clinical measures, developing optimal selection 
criteria using cohorts from an observational dataset of treated and untreated patients, 
and that we could validate our criteria within a separate existing dataset of pooled RCT 
data.  
Due to the absence of available data on patients treated with thrombolysis after 4.5h, it 
was necessary to disregard OTT for the development and initial testing of our strategy. In 
light of the assumptions we had to invoke in generating our selection criteria, we planned 
prospective validation among patients treated in the 4.5-6h time window from the RCT 
pooled dataset.  Our objective was to demonstrate a net benefit from treatment after 
offsetting any harm, with intravenous thrombolysis initiated 4.5-6h from stroke onset 
using simple clinical measures. 
5.2. Methods 
5.2.1. Data source and patients 
For the development phase we gathered demographics, clinical data and functional 
outcome measures from neuroprotection trials in ischaemic stroke conducted in the 
period 1998 to 2007. We obtained our data, anonymised in relation to patients and trials, 
from the Virtual International Stroke Trials Archive (VISTA)204. We excluded trials that had 
tested effects of thrombolysis or of any drug now known to influence outcome after 
stroke. We retained patients who received intravenous thrombolysis as standard care, at 
the time of analysis information on the time of administration of thrombolysis was 
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unavailable but within the data was known to be <3h. Trials included within VISTA 
stipulated only basic imaging requirements for patient eligibility and did not routinely 
record detailed imaging parameters. These patients formed our “VISTA thrombolysis 
group”, and were complemented by VISTA patients who were managed without 
thrombolysis, “VISTA controls”. Finally, we excluded patients who lacked relevant 
baseline and outcome information: enrolment National Institutes of Health Stroke Scale 
score (NIHSS), age, modified Rankin score (mRS) day 90 and NIHSS day 90. Death was 
recorded as mRS grade 6.  
For the validation phase, we used the pooled individual patient data from the published 
randomised trials of thrombolysis98 166-171 291. These data have been described 
previously171 and trials included patients based on a defined onset time of stroke <6h and 
a CT scan to exclude haemorrhage. 
It is important when performing such analyses that separate data are used for the 
development stage and the validation stage, first to avoid data mining and second to 
ensure the methods are applicable externally. 
5.2.2. Outcome measures 
Our primary outcome measure was mRS, analysed as an ordinal scale, with 
dichotomisation at mRS 0-1 v 2-6, and mortality (0-5 vs. 6) as secondary endpoints. 
Symptomatic haemorrhage, defined as parenchymal haemorrhage type 2 (PH2) was also 
a secondary outcome166. Due to lack of data on parenchymal haemorrhage within VISTA, 
PH2 was only used as a secondary outcome within the validation analysis.  
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5.2.3. Protocol 
We conducted our study according to a pre-specified analysis plan shared with the VISTA 
steering committee and RCT investigators. We completed the development phase and 
declared our results including prognostic thresholds before accessing the RCT data for 
validation. As we were working with existing anonymised data, we did not require ethical 
review under institutional rules. 
5.2.4. Exploratory analysis 
Rather than developing a new prognostic score we chose to use a score which had been 
previously published and validated on different datasets, ensuring a robust and reliable 
analysis. Weimar et al143 had developed a score to describe probability of functional 
independence after ischaemic stroke, using age and baseline NIHSS score. This prognostic 
score has been validated by Köenig et al on data from VISTA141 and can be summarised in 
the formula Score=145-0.46*age-2.5*NIHSS. The authors limited the score to these two 
variables after rigorous analysis showing no other assessed factor to be an independent 
predictor of outcome alongside age and baseline NIHSS. Trials included within VISTA 
stipulated only basic imaging requirements for patient eligibility and did not routinely 
record detailed imaging parameters: we could not incorporate imaging data to the 
prognostic score. We chose this validated score for its simplicity, practicality and 
relevance to our data. 
We ranked patients in the VISTA thrombolysis versus control dataset according to 
prognostic score, and generated ROC curves for benefit on each cut-point of mRS by 
selecting cut-offs across this range.  After exploratory work confirming expected 
outcomes according to case mix distributions and treatment effects in patients treated 
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with thrombolysis within 3 hours OTT versus control, we estimated likely effects in a 
population treated between 4.5 and 6.0 hours OTT as follows. 
5.2.5. Development of prognostic score thresholds 
We began with the known distribution of mRS outcomes for a thrombolysed versus 
control population treated 4.5-6h after stroke onset as shown in Figure 5-1, taken from 
the recent published analysis of pooled RCT data171. As onset time of thrombolysis was 
not recorded in VISTA though required to be within 3h of stroke onset, we needed to 
generate a development population which would be comparable to the RCT data for 
later-treated patients171. We populated a training dataset from VISTA to match the known 
distribution of outcomes in the 4.5-6h treated group: on the basis of their 90-day mRS, 
500 VISTA control patients and 500 VISTA thrombolysis patients were selected at random 
to supply the correct number of patients within each outcome category to match those of 
the pooled RCT data171. We did not permit prognostic factors of these patients to 
influence their selection. This generated a ‘VISTA trial population’ of 1000 patients who 
had outcomes that almost exactly matched the known outcomes of late-treated RCT 
patients, differing appropriately between thrombolysis and control groups. This sample 
was used for all further first stage analyses. 
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Figure 5-1: Distribution of mRS scores from pooling analysis by Lees et al
171
 for 
patients treated above 4.5h. 
We ranked patients in the VISTA trial population according to their prognostic score. We 
then excluded patients with the worst prognosis and at the other end of the range also 
excluded patients with the best prognosis, effectively applying a prognostic score 
“window”, within which we retained the patients in our treatment sample.  We hoped to 
maximise the size of this retained sample, since statistical power is partly driven by 
sample size; but also to maximise the treatment effect size through exclusion of “minimal 
responders”, since statistical power is also driven by the extent of the effect. We assumed 
that the optimal window of prognostic scores for identifying our study sample would 
represent a compromise between those that delivered a large sample with modest 
average treatment effect versus criteria delivering a small sample deriving a large 
treatment effect.  
We used an iterative approach to select the optimal prognostic score window, first to 
identify a patient sample that had a treatment benefit identifiable at a statistical 
threshold of p<0.05 and then a more restricted dataset with benefit detectable at p<0.01.  
Using logistic regression with the proportional odds model, adjusting for age and baseline 
NIHSS, we generated odds ratios for more favourable mRS between thrombolysed and 
control groups for each selected (better predicted outcome) or excluded (poorer 
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outcome) population, with 95% confidence intervals. Significance was assessed by 
Cochran Mantel Haenszel (CMH) test. 
Focussing on limits that appeared likely to select a group of patients with moderate 
prognosis in whom the treatment effect of thrombolysis may be optimal, we then sought 
to optimise the sample.  Our strategy was to keep the selection criteria as wide as 
possible, since this would maximise the population benefit and the sample size, thereby 
delivering both statistical power and clinical relevance; but we also sought to ensure that 
our final sample was likely to show a statistically significant net benefit, and for this we 
had to limit inclusion to patients in whom odds of net benefit would be larger.  We 
recognised that our training dataset would likely differ from the RCT population in certain 
respects and that any choice of prognostic score limits may be only preliminary.  We 
therefore base our final choice of prognostic score limits on those that maximise the 
sample whilst still delivering a significant net treatment benefit at p<0.01, ie the 99% 
confidence interval for the odds ratio estimated by ordinal regression does not 
encompass 1.0.   
5.2.6. Validation procedure 
We supplied the chosen prognostic score thresholds to an independent statistician who 
undertook CMH test, ordinal logistic regression and dichotomised analysis of the 
individual patient data from the pooled RCT for patients treated 4.5-6h from stroke onset.  
Results are expressed as odds ratios and 95% CI for more favourable mRS distribution 
under thrombolysis versus control, with p values from CMH test. Secondary dichotomised 
outcomes (mRS 0-1, mortality and PH2 rate) were analysed as previously described 171. 
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We ran exploratory analyses among 3-4.5h and 0-3h (0-90’ and 91-180’ combined) groups 
in a similar manner, recognising that here the small sample sizes undermined power. 
5.3. Results VISTA stage 
5.3.1. Prognostic score validity 
Table 5-1 to Table 5-4 display the cross tabulations of prognostic score against mRS 
category for various VISTA populations, before selection according to the prognostic 
score. Figure 1 shows the ROC curves for identifying good prognosis according to each of 
the possible dichotomisations of mRS (0 versus 1-6 through 0-5 versus 6).  
Table 5-1: Descriptive statistics of prognostic score applied to VISTA data for 
entire dataset, control and thrombolysis 
Group N Mean Median Minimum Maximum Lower 95% 
CL for Mean 
Upper 95% 
CL for Mean 
All data 8692 79.97 82.00 14.00 122.00 79.62 80.31 
Control 6166 80.53 83.00 14.00 122.00 80.11 80.94 
Thrombolysis 2526 78.59 79.00 20.00 118.00 78.00 79.19 
 
Table 5-2:Descriptive statistics of prognostic score by mRS grade for the full 
dataset 
mRS 
 grade 
N Mean Median Lower 95% 
CL for Mean 
Upper 95% 
CL for Mean 
0 979 92.16 94.00 91.41 92.92 
1 1475 90.37 93.00 89.75 90.99 
2 1106 87.11 89.00 86.35 87.87 
3 1246 80.90 82.00 80.15 81.66 
4 1656 75.18 76.00 74.54 75.81 
5 687 66.73 66.00 65.71 67.75 
6 1543 67.44 66.00 66.70 68.18 
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Table 5-3: Descriptive statistics of prognostic score by mRS grade for patients 
not treated with thrombolysis 
mRS 
 grade 
N Mean Median Lower 95% 
CL for Mean 
Upper 95% 
CL for Mean 
0 664 93.64 95.00 92.76 94.51 
1 1039            91.74            93.00            91.02            92.46 
2  735            88.58            90.00            87.68            89.48 
3  855            82.18            84.00            81.28            83.08 
4  1191            76.06            77.00            75.30            76.83 
5  514            66.48            66.00            65.28             67.68 
6  1168            67.56            67.00            66.69            68.42 
 
Table 5-4: Descriptive statistics of prognostic score by mRS grade for patients 
treated with thrombolysis 
mRS 
grade 
N Mean Median Lower 95% 
CL for Mean 
Upper 95% 
CL for Mean 
0  315  89.06                        91.00            87.65            90.48 
1 436    87.11                    88.00            85.94            88.28      
2  371 84.19            86.00            82.83            85.55 
3  391 78.11            79.00            76.76            79.47 
4  465              72.90            73.00            71.79            74.01                    
5  173 67.45            67.00            65.50            69.40             
6  375 67.06            66.00            65.64            68.48 
 
These simple descriptive statistics show an association between prognostic score and 
outcome, with thrombolysis treatment influencing this association. Within both treated 
and untreated groups, the mRS at day 90 increases as the prognostic score at baseline 
decreases. In Table 5-3 and Table 5-4  it is evident that patients treated with thrombolysis 
achieve lower mRS scores despite lower prognostic scores at baseline, highlighting the 
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treatment effect. For example in the placebo group the average prognostic score among 
patients with a 90 day mRS of 2 is 88.6 whereas the average prognostic score among 
treated patients attaining a 90 day mRS of 2 is 85.6. 
The ROC curves in Figure 5-2 demonstrate that the prognostic score has a comparable 
association with each mRS grade, underlining the proportionality of the relationship in 
the overall population. 
 
Figure 5-2: ROC curves showing the sensitivity and specificity corresponding to 
prognostic score as a test for outcome measured by dichotomised mRS day 90 
5.3.2. Choice of selection criteria based on prognostic score 
From the VISTA dataset we sampled 1000 patients for our trial population to match the 
outcome distributions in the RCT data171. Their baseline characteristics were, control: Age 
69 ± 13, baseline NIHSS 10 IQR 7, 16; Thrombolysis: Age 68 ± 13, baseline NIHSS 13 IQR 9, 
18. 
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Table 5-5 shows the most promising boundaries of prognostic score for selection of a 
population that appeared to benefit from thrombolysis. This was based on a significance 
level of 0.01, with 99% confidence intervals calculated. Figure 5-3 shows the distribution 
of day 90 mRS for the VISTA sample contained within this group, these boundaries show 
net benefit for treatment with thrombolysis (OR=1.41, p=0.008) but still retains a large 
proportion of the original sample.  
Figure 5-4 and Figure 5-5 illustrate the distribution of mRS for those above and below the 
prognostic interval respectively.  These figures illustrate the ability of the prognostic 
boundaries to exclude those who are predominantly asymptomatic at 90 days and those 
who are severely symptomatic at 90 days. 
Table 5-5: Finding boundaries of prognostic score above and below which 
thrombolysis should not be given, with 99% confidence limits and significance 
level of 0.01 
Lower 
Prog Cut  
Upper 
Prog cut  
Total in 
group 
OR for more 
favourable 
mRS  
Lower 
99% CI  
Upper 
99% CI  
CMH   N given 
Thrombolys
is  
N 
  Controls 
53  98  801  1.388  1.00  1.926  0.0219  421  380  
54  98  790  1.383  0.994  1.925  0.0226  416  374  
54  97  774  1.374  0.985  1.919  0.0413  409  365  
55  97  767  1.382  0.988  1.933  0.0413  405  362  
55  96  746  1.429  1.017  2.008  0.0143  395  351  
56  96  738  1.427  1.014  2.008  0.0100  390  348  
56  95  714  1.412  1.000  1.998  0.0080  380  334  
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Figure 5-3: Distribution of mRS for those between prognostic cut-off of 56 and 
95 N=714 control=334 Thrombolysis=380, OR=1.412, 99% CI = (1.000, 1.998) 
 
Figure 5-4: Distribution of mRS for those above cut of 95 N=201 control=125 
Thrombolysis=76, OR=0.961, 99% CI = (0.470, 1.964) 
 
Figure 5-5: Distribution of mRS for those below cut of 56 N=85 control=41 
Thrombolysis=44, OR=0.954, 99% CI = (0.334, 2.726) 
Odds of favourable outcome were investigated for secondary outcomes and are given in 
Table 5-6. Significance was assessed at a level of 0.01 with 99% CI’s calculated. 
Dichotomised mRS at both 0-1 and 0-2 show increased odds of favourable outcome given 
treatment with thrombolysis.  
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Table 5-6: Binary regressions for different mRS dichotomisations. Data 
between chosen boundaries of 56 and 95, looking at 99% CI 
mRS cut OR for 
rtPA  
Lower 99% 
CI 
Upper 
99% CI 
CMH 
significance  
% excess or 
deficit(-) of 
thrombolysis 
group 
0-1 vs. 2-6 1.977 1.238 3.155 0.0036 9.33 
0-2 vs. 3-6 1.743 1.129 2.691 0.0262 7.55 
Mortality 0.707 0.374 1.336 0.2209 -3.5 
 
This was then repeated to find wider prognostic boundaries showing significance at the 
5% level. These boundaries were found to be prognostic scores of 47 to 104. The 
distribution of the mRS for those contained within these boundaries is given in  
Figure 5-6. This interval is more inclusive than the first calculated as it contains around 
90% of the sampled population. These boundaries showed a net benefit of thrombolysis 
treatment, giving odds of favourable outcome OR=1.264 with 95% CI (1.003, 1.593), CMH 
p-value=0.024.  Figure 5-7 and Figure 5-8 show the distribution of mRS for those above 
and below the interval respectively. This shows a similar trend to the initial boundaries, 
excluding those who are asymptomatic and severely symptomatic at 90 days. 
 
Figure 5-6: Distribution of mRS for those between prognostic cut-off of 47 and 
104 N=937 control=462 Thrombolysis=475, OR=1.264, 95% CI = (1.003, 1.593) 
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Figure 5-7: Distribution of mRS for those above cut of 104 N=43 control=27 
Thrombolysis=16, OR=0.782, 95% CI = (0.190, 3.212) 
 
Figure 5-8: Distribution of mRS for those below cut of 47 N=20 control=11  
Thrombolysis=9, OR=1.384, 95% CI=(0.199, 9.645) 
 
Table 5-7: Binary regressions for each cut of mRS. Data between chosen 
boundaries of 47 and 104, looking at 95% CI 
mRS cut OR for 
rtPA  
Lower 95% 
CI 
Upper 
95% CI 
CMH 
significance  
% excess or 
deficit(-) of 
thrombolysis 
group 
0-1 vs. 2-6 1.671 1.223 2.284 0.007 2.65 
0-2 vs. 3-6 1.536 1.133 2.083 0.054 1.01 
0-5 vs. 6 0.643 0.415 0.995 0.136 -5.22 
 
From this exploratory work we identified the prognostic score range of 56-95 inclusive as 
delivering a population who may derive treatment benefit, significant at p<0.01 and 
representing over 70% of the available patients. Wider limits of 47-104 inclusive retained 
approximately 90% of the population and appeared to offer benefit significant at p=0.05. 
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5.4. Conclusions from preliminary analysis 
From preliminary analysis performed on the VISTA data, it would appear that adequate 
initial boundaries of prognostic score to apply to the pooling dataset would be 56 and 95. 
This encapsulates around 85% of the sample selected to match those outside the 4.5h 
time window in the pooling dataset.  Secondary boundaries to apply to this dataset are 47 
and 104. 
However, as this analysis has been performed on data for which the time window for 
thrombolysis treatment has not been given and is known to be below 4.5 h when applying 
the prognostic scores to the real data these boundaries may narrow further. 
5.5. Results of validation analysis 
The pooled RCT data consisted of 3670 patients, of whom 1120 were treated between 4.5 
and 6h with thrombolysis or placebo, patient demographics as previously described 171. 
When applied to the 1120 patients in the pooled RCT 4.5-6h dataset, score limits of 56-95 
retained 711 patients (64%) and gave OR for improved mRS distribution of 1.13, 95% CI 
0.87-1.47, CMH p=0.89. The distribution of mRS scores for this population is given in 
Figure 5-9. More patients treated after 4.5h who fulfilled the score limits achieved mRS 0-
1 (OR 1.44, 1.02-2.05, p=0.04) than in the overall population (OR 1.15, 0.88-1.51, p=0.30). 
However PH2 bleeds showed a trend to increase further, from OR 7.67, 2.99-19.7, p 
<0.0001 to OR 15.6, 3.7-65.8, p=0.0002. The OR for elevated mortality observed in the 
overall population was not limited by applying the selection score, the confidence interval 
simply widening: from 1.58 (1.07-2.33) p=0.02 the OR for mortality became 1.56, (1.01-
2.40), p=0.04. 
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The wider prognostic boundaries of 47-104 gave ordinal OR 1.13 (0.90-1.41, CMH p=0.40) 
in 988 patients (88%) The distribution of mRS scores for this population is given in Figure 
5-10. 
 
Figure 5-9: mRS distribution in pooled data with prognostic cut-points of 56-95 
applied. 
 
Figure 5-10: mRS distribution in pooled data with prognostic cut 47-104 
applied. 
When applied to the 1620 patients in the pooled RCT 3-4.5h dataset, among whom there 
is known benefit171, score limits of 56-95 retained 1013 patients (63%) and gave OR for 
improved mRS distribution of only 1.05, 95% CI 0.84-1.30, CMH p=0.27. Odds of achieving 
mRS 0-1 decreased as the boundaries were applied and there was no advantageous effect 
on mortality or PH2 bleeds, shown in Table 5-8. 
When applied to the 930 patients in the pooled RCT 0-3h dataset, score limits of 56-95 
retained 624 patients (67%) and similarly offered no advantage in terms of any outcome 
as given in Table 5-8.  
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Table 5-8: Odds ratios, 95% CIs and p-values from logistic regressions. Investigating achieving mRS 0-1, mortality and the occurrence of PH2 
bleeds, all analysis adjusted for baseline NIHSS and age on admission. Score I represents the initial prognostic cut points of 56-95 and score II 
represents the secondary cut points of 47-104. 
Group (N) OR for ordinal 
analysis 
(Proportional Odds) 
(95% CI) 
P-value 
from CMH 
test  
OR (95% CI) for 
achieving 
mRS 0-1  
P-value  
mRS 0-1 
OR (95% CI)  
mortality 
P-value  
mortality 
OR (95% CI)  
PH2 Bleeds 
P-value  
PH2 
bleeds 
4.5-6h all (1118)  1.05(0.85-1.29) 0.39 1.15(0.88-1.51) 0.299 1.58(1.07-2.33) 0.02 7.67(2.99-
19.66) 
<0.0001 
4.5-6h Score I (711) 1.13(0.87-1.47) 0.89 1.44(1.02-2.05) 0.04 1.56(1.01-2.40) 0.04 15.6(3.7-65.8) 0.0002 
4.5-6h Score II 
(988) 
1.13(0.90-1.41) 0.40 1.27(0.96,1.70) 0.097 1.54(1.04-2.28) 0.03 6.71(2.60-
17.32) 
<0.0001 
3-4.5h all (1620)  1.15(0.97-1.37) 0.022 1.30(1.04-1.63) 0.024 1.18(0.84-1.66) 0.34 3.82(1.87-
7.78) 
0.0002 
3-4.5h Score I 
(1013) 
1.05(0.84-1.30) 0.27 1.23(0.92-1.65) 0.16 1.24(0.85-1.79) 0.26 3.52(1.64-
7.55) 
0.0012 
3-4.5h Score II 
(1423) 
1.12(0.93-1.35) 0.04 1.27(0.997,1.62) 0.053 1.22(0.86-1.72) 0.26 3.82(1.81-
7.54) 
0.0003 
0-3h all (930)  1.35(1.07-1.70) 0.11 1.81(1.34-2.46) 0.0001 1.02(0.70-1.47) 0.93 7.37(2.19-
14.84) 
0.001 
0-3h Score I (624) 1.23(0.93-1.62) 0.12 1.56(1.09-2.23) 0.016 1.05(0.68-1.64) 0.82 6.37(1.84-
21.99) 
0.0034 
0-3h Score II (819) 1.37(1.07-1.75) 0.10 1.77(1.28,2.43) 0.0005 0.96(0.65-1.43) 0.85 6.42(1.87-
22.05) 
0.0032 
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5.6. Discussion 
Selection of patients for treatment initiation between 4.5 and 6h based on simple clinical 
measures developed from an observational dataset failed to deliver a population in 
whom the thrombolysis effect would be both safe and effective.  
We had postulated that by concentrating treatment among patients with low absolute 
risk of adverse outcomes, the adverse consequences of delayed treatment initiation may 
be limited sufficiently to uncover a net benefit. When we sought to validate this 
approach, we found that while favourable outcome by mRS 0-1 was improved, the risk of 
PH2 bleeds was also greatly exaggerated, and that there was no net benefit.  This mirrors 
the effects that are observed in the unselected 4.5-6h dataset171.  It is possible that our 
approach correctly identifies patients with neither a fixed deficit nor almost certain 
recovery, but that restoration of perfusion in these remaining patients simply carries 
substantial risk through bleeding. This undermines the use of “clinical judgement” to 
choose patients for delayed treatment unless the patient prefers to accept a higher risk of 
mortality to try for functional independence, because we are not able to improve the 
risk/benefit ratio for treatment within this time window by use of these simple selection 
criteria.  Indeed, our approach also failed validation in the earlier time windows. While we 
recognise that imaging could be an instructive tool, our approach here does not inform 
the debate on use of more sophisticated imaging methods for patient selection. However, 
at this stage,  perfusion-diffusion mismatch imaging has not developed sufficiently to be 
incorporated into routine practice for this purpose292. 
Our selection of prognostic score boundaries derives strength from the large, 
independent sample used to generate them, and from the clinically relevant size of the 
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selected population, around two thirds of patients who had been treated within this time 
window in the RCT. Weaknesses include the non-randomised nature of our VISTA 
treatment groups, the restriction of our prognostic score to only two variables, age and 
NIHSS, rather than including imaging parameters or other clinical variables, an absence of 
reliable data on PH2 bleeds among controls, and possibly most crucial, the absence of real 
data from treatment administered beyond 4.5h. While adding further variables such as 
blood glucose and blood pressure into the prognostic score could give a more precise 
answer these explain only a limited proportion of the variability and were previously 
discounted for the prognostic score by Weimar et al." 
 It is likely that most VISTA thrombolysis patients were treated within 3h of stroke onset. 
The natural history of NIHSS scores is for them to fall over the first hours after stroke 
onset. By using data from patients examined within 3h of stroke onset to generate a 
simulated population 4.5-6 h from stroke onset, without allowing for this average 
improvement, we will have slightly inflated our estimate of the baseline severity. 
While our analysis based on ordinal outcomes failed to deliver a population in whom 
treatment >4.5h was safe and effective, analysis based on net benefit (mRS 0-1) showed 
significance. The analysis of trial data according to net benefit has proponents and 
opponents, the latter arguing that it may conceal useful treatment effects among 
subpopulations.  Unless we can prospectively select patients for these sub-populations, 
the ordinal approach to interpretation may remain optimal as it better reflects the true 
outcome of clinical practice. 
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Chapter 6  
Day 7 NIHSS is a Sensitive 
Outcome Measure for 
Exploratory Clinical Trials in 
Acute Stroke 
6.1. Background 
Acute stroke trials typically record outcomes after at least 90 days293. Prolonged follow-up 
increases the costs and duration of trials, and risks weakening conclusions due to patient 
attrition.  To enhance efficiency of exploratory trials, there may be benefit from reliance 
on earlier assessment of outcomes, e.g. after 7 or 30 days. This may also minimise 
confounding due to unrelated adverse events. With established efficacy of recombinant 
tissue plasminogen activator (thrombolysis) on mRS at 90 days we have an opportunity to 
explore alternative approaches171 291 294.  
The NINDS thrombolysis trial group proposed 24h change in National Institutes of Health 
Stroke Scale (NIHSS) as endpoint for part 1 of their trial but abandoned this for part 2; 
they later concluded that early NIHSS measures may be more sensitive than 90 day 
measures230. This reversal of choice for the NINDS trials, the conflicting rank order of 
power in subsequent endpoint analysis work and a general acceptance that sustained 
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functional benefit should be demonstrated in pivotal trials may together account for the 
limited implementation of their suggestion.  
Nevertheless, if earlier outcome measures are more sensitive to treatment effects than 
90 day mRS, they should be implemented in exploratory trials. We investigated the 
sensitivity of 7 day NIHSS score and 30 day mRS to the established treatment effect of 
thrombolysis on 90day mRS, to inform their validity as endpoints in clinical trials in acute 
stroke.  
While simulated trials based on registry data can generate useful hypotheses, non-
randomised data are open to several sources of bias. Any conclusions should be validated 
on an external dataset in which treatment with thrombolysis has been randomised. If 
validated, application of an earlier endpoint such as 7 day NIHSS into exploratory stroke 
trials could potentially reduce cost and increase power. This approach may be of 
particular benefit with treatments that show efficacy rapidly; such as reperfusion 
strategies. We sought to validate our hypothesis using data from published randomised 
trials of thrombolysis in acute ischaemic stroke.8  
6.2. Methods 
6.2.1. VISTA Analysis 
6.2.1.1. Data source and patients 
Data were extracted from VISTA who met overarching selection criteria on data 
availability, namely: NIHSS recorded within 6h of stroke onset and at 24h; modified 
Rankin Scale score recorded at 90 days; age; exposure to iv thrombolysis (or not) as 
standard of care; no investigational drug administered that has a confirmed influence on 
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stroke outcome (ie source trials tested neuroprotectants, not thrombolysis); date of trial 
falls within period 1998-2008. 
6.2.1.2. Statistical analysis 
We undertook a controlled comparison of thrombolysis treated patients versus untreated 
controls from VISTA. The characteristics of this database have been described 
previously237. VISTA operating procedures preclude reanalysis of randomised controlled 
trials of thrombolysis for the thrombolysis effect. Instead we considered participants from 
trials of putative neuroprotectant agents. In these trials up to 50% of patients received 
thrombolysis as part of standard care alongside the trial drug. The decision to administer 
thrombolysis was not randomised, but comparison of thrombolysis treated patients with 
untreated controls offers an approximation of thrombolysis related treatment effects that 
have previously appeared to give a valid estimate. From VISTA we considered patients 
with complete data on receipt of thrombolysis, mRS at 30 and 90 days, and NIHSS score at 
7 and 90 days. For patients known to have died during follow-up, a mRS score of 6, and 
NIHSS score of 42 were ascribed. Baseline patient characteristics were compared using 
Mann Whitney U tests for continuous variables and Χ2 tests for categorical variables. 
6.2.1.3. Simulation technique 
Multiple re-sampling was performed to assess the sensitivity of each variation of the two 
outcome measures to the treatment effect of thrombolysis. From our VISTA dataset 
10,000 random samples of patients were drawn at each of a series of sample sizes ranging 
from 1000 downwards in decrements of 10. Each sample consisted of equal numbers of 
thrombolysis treated and control patients. For every sample size, the percentage of trials 
yielding a statistically significant treatment effect was recorded. This percentage 
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approximates the statistical power of each outcome measure to detect thrombolysis 
treatment effects at that sample size.  
In testing for the treatment effect of thrombolysis our primary analysis used ordinal 
logistic regression. This compares shifts across all categories of the mRS or NIHSS rather 
than arbitrarily privileging one health state as in dichotomised analysis295. For the 
purposes of this analysis NIHSS scores were grouped into the following categories: 0 (no 
measurable deficit), 1-4, 5-8, 9-12, 13-16, 17-20, 21-24, and ≥25296.  
The EMEA Points to Consider for stroke trial design advises that ordinal analysis may be 
supported by supplementary analysis of secondary outcome measures297. In this regard 
we undertook dichotomised analysis using binary logistic regression. The power of 
dichotomous endpoints depends on case-mix and the specific treatment effect studied10. 
To find the optimal dichotomised endpoint for each outcome measure a range of 
dichotomies were included in our simulations. For mRS outcome measures we used 
excellent (mRS 0-1 vs 2-6) and good (mRS 0-2 vs 3-6) functional outcomes; for NIHSS we 
used the dichotomies 0-1, 0-1 or improvement by 8 or more points from baseline, and 0-1 
or improvement by 11 or more points from baseline. The most sensitive dichotomy for 
each outcome measure was used for comparisons. 
In all analyses we adjusted for age and baseline NIHSS score. These are established as the 
most important predictors of stroke mortality and functional outcomes298. Sensitivity 
analyses performed on the total sample found adjustment for additional variables to have 
negligible influence on the results.  
Simulations were performed using R version 2.12.1, all other analyses used PASW 18. A p-
value <0.05 was considered significant. 
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6.2.2. Validation analysis 
We included data from patients who had been enrolled and treated within 270 minutes 
of stroke onset, in any of 8 published randomised trials171. We compared thrombolysis 
treated patients against untreated controls using a multiple resampling approach known 
as bootstrapping. We repeatedly drew 1000 samples of unique patients, each time 
constraining the treated and untreated subsets (the simulated treatment groups) to be of 
equal size. A range of such sample sizes were tested. Each time we simulated a trial, we 
tested for a significant treatment effect based on outcome measures that included mRS 
day 90, 7 and 90 day NIHSS. The percentage of samples yielding significant results 
approximates the power of each endpoint at that sample size.  
The validation study followed a predefined analysis plan and was conducted by an 
independent statistician.  Missing data were handled using a last observation carried 
forward approach. 
Our primary analysis included both ordinal and binary logistic regression. The ordinal 
approach compares shifts across all categories of the mRS or NIHSS. The binary approach 
arbitrarily privileges one health state (eg mRS 0-1 versus mRS 2-6) in a dichotomised 
analysis295. In all analyses we adjusted for age and baseline NIHSS score. 
Simulations were performed in SAS 9.2. A p-value <0.05 was considered significant. 
6.3. Results 
6.3.1. VISTA Analysis 
From VISTA we obtained data on 7886 patients, of who 4712 met the data requirements 
for inclusion. 1934 (41.0%) of our sample were treated with thrombolysis. The baseline 
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demographics of our sample are shown in Table 6-1. The groups were highly imbalanced 
at baseline: thrombolysis treated patients were younger and had more severe strokes. 
Table 6-1: Baseline demographics from the VISTA data 
 thrombolysis (n= 1934) Control (n=2778) P-value for difference 
Age     
Mean (SD) 67.2 (12.8) 68.9 (12.2) <0.0001 
Median (IQR) 69.5 (18) 71 (17) <0.0001 
Male Sex 1094 (56.6%) 1485 (53.5%) 0.035 
AF 440 (22.8%) 707 (25.4%) 0.034 
Diabetes 357 (18.5%) 677 (24.4%) <0.0001 
Hypertension 1339 (69.2%) 2113 (76.1%) <0.0001 
CHF 150 (7.8%) 216 (7.9%) 0.98 
IHD 432 (22.4%) 889 (32.0%) <0.0001 
MI 254 (13.1%) 322 (11.6%) 0.112 
Prior Stroke 242 (12.5%) 623 (22.4%) <0.0001 
Baseline NIHSS    
Mean (SD) 13.6 (5.0) 11.7 (5.1) <0.0001 
Median (IQR) 13 (8) 10 (8) <0.0001 
The relationships between sample size and power for each of outcome measures, by 
ordinal and dichotomised analysis are shown in Figure 6-1 and Figure 6-2 respectively.  
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Figure 6-1: Line graph showing the relationship between sample size and 
statistical power for each of the 4 outcome measures using ordinal analysis. 
 
Figure 6-2: Line graph showing the relationship between sample size and 
statistical power for each of the four outcome measures using dichotomised 
analysis. For each outcome measure the most sensitive dichotomy was used. 
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Table 6-2 shows the minimum sample size required for each outcome measure to achieve 
statistical power greater than 80% and 90%. By both methods of analysis 7 day NIHSS is 
the most sensitive outcome measure and 30 day mRS the least. Between the two 90 day 
outcome measures, the NIHSS is modestly more sensitive than the mRS, though this 
difference is negligible on dichotomised analysis. 
Table 6-2: Table showing the minimum sample size required to achieve 
statistical power of 80% for each outcome measure using ordinal and 
dichotomised methods. For each outcome measure the most sensitive 
dichotomy was used. 
Endpoint Ordinal Dichotomised 
80% Power   
90 day mRS 480 610 
30 day mRS 620 860 
90 day NIHSS 420 600 
7 day NIHSS 370 310 
90% Power   
90 day mRS 640 780 
30 day mRS 800 >1000 
90 day NIHSS 540 770 
7 day NIHSS 480 410 
Figure 6-3 shows the sensitivities of all of the 7 day NIHSS endpoints investigated. With 
the exception of the dichotomy 0-1, all methods of analysing 7 day NIHSS show high levels 
of sensitivity. The dichotomy: NIHSS score of 0-1 or an improvement by 8 or more points 
from baseline appears the most sensitive however the differences in sensitivity between 
the 3 most sensitive methods are modest. 
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Figure 6-3: Line graph showing the relationship between sample size and 
statistical power for each of the 7 day NIHSS endpoints studied. 
6.3.2. Validation Analysis 
From the pooled thrombolysis trials, data on 2230 patients were available, of whom 2199 
had a measure for each of the investigated outcomes. 1111 (49.8%) were treated with 
thrombolysis. The baseline demographics, previously published171 229, were comparable 
between groups. 
In this cohort of patients, dichotomised endpoints were more sensitive to thrombolysis 
treatment effect, Day 7 NIHSS requiring the lowest sample size per group. This was 
supported by results from ordinal analysis. The distributions of power and sample size for 
each (dichotomised) outcome measure are shown in Figure 6-4. 
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Figure 6-4: Line graph showing the relationship between sample size and 
statistical power for each of the 3 outcome measures using dichotomised 
analysis. 
Table 6-3 shows the minimum sample sizes required for each outcome measure to 
achieve statistical power at typical choices of 80% or 90%. 
For outcome at day 90 the NIHSS was only moderately better than the mRS, irrespective 
of whether these were analysed as ordinal or dichotomised measures.  
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Table 6-3: Table showing the minimum sample size required to achieve 
statistical power of 80% for each outcome measure using ordinal or 
dichotomised methods. 
Endpoint Ordinal Dichotomised 
80% Power   
90 day mRS 930 590 
90 day NIHSS 910 440 
7 day NIHSS 410 300 
90% Power   
90 day mRS >1000 740 
90 day NIHSS >1000 590 
7 day NIHSS 590 400 
6.4. Discussion 
6.4.1. VISTA Analysis 
We found NIHSS as measured at 7 days to be the outcome measure most sensitive to the 
treatment effect of thrombolysis. This is consistent with conclusions from independent 
datasets. Nevertheless, potential confounding influences should be considered. 
Allocation to the thrombolysis and control groups in our study was not randomised, with 
choice to treat based on a range of clinical factors, some undocumented. Also, outcome 
assessors, although masked to investigational treatment allocation were not blinded to 
use of thrombolysis. Some reassurance derives from correspondence of the overall 
treatment effect, as measured by 90day mRS, with results of the pooled randomised 
trials.7 Given these limitations our results deserve external validation using randomised 
trial data. 
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The VISTA analysis presented here complements reports by Young et al299 and Broderick 
et al230. Both found dichotomised NIHSS endpoints to be more sensitive to a simulated 
treatment effect than various dichotomised disability endpoints. Broderick et al reported 
24h dichotomised NIHSS to be the most powerful endpoint. Our analysis is based on a 
sample that is eight-fold larger, and could adjust for known baseline prognostic factors 
such as age and NIHSS. We have considered the recently favoured and statistically more 
powerful ordinal approaches. 
The NIHSS reflects impairment, the clinical domain in which the effects of acute stroke 
therapies are likely to be most marked299-300. In contrast,  the mRS covers a broader 
domain and is influenced by extraneous factors300 that acute stroke therapies may not 
influence.  Restricting such background noise may improve sensitivity to acute treatment 
effects. 
This interpretation may also contribute to the greater sensitivity of the NIHSS as 
measured at 7 days compared to 90 days. Extraneous factors may have a greater 
influence on 90 day than 7 day NIHSS, with the latter better reflecting treatment effects 
in isolation from the myriad factors which come into play after discharge.  
For pivotal trials in acute stroke, EMEA supports neurological scales mainly as a 
supplement to ordinal analysis of an activity scale (primarily mRS)297. However for early 
phase, exploratory research, 7 day NIHSS score has much to recommend it as an 
endpoint. It is sensitive to treatment effects, requiring comparatively low sample sizes to 
achieve desirable levels of statistical power. Moreover by recording outcome at 7 days, 
when most participants may still be in hospital, losses to follow-up will be minimised and 
unrelated adverse events should have less influence on detection of adverse reactions.  
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Trial management decisions, such as dose escalation between patient cohorts, can be 
expedited and costs contained.  
In summary, seven day NIHSS score appears an ideal endpoint for the early exploratory 
testing of novel agents. Promising agents could then be validated in larger phase III trials 
using the mRS at 90 days to inform licensing and purchasing decisions, with validation of 
the 7-day NIHSS endpoint on the same sample to permit use of prior data as the 
necessary supporting evidence for regulatory submissions.  
6.4.2. Validation Analysis 
We found NIHSS as measured at 7 days to be the outcome measure most sensitive to the 
treatment effect of thrombolysis222. This is consistent with NINDS trial data230. 
Our present analysis is based on an observed rather than simulated treatment effect, and 
is adjusted for baseline prognostic factors such as age and NIHSS. In addition, we consider 
ordinal endpoints, which have recently been favoured over dichotomisation221 294.  
The validation analysis presented here favours dichotomised endpoints for all outcomes 
presented. This contrasts with most trial circumstances, including explorations within 
VISTA, in which ordinal analysis is considered more powerful. Whilst this differs also from 
our prior publication which for all outcomes other than NIHSS day 7 favoured ordinal 
analysis, the case mix in the pooled RCT data includes a large cohort of patients in whom 
thrombolysis treatment was initiated after 3h. This cohort makes up over half of the 
data171. Patients treated with thrombolysis between 3 and 4.5 h derive benefit according 
to mRS 0-1 but there is also a neutral or even marginal adverse effect on severe outcomes 
of disability and mortality:4 in this case mix, the ordinal analysis still better represents the 
net effect of treatment across a population but the dichotomised approach is more 
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sensitive to the biological signal. It is illustrated by comparison of the mRS distributions 
shown in figure 2 of the updated pooled analysis paper 171. 
90 day mRS remains the preferred outcome measure for pivotal trials in acute stroke, as 
the functional domain it measures is more relevant to individual patients and healthcare 
providers than the domain of disability measured by the NIHSS140 240.  
However, 7 day NIHSS has much to commend it for use in exploratory trials of novel 
agents. Its sensitivity would allow desirable levels of statistical power to be achieved with 
comparatively small sample sizes; and by recording outcome at 7 days when most 
patients will still be in hospital losses to follow-up will be minimised. During conduct of a 
trial, early access to relevant data could inform trial management decisions such as dose 
escalation. The use of 7 day NIHSS would allow exploratory phase II trials to be 
undertaken more quickly and with smaller sample sizes, reducing costs and hastening the 
arrival of promising agents to the market (or more timely discontinuation of 
development). Promising agents could then be validated in larger phase III trials using the 
more relevant outcome measure of 90 day mRS. 
In summary, validation on external RCT data has shown that seven day NIHSS score offers 
statistical advantages as an endpoint for the early exploratory testing of novel agents, 
particularly reperfusion strategies. Detecting an early signal of treatment benefit or 
futility in acute stroke trials is economically, scientifically and ethically desirable. 
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Chapter 7  
Exploration of time-course 
combinations of outcome 
scales in stroke recovery. 
7.1. Background 
Clinical trials for treatment of acute ischaemic stroke require large numbers of patients 
and are expensive to conduct.  Treatment is typically administered within the first hours 
or days after stroke onset. Outcome is usually assessed by a single measure, the most 
common being the modified Rankin scale (mRS)127 260. Any strategy that can reduce cost 
or deliver more reliable answers on safety and efficacy of the investigational treatment 
would be welcome for future exploratory testing of novel treatments.  
Some trialists have taken advantage of the fact that there are numerous scales available 
to measure various domains of neurological and functional recovery96 200. The ICTUS trial 
was designed to replicate results of meta-analysis of citicoline in acute stroke. The chosen 
primary outcome was recovery at 90 days as measured by a global test combining the 
favourable responses from Barthel index (BI), mRS, and National Institutes of Health 
Stroke Scale (NIHSS).  If the direction of change generated by the experimental treatment 
is the same on each of these measures, then the statistical analysis is most efficiently 
achieved by testing with a global procedure96. The clinical relevance of this procedure 
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may be strengthened if it combines outcome scales that measure different aspects of 
expected stroke recovery, e.g. mobility and cognitive function. Both the ICTUS and NINDS 
trial Part 2 investigators considered that a multidimensional outcome measure was 
desirable96 200 301. Pocock has indicated that the use of such a combined outcome can 
enhance statistical power302.  
However, global procedures need not be limited to data from a day 90 assessment. All 
clinical trials include longitudinal assessments of outcome which may include day 7 NIHSS 
score, day 30 mRS and day 90 mRS. The incorporation of all these measures could afford a 
more subtle assessment of outcome and recovery. For example a participant with an mRS 
score of 3 at both 30 and 90 days after stroke has perhaps experienced a more favourable 
outcome than a participant who attained a day 90 mRS score of 3 after a day 30 mRS of 5. 
A subjective ranking technique allows each patient in a clinical trial to be ordered 
according to all their trial experiences and the distribution of ranks between treatment 
groups can then be compared. This method was applied to data from the Systolic 
Hypertension in the Elderly Program303 and there provided a sensitive measure of 
treatment effect.  
In Chapter 6 it was shown that an outcome assessment just 7 days after stroke onset 
gives a statistically stronger indication for putative treatment effect than a 90 day 
functional recording222. Feng et al304 proposed repeated-measures analysis as an 
alternative method for assessing treatment effect, which could be used in future stroke 
trials if outcomes of interest are collected across several time points. In their analysis, the 
mRS, NIHSS, BI and GOS were each sensitive to treatment effect with this approach.  Li et 
al305 examined the various mRS time points used in NINDS rt-PA stroke trial and showed 
that a treatment effect could be observed at 7–10 days, 3 months, 6 months, and 12 
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months post stroke onset. We aimed to examine whether the combination by a global 
testing procedure of early and late assessments into an integrated view of recovery 
across the first 90 days after stroke offers yet more statistical information or power than 
standard outcome assessment. We also investigated a more simple approach by, 
combining ranks of different scores. 
Feng et al showed that both NIHSS and mRS were sensitive to treatment effect at 90 and 
7 days post stroke304. We hypothesised that after adjustment of outcomes for known 
prognostic variables (age, baseline NIHSS), the apparent treatment effect of the proven 
therapy intravenous thrombolysis would be detected more strongly if the outcome 
measure uses a combination of early and late measures (e.g. 7 day NIHSS combined with 
90-day mRS) than either early or late measure alone.  
7.2. Methods 
7.2.1. Data source and patients 
Data were sought and extracted from the Virtual International Stroke Trials Archive 
(VISTA) on participants enrolled in neuroprotectant trials from between 1998-2007. To be 
eligible for analysis, participants needed to have recordings available for initial stroke 
severity (baseline NIHSS score), and prognostic factors such as age, prior atrial fibrillation, 
hypertension and diabetes available; documentation of use or avoidance of thrombolysis; 
and post-treatment measurements of outcome.  We restricted our analysis to patients 
who had measurements of modified Rankin scale at 90 days (mRS90), 30 days (mRS30), 7 
days (mRS7) and National Institutes of Health Stroke Scale at 90 days (NIHSS90) and 7 
days (NIHSS7).  
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7.2.2. Preliminary analysis 
Interdependence between early and late outcome measures was examined using 
Spearman-Rank correlation calculated as partial correlations, adjusting for prognostic 
covariates. Amongst other values, this provided correlation coefficients (r) i.e. the 
strength and direction of the relationship between two outcome scales. For reporting 
purposes we calculated coefficients of determination (R2), i.e. the percentage variation of 
one scale explained by another scale after adjusting for the effect of any covariates. Due 
to the ordinal nature of mRS, R2 values adjusted for covariates were calculated as pseudo 
R2. This was done using the Logistic procedure in SAS, discussed further in Chapter 2.  
Treatment responsiveness was explored, analysing adjusted outcomes among the 
following two populations: thrombolysed (as standard of care) patients versus non-
thrombolysed (as standard of care) patients. Odds ratios (OR) were indicative of this 
sensitivity to treatment effect. For the thrombolysed group, patients were selected 
regardless of the time from treatment onset at which t-PA was started, though this was 
generally below 3 hours. For the control group, the time window from onset time to 
treatment was between 1 and 7 hours.  Patients were not excluded on account of stroke 
severity. Outcomes were handled as ordinal measures as appropriate to maximise power, 
and adjustment for major covariates was undertaken. 
MRS at 90 days, 30 days and 7 days (mRS90, mRS30 and mRS7 respectively) and NIHSS at 
90 days and 7 days (NIHSS90 and NIHSS7 respectively) were considered as ordinal scales. 
For global outcome, three combinations were considered: [mRS7, mRS30, mRS90], 
[NIHSS7, NIHSS90] and [NIHSS7, mRS90]. MRS was analysed in its standard form, whereas 
NIHSS was stratified into groups: ≤4, 5-8, 9-12, 13-16, 17-20, 21-24, and ≥25222 272. Death 
was considered as a separate group.  
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We analysed sensitivity to treatment effect, using proportional odds logistic regression272 
for ordinal scales individually. Generalised Estimating Equations (GEEs) were used, when 
analysing this for scales combined in a global outcome. The OR that we derived are 
allowed comparison between ordinal scales and global outcomes, discussed further 
below. We chose ordinal logistic regression in favour of linear regression since the scales 
are neither truly linear nor normally distributed. We adjusted for age and baseline NIHSS, 
treated as continuous variables. Our choice of baseline factors for adjustment was based 
mainly on the fact that age and baseline severity are the two most powerful prognostic 
factors for stroke63 241 and are the most common adjusting factors used in analysis of 
stroke data. Testing for significance of any association, with ordinal scales, was performed 
using the Cochran Mantel Haenszel (CMH) statistic. The CMH test provides a conservative 
estimate of statistical significance272 and was performed for illustrative purposes. 
Stratification by covariates in the CMH test is limited by the sample size and precludes 
simultaneous adjustment for all possible variables.  
7.2.3. Simple combination of ranks 
A simple method of combining scales within each time-point was initially proposed. NIHSS 
was converted to an ordinal measure in order to make it comparable to the ordinal NIHSS 
that was used within the global test. This method treats scale1 as the scale taken at the 
latest time point. The next scale was ordered within each grade of the first scale and so 
on. This is done using the formula                                        . 
For example: if we were interested in a subject with an mRS90 score of 3, an mRS30 score 
of 2 and an mRS7 score of 2 their combined score would be 20203. Each of these 
calculated scores were then ranked in ascending order to generate a discrete outcome 
measure. 
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7.2.4. Global test 
The calculation of a global test statistic is somewhat complex. For binary outcomes, 
calculation is based on the proportion of good outcome (success) in each group, as 
discussed by Dymova et al306 and Bolland et al307. Calculating this statistic manually 
becomes more difficult when the scales have more than two groups so an alternative 
approach was sought. Here we used the approach outlined by Bolland et al307 allowing for 
prognostic covariates, applying generalised estimating equations (GEE) using PROC 
GENMOD in SAS308 and the non-linear mixed effects library in R309. The GEE approach was 
used as an initial strategy in the ICTUS trial307 and was also applied in the NINDS trial of rt-
PA part 296. The method proposed here has been adapted for use with ordinal scales by 
using the multinomial distribution.  
For each global test combination a GEE multinomial regression model was fitted to the 
patient data. A factor distinguishing each assessment scale was included in the model and 
prognostic covariates were fitted allowing for a separate effect for each outcome. This 
was done by fitting each covariate as an interaction with outcome scale.  The parameter 
estimate obtained for treatment effect from this regression corresponds to a common 
log-odds ratio for treatment on all of the combined scales. This along with the standard 
error for this estimate can be used to calculate the OR and the 95% CI for OR.  
A sequential design approach to the global test has also been proposed by Whitehead et 
al301 but was not used here. The benefit of the GEE approach is both its simplicity and 
compatibility across statistical packages so simulations could be performed in R. 
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7.2.5. Simulations 
We performed multiple re-sampling to assess relation between sample size and power for 
each ordinal scale and global outcome. From our VISTA dataset, 10,000 random samples 
of patients were drawn at each of a series of sample sizes ranging from 1000 downwards 
in decrements of 10. Each sample consisted of equal numbers of rt-PA treated and 
control patients. For every sample size, the percentage of trials yielding a statistically 
significant treatment effect was recorded. This percentage approximates the statistical 
power of each outcome measure to detect thrombolysis treatment effects at that sample 
size. We present this graphically, plotting sample size against power, setting p<0.05. For 
treatment effect, if 95 out of 100 simulated trials achieved p<0.05, this is 95% power.  
Simulations were performed using R version 2.12.1, all other analyses used SPSS 19 and 
SAS 9.2. 
7.3. Results 
7.3.1. Preliminary Analysis 
Data on 4077 patients were available, containing a value for each of the outcome 
measures. The age range of patients included in the cohort was 20 to 97 years, with a 
mean of 68.0 years. Baseline characteristics are displayed in Table 7-1. 
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Table 7-1: Baseline characteristics of patients included in VISTA dataset. 
Percentages refer to baseline characteristic % within each treatment group 
  rt-PA  
  Yes No Total 
Previous Stroke 
n(%) 
Yes 210 (13.6) 589 (23.2) 799 (19.6) 
No 1330 (86.4) 1948 (76.8) 3278 (80.4) 
Hypertension 
n(%) 
Yes 473 (30.7) 597 (23.5) 1070 (26.2) 
No 1067 (69.3) 1940 (76.5) 3007 (73.8) 
Diabetes 
n(%) 
Yes 287 (18.6) 617 (24.3) 904 (22.2) 
No 1253 (81.4) 1920 (75.7) 3173 (77.8) 
Myocardial Infarction 
n(%) 
Yes 210 (13.6) 296 (11.7) 506 (12.4) 
No 1330 (86.4) 2241 (88.3) 3571 (87.6) 
Atrial Fibrillation 
n(%) 
Yes 344(22.3) 639 (25.2) 983 (24.1) 
No 1196(77.7) 1898 (74.8) 3094 (75.9) 
Gender 
n(%) 
Male 900 (58.4) 1355 (53.4) 2255 (55.3) 
Female 640 (41.6) 1182 (46.6) 1822 (44.7) 
Time to treatment Median (IQR) 3 (1) 4 (2) - 
Age Mean (SD) 67 (13) 69 (12) - 
Baseline NIHSS Mean (SD) 13 (5) 11 (5) - 
 
We assessed the interdependence between scales amongst patients who had a 
measurement for each of mRS90, mRS30, mRS7, NIHSS90 and NIHSS7. Estimates of 
adjusted interdependence among the five outcome scales are displayed in Table 7-2 as 
both partial correlation coefficients (r) and adjusted coefficients of determination (R2). 
Within this cohort of 4,077 patients, median scores (and IQR) for the outcomes were as 
follow:  3 (3) for mRS90; 3 (3) for mRS30; 4 (2) for mRS7; 3 (7) for NIHSS90; and 5 (9) for 
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NIHSS7. Median scores of NIHSS relate to the full scale and not the ordinal form used in 
further analysis.  
Table 7-2: Interdependence of ordinal stroke scales. Values are adjusted for 
baseline NIHSS and age. 
  mRS90 mRS30 mRS7 NIHSS90 NIHSS7 
mRS90 r 
R
2 
(%) 
p-value 
n 
1 
100 
 
4077 
0.811 
73.8 
<.0001 
4077 
0.70 
61.1 
<.0001 
4077 
0.719 
69.2 
<.0001 
4077 
0.658 
51.1 
<.0001 
4077 
mRS30 r 
R
2 
(%) 
p-value 
n 
 
 
1 
100 
 
4077 
0.820 
74.6 
<.0001 
4077 
0.613 
47.8 
<.0001 
4077 
0.716 
59.6 
<.0001 
4077 
mRS7 r 
R
2 
(%) 
p-value 
n 
  1 
100 
 
4077 
0.531 
40.3 
<.0001 
4077 
0.723 
60.9 
<.0001 
4077 
NIHSS90 r 
R
2 
(%) 
p-value 
n 
   1 
100 
 
4077 
0.672 
52.4 
<.0001 
4077 
 
All scales appeared sensitive to rt-PA therapy, after adjustment for age and baseline 
NIHSS. The mRS90 had an unadjusted OR for better outcome with rt-PA of 1.16 and 
adjusted OR of 1.56. The NIHSS90 had an unadjusted OR of 1.10 and adjusted OR of 1.62. 
The adjusted ORs for all scales individually, incrementally ranked and combined with a 
global test are given in Table 7-3 below. Two combinations of the global test give the 
strongest sensitivity to treatment effect with adjusted OR for the global outcomes of 
(mRS90, NIHSS7) and (NIHSS90, NIHSS7) were 1.69 and 1.73 respectively. The 
combination of mRS90, mRS30 and mRS7 is the least sensitive to treatment effect when 
using both the global test and the incremental ranking method. It would appear from 
 147 
these results that by incrementally ranking the outcome measures no benefit is gained in 
comparison to the use of individual scales.  
Table 7-3: Scales and combinations ranked in order of responsiveness to 
treatment effect. Adjusted for Baseline NIHSS & Age 
Scale(s) OR 95% CI p-value 
Global test2 (NIHSS7, NIHSS90) 1.73 (1.52, 1.95) <0.0001 
Global test3 (mRS90, NIHSS7) 1.69 (1.51, 1.90) <0.0001 
NIHSS7 1.69 (1.50, 1.92) <0.0001 
Rank2 (NIHSS90, NIHSS7) 1.67 (1.47, 1.89) <0.0001 
NIHSS90 1.62 (1.41, 1.87) <0.0001 
Rank3 (mRS90, NIHSS7) 1.61 (1.44, 1.80) <0.0001 
mRS90 1.56 (1.39, 1.75) <0.0001 
Global test1 (mRS90, mRS30, mRS7) 1.55 (1.39, 1. 27) <0.0001 
Rank1 (mRS90, mRS30, mRS7) 1.53 (1.37, 1.71) <0.0001 
mRS30 1.47 (1.31, 1.65) <0.0001 
mRS7 1.40 (1.25, 1.58) <0.0001 
 
7.3.2. Simulations 
Table 7-4 shows the simulation results giving minimum sample sizes required for each 
end point to achieve statistical power at typical choices of 80% or 90%. The smallest 
sample size required obtaining statistical power of ≥ 80% for mRS90, NIHSS7, and global 
outcomes of mRS0 and NIHSS7 combined and NIHSS90 and NIHSS7 combined, were 500, 
490, 400, and 380, respectively. A global outcome combining NIHSS7 with NIHSS90 was 
found to be the most sensitive measure and mRS7 the least.  
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Table 7-4: Estimates of minimum sample size required to achieve power of 
80% and 90% for ordinal scales, global outcomes and ranking combinations of 
these scales. mRS indicates modified Rankin Scale; NIHSS, National Institutes 
of Health Stroke Scale. 
 80% Power 90% Power 
End-point Sample size Sample size 
mRS7 - - 
mRS30 740 - 
mRS90 500 650 
NIHSS7 490 630 
NIHSS90 610 800 
Rank1 (mRS90, mRS30, mRS7) 540 710 
Rank2 (NIHSS90, NIHSS7) 460 580 
Rank3 (mRS90, NIHSS7) 440 590 
Global test1 (mRS90, mRS30, mRS7) 700 - 
Global test2 (NIHSS90, NIHSS7) 400 530 
Global test3 (mRS90, NIHSS7) 380 480 
 
As was anticipated, given the GEE regressions in Table 7-3 the incremental ranking 
method provides no benefit when compared to individual measures.  Figure 7-1 below 
shows the relationship between desired power and required sample size for each of the 
three ranking methods rank1, rank2 and rank3, the ‘gold standard’ outcome measure of 
mRS day 90 most frequently used in trials and ordinal NIHSS day 7 shown in Chapter 6 to 
be the most sensitive ordinal measure when testing the treatment effect of thrombolysis.  
This confirms the assumption that none of the three ranking methods provide any benefit 
to the individual scales as there are no clear distinctions between the lines and there is a 
great deal of overlap. 
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Figure 7-2 below shows the relationship between desired power and required sample size 
for each of the three global test using the GEE methods, the ‘gold standard’ outcome 
measure of mRS day 90 and ordinal NIHSS day 7.  This confirms the results from Table 7-3, 
showing that the global test combination 2(NIHSS90, NIHSS7) and global test combination 
3 (mRS90, NIHSS7) are the most sensitive to treatment effect. Looking at the plot both 
perform consistently better than all other scales with the (NIHSS90, NIHSS7) combination 
proving the most sensitive to the treatment effect of thrombolysis.  Figure 7-3 shows the 
global testing and ranking methods alone. It can be seen that the global test 2 (NIHSS7, 
NIHSS90) and 3 (mRS90, NIHSS7) perform consistently better than all of the incremental 
ranking methods. The combination of (mRS90, mRS30 and mRS7) using both the ranking 
(ranking1) and global test (global1) appears to perform worse than any other. 
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Figure 7-1: Relationship between power and sample size for each of the 
combinations of ranks as well as the standard ordinal outcome of mRS day 90 
and the most sensitive outcome measure found in Chapter 6, NIHSS day 7. 
 
Figure 7-2: Relationship between power and sample size for each of the global 
test combinations as well as the standard ordinal outcome of mRS day 90 and 
the most sensitive outcome measure found in Chapter 6, NIHSS day 7. 
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Figure 7-3: Relationship between power and sample size for each of the 
combinations of ranks and each of the global tests. 
7.4. Discussion 
The global test combination of NIHSS90 with NIHSS7 appears to offer incremental 
sensitivity to treatment effect compared to the ordinal forms of these scales alone. The 
combination of mRS90 with NIHSS7 did not increase the sensitivity to treatment effect 
when compared to NIHSS alone, but offers a broader clinical measure without loss of 
statistical power.  This may have practical importance, since regulatory bodies may 
consider NIHSS at day 7 to be too early a measure and too neurological, i.e. divorced from 
function, for treatment approval purposes; but may be more open to consider the 
enhancement of traditional 90-day mRS with NIHSS7. 
As expected, we found greater advantage from the combination of measures that 
correlated with each other only modestly.  However the use of a more simple incremental 
approach combining the scales using a ranking method offered no benefit to the ordinal 
scales. 
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The increments in treatment effect estimates that we observed when using the global 
test approach were modest but the impact that these limited benefits deliver to sample 
sizes is surprisingly great.  For an enhancement in the odds ratio for treatment benefit of 
only 0.13 (from 1.56 with mRS 90 to 1.69 with mRS90 and NIHSS7), the necessary sample 
size for 80% power fell by 20% from 500 to 400 patients. A second advantage may accrue 
from the combination approach: treatments that reduce early disability should also limit 
in-hospital and rehabilitation costs:  it is desirable that we should detect such benefits as 
part of the outcome measure. 
Our analyses gain strength from the large size of our dataset, the rigorous conditions 
under which the data were collected and the breadth of the trials and centres from which 
they derive.  However, our estimates are weakened by the non-random allocation in this 
sample between “treatment” and “control” and by differences in baseline prognostic 
factors between our two treatment groups. In particular, there may be a difference in the 
timing of baseline NIHSS measurements between our treatment groups, with NIHSS 
assessments possibly undertaken earlier in the thrombolysed patients than controls. This 
may affect the overall estimate of “treatment” effect size, but should not interfere with 
the relative power of various outcome measures.  
Analysis of the NIHSS or mRS across time has been described in the statistical 
literature305. Feng et al recently demonstrated that “repeated-measures analysis allows 
for a more comprehensive understanding of the clinical benefit of study intervention at 
any defined study point or throughout the entire study period”304. Our findings take this a 
step further since unlike Li et al or Feng et al, we combined different scales across time 
(i.e. day 90 mRS and day 7 NIHSS).  
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Consideration of the time course of recovery and statistical approaches to combine 
measures that best reflect the nature of the deficit at set intervals after stroke both have 
biological plausibility. Our report suggests that this deserves further exploration since 
statistical gains could be meaningful and inexpensive. 
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Chapter 8  
Exploration of case-control 
matching using historical 
controls 
8.1. Background 
Clinical trials for treatment of acute ischaemic stroke require large numbers of patients 
enrolled under tight timelines across many centres and are expensive to conduct. Patients 
or their relatives may be asked to consent urgently to research participation that carries 
life-threatening clinical implications during a time of extreme anxiety and diagnostic 
uncertainty.  
With increasing use of thrombolysis96 171 310 and in some centres endovascular 
approaches, and with disappointing results from recent trials of neuroprotectant 
approaches188 195 311, translational development of treatments for acute stroke is 
becoming more challenging. Investigators are seeking research strategies that will ease 
ethical burdens and will limit sample sizes and cost without compromising reliability:  any 
valid method to detect or exclude a biological signal with a new treatment and reach an 
early “go/no go” decision would be attractive.  
For early phase research, especially when endovascular devices are involved, employing 
invasive procedures for which a placebo control may be considered impractical or 
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unethical, researchers are turning towards single arm designs or comparisons against 
historical controls312-313 Also in pilot studies and when patients are considered at very 
high risk if untreated, i.e. if clinical equipoise is not considered to be present, comparisons 
against historical controls have been considered314-317.  
Abandoning the rigour of the blinded RCT carries substantial penalty in loss of reliability 
and should not be undertaken lightly. However, there may be statistical strategies that 
can strengthen these compromises when they have been considered unavoidable. 
Numerous strategies have been discussed in statistical literature263 268 318-323 with diverse 
opinions. Such strategies are now attracting at least tacit support from regulatory 
bodies320 324. 
With the increasing availability of data-banks and registries such as VISTA and SITS, 
opportunities to access historical controls are likely to be grasped, possibly without close 
attention to the reliability of the ensuing comparisons. Rather than opting for a ‘quick fix’ 
prompted by ready access to generous historical patient data, we wished to explore 
aspects of reliability in a systematic manner.  
Within the Virtual International Stroke Trials Archive (VISTA), we have access to datasets 
from several trials. Most of these trials made careful recordings of a variety of baseline 
measures along with recordings of outcome at three months after stroke onset, giving us 
the opportunity to investigate the matching process.  Various methods of matching as 
well as a variety of variable combinations for matching will be assessed under different 
conditions. Variables for matching are generally chosen based on clinical knowledge of 
the disease itself325,however we will use a multiple re-sampling approach, discussed 
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below, to assess which combination of the variables widely accepted as being predictive 
of outcome is the most responsive for matching. 
8.2. Methods 
8.2.1. Data Source and Patients 
Data were extracted from VISTA that met overarching selection criteria on data 
availability, namely: NIHSS recorded within 6h of stroke onset and at 90 days; modified 
Rankin Scale score recorded at 90 days; age; exposure to iv thrombolysis (or not) and date 
of trial falling within period 1998-2008. All available medical history data were sought 
where available. 
The data contained two distinct populations. One population originating from pooled 
neuroprotectant trials and the other from pooled thrombolysis trials.  Due to the nature 
of thrombolytic therapy, inclusion into a thrombolysis trial would be more restrictive than 
that of a neuroprotectant. Neuroprotectant trials tend to be more inclusive and to have 
had a wider time window for inclusion (Figure 8-1). Inclusion criteria of OTT <6h, baseline 
NIHSS 4-20 and an age range of 18-80 were applied to all data to ensure consistency with 
the entry criteria for European thrombolysis trials. Initially no further restriction was 
placed to ensure the largest sample for matching. 
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`  
Figure 8-1: Venn diagram illustrating overlapping inclusion in thrombolysis 
and neuroprotectant trials 
8.2.2. Simulation study comparing methods and models for matching 
The goal was to simulate a trial population using VISTA data that consisted of a sampled 
‘case’ group and a ‘control’ group. The control group are matched to the case group by 
propensity scores utilising various matching methods.  Propensity score matching can be 
performed with any combination of covariates. Within the simulation study six variations 
of covariate models were considered (Table 8-1). Each model generated a different 
matched group by attempting to balance all covariates between the case and control 
groups.  
Propensity score matching was performed using the MatchIt package in R. The matching 
methods utilised were nearest, full, optimal and genetic as discussed in Chapter 2. The 
exact matching method was not utilised as this has been previously investigated within 
VISTA178 236. In any case finding exact matches on all continuous variables such as age, 
glucose and diastolic blood pressure would be problematic. Due to the limitations of the 
MatchIt package only subjects with recorded values for all covariates can be employed for 
the matching process.  
Neuroprotectant 
Trials 
Thrombolysis 
Trials 
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Table 8-1: Covariate models for matching 
Model 
Number 
Variables for matching 
1 Age, baseline NIHSS and Hemisphere of stroke 
2 Age, Baseline NIHSS, Hemisphere and onset time to study drug (OTT) 
3 Age, Baseline NIHSS, Hemisphere, OTT, Glucose at baseline (mmol/L), Diastolic blood 
pressure (DBP) at baseline (mg/Hg) 
4 Age, Baseline NIHSS, Hemisphere, OTT, History of Diabetes, History of 
Hypertension 
5 Age, Baseline NIHSS, Hemisphere, OTT, Diabetes, Hypertension, Glucose at baseline and 
DBP at baseline 
6 Age, Baseline NIHSS, Hemisphere, OTT, Diabetes, Hypertension, Glucose at baseline and 
DBP at baseline, Atrial Fibrillation (AF) 
We undertook simulations to model the error that occurs due to the matching process.  
Using R statistical programming language, 1,000 mock trials were simulated. For each trial 
500 subjects were sampled from all eligible untreated subjects, without replacement. This 
generated a case group with inclusion criteria already applied.  A control group was 
generated from the remaining untreated subjects by propensity score matching as 
illustrated in Figure 8-2. In order to directly compare methods and covariate models for 
matching each were applied simultaneously to the data throughout the 1,000 
simulations. 
 159 
 
Figure 8-2: How matching for each subject works within each simulation 
The aim of matching is to create a data set similar to what you would expect from a 
randomised design. Therefore we need to assess how close the distributions of the 
covariates are between the two groups, also referred to as the balance269. As outlined in 
Chapter 2, a propensity score is calculated for each subject based on all matching 
variables; this gives a one dimensional continuous variable for matching, sometimes 
referred to as ‘distance’. The mean difference in propensity score between the case and 
control groups was recorded before and after matching. The smaller this difference is the 
more balanced the control and treatment groups are. This measure of balance is based 
solely on the matching variables. Along with these differences the overall percentage 
balance improvement in propensity score was recorded.  
While these measures can be informative they can also be misleading: if the two groups 
were reasonably balanced before matching there could be very little improvement in 
balance. Alternatively, a large reduction in difference leading to a high percentage 
balance improvement may still yield unbalanced groups.  
All subjects
after any restriction to simulate 
inclusion criteria
Pool of controls for 
matching size p
‘Treatment’ subject 1
t1
Apply matching method and obtain match 
denoted  m1. Remove match from pool now size 
p-1.
Matched 
control 
subject for t1
Randomly select n 
patients from treatment 
population
‘Case‘
group
Repeat for 
each 
treatment 
subject
‘Control’ 
group
 160 
To investigate the matching process further: each simulated trial was analysed for 
treatment effect based on ordinal mRS day 90 and ordinal NIHSS day 90 illustrated in 
Figure 8-3. This treatment effect was analysed using proportional odds logistic regression 
across the full scale of the mRS and NIHSS,  stratified into groups: ≤4, 5-8, 9-12, 13-16, 17-
20, 21-24, and ≥25222 272, recording both the p-value and odds ratio for treatment effect. 
In order to account for the variation related to the matching variables the analysis was 
adjusted for all covariates used for the propensity score calculation263. 
By sampling the two groups from one untreated population we exclude the influence of a 
treatment effect as well as any bias occurring when sampling from two separate 
populations. Given this we would expect to yield no treatment effect between groups. 
Consequently retaining the p-values from the analysis allows us to obtain the type I error 
rates. This is calculated as the proportion of times the null hypothesis was wrongly 
rejected. If matching was successful the type I error rate would be expected to be <0.05. 
This is assuming 5% error may occur by chance alone. 
After separating the data into the two distinct populations, these simulations were 
repeated. Here the case group was sampled from the untreated thrombolysis trial 
population and the control group matched from the untreated neuroprotectant trial 
population. Again if matching was successful we would expect no observable treatment 
effect. By matching a control group to a case group taken from a different population we 
aimed to investigate if matching accounts for the disparity between the two populations. 
Further restrictions were applied to the inclusion criteria, reducing the OTT to <4.5 hours 
and the simulations repeated again.  Due to the lack of data availability covariate models 
4, 5 and 6 (Table 8-1) could not be used for these simulations.  
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Finally, for investigative purposes only, untreated subjects from neuroprotectant trials 
were matched to those treated with thrombolysis as standard of care. Due to VISTA 
regulations subjects from the thrombolysis trial population could not be used here. 
Retaining the p-values when there is a known treatment effect allows us to calculate the 
type II error rate. This is calculated as the proportion of times a null hypothesis was 
wrongly accepted. The power of a study can be calculated from this as 1-type II error rate. 
Ideally this error rate would be as low as possible ensuring an adequately powered and 
precise study. The odds ratios allow us to see the direction of any observed treatment 
effect. 
 
Figure 8-3: Outline of simulation process 
8.3. Results 
8.3.1. Available Data  
After applying the initial restrictions to the entire dataset, data on 5076 patients were 
available. 2118 (41.7%) of subjects were thrombolysed. Baseline characteristics are 
displayed in Table 8-2.  
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Table 8-2: Baseline demographics of VISTA dataset after initial restriction 
applied.  Demographics displayed for entire data broken up by treatment 
group as well as population. 
Variable Statistic 
All 
Controls 
All 
Treated 
Control 
Neuroprotectant 
Control 
Thrombolysis 
Treated 
Neuroprotectant 
Age (years) 
N 2958 2118 2339 619 1526 
Mean(SD) 65.9 (10.9) 64.9 (11.5) 66.1 (10.9) 65.3 (11.1) 12 (7) 
Onset time to 
treatment 
(hours) 
N 2958 2118 2339 619 1526 
Mean(SD) 3.9 (1.1) 2.69 (1.1) 4.04(0.96) 3.45 (1.52) 2.42 (0.57) 
Baseline NIHSS 
N 2958 2118 2339 619 1526 
Median (IQR) 10 (7) 12 (7) 10 (7) 12 (7) 12 (7) 
Glucose baseline 
(mmol/l) 
N 2958 2118 2339 619 1526 
Mean (SD) 7.8 (3.4) 7.5 (3.5) 7.8 (3.3) 7.9 (3.9) 7.3 (2.9) 
Diastolic blood 
pressure at 
baseline (mmHg) 
N 2952 2107 2338 614 1526 
Mean (SD) 85 (15) 83 (15) 85.3 (16) 85.8 (13) 82.8 (15.9) 
Sex 
Female N (%) 1311 (44.3) 880 (41.6) 1010 (43.2) 301 (48.6) 607 (39.8) 
Male N (%) 1647 (55.7) 1238 (58.4) 1329 (56.8) 318 (51.4) 919 (60.2) 
Hemisphere of Stroke 
Left N (%) 1302 (44.0) 911 (43.0) 1018 (43.5) 284 (45.9) 646 (42.3) 
Right N (%) 1656 (56.0) 1207 (57.0) 1321 (56.5) 335 (54.1) 880 (57.7) 
Diabetes 
No N (%) 2265 (76.6) 1733 (81.9) 1731 (74.0) 534 (86.3) 1218 (79.8) 
Yes N (%) 693 (23.4) 384 (18.1) 608 (26.0) 85 (13.7) 308 (20.2) 
Hypertension 
No N (%) 825 (29.0) 731 (36.4) 565 (24.2) 260 (51.1) 486 (31.8) 
Yes N (%) 2023 (71.0) 1276 (63.6) 1774 (75.8) 249 (48.9) 1040 (68.2) 
AF 
No N (%) 2095 (78.8) 1486 (81.9) 1815 (77.6) 280 (88.1) 1224 (80.2) 
Yes N (%) 562 (21.2) 328 (18.1) 524 (22.4) 38 (11.9) 302 (19.8) 
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8.3.2. Simulation Study 
8.3.2.1. Matching from the same population 
It was postulated that sampling and matching from the same population would generate 
very similar groups regardless of the covariate model used. This was investigated in Table 
8-3 below. 
Table 8-3: Difference in propensity score between groups before and after 
matching along with percentage balance improvement between groups after 
matching. Case and control groups sampled from the same population. 
Distance information for each model 
Covariate 
model 
Difference in 
propensity score 
between groups 
Full 
matching 
Nearest 
matching 
Optimal 
matching 
Genetic 
matching 
1 Mean before 
Mean after 
% Balance improvement 
0.000824 
0.00000397 
96.13 
0.00202 
0.0000143 
99.20 
0.00124 
0.0000224 
96.88 
0.00127 
0.0000172 
99.30 
2 Mean before 
Mean after 
% Balance improvement 
0.00135 
-0.0000033 
98.23 
0.00225 
0.000021 
99.01 
0.00147 
0.000020 
98.12 
0.00211 
0.000000297 
99.55 
3 Mean before 
Mean after 
% Balance improvement 
0.00177 
-0.00000204 
98.77 
0.00409 
0.0000359 
99.16 
0.00259 
0.0000134 
99.10 
0.00275 
-0.00000328 
97.89 
4 Mean before 
Mean after 
% Balance improvement 
0.00275 
0.000000122 
99.21 
0.00272 
0.0000257 
99.04 
0.00243 
0.0000182 
98.84 
0.00320 
0.00000494 
99.20% 
5 Mean before 
Mean after 
% Balance improvement 
0.00345 
0.000000308 
99.21 
0.00458 
0.0000392 
99.08 
0.00429 
0.0000279 
99.24 
0.00413 
-0.00000343 
96.92 
6 Mean before 
Mean after 
% Balance improvement 
0.00375 
0.00000534 
99.35 
0.0538 
0.0000538 
99.07 
0.00451 
0.000268 
99.32% 
0.00559 
-0.0000362 
96.91 
 
In Table 8-3 it is clear that for all covariate models matching has successfully reduced the 
mean difference in propensity score.  Regardless of matching method used the 
percentage balance improvement is very high. The consequence of propensity score 
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matching on outcome analysis at day 90 was investigated using type I error rates given in 
Table 8-4.  
Table 8-4: Type I error rate for each method and model being evaluated. 
Outcomes analysed are mRS day 90 and ordinal NIHSS day 90.   Case and 
control groups sampled from the same population. 
Type I error rates 
Covariate 
model 
Scale used for 
outcome assessment 
Full 
matching 
Nearest 
matching 
Optimal 
matching 
Genetic 
matching 
1 mRS 90 
NIH 90 
12.1% 
0.5% 
2.1% 
0.6% 
0.4% 
0.8% 
0.9% 
0.9% 
2 mRS 90 
NIH 90 
11.5% 
0.5% 
0.9% 
0.9% 
0.3% 
1.1% 
0.1% 
4.3% 
3 mRS 90 
NIH 90 
12.4% 
0.8% 
0.7% 
1.6% 
0.4% 
0.9% 
1.3% 
1.9% 
4 mRS 90 
NIH 90 
8.1% 
0.5% 
0.9% 
0.9% 
0.1% 
0.9% 
0.9% 
2.1% 
5 mRS 90 
NIH 90 
9.2% 
0.7% 
1.4% 
1.7% 
0.3% 
0.4% 
0.8% 
2.2% 
6 mRS 90 
NIH 90 
9.3% 
0.8% 
1.7% 
1.7% 
0.2% 
0.8% 
1.6% 
2.9% 
 
Comparing the type I error rates given in Table 8-4 the full matching method performs 
poorly in comparison to other methods for all covariate models. This is highlighted in 
Figure 8-4. If matching was successful, we would anticipate the OR for treatment effect to 
be close to 1. For all matching methods excluding full matching the odds ratios cluster 
around 1. 
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Figure 8-4: Forest plot illustrating the odds ratio for treatment effect 
measured by full scale mRS day 90. Mean OR and 95% CI given for each model 
with each matching method. Case and control groups sampled from the same 
population. 
This analysis was repeated using the entire pool of treated subjects.  Results are given in 
Appendix B. Due to the extensive computational time taken to run, the genetic matching 
method was not used for any further simulations. 
8.3.2.2. Matching from a different population 
By matching an untreated control group to an untreated case group taken from a 
different population it was hypothesised that the difference between the two groups 
would be larger compared to the simulations above. Table 8-5 illustrates the difference in 
propensity score before and after matching. This is given for both the original data 
restriction and the further restriction applied.  Due to data availability only covariate 
models 1, 2 and 3 could be used here. 
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Table 8-5: Difference in propensity score between groups before and after 
matching along with percentage balance improvement between groups after 
matching. Case and control groups sampled from different populations. 
Results are given for initial inclusion criteria and after further restriction were 
applied. 
Distance information for each model 
Covariate model  
and matching method 
Difference in propensity  
score between groups 
Initial inclusion  
criteria applied 
Further inclusion  
criteria applied 
1 
Full matching 
Mean before 
Mean after 
% Balance improvement 
0.0210 
-0.0000718 
99.68 
0.029059 
-0.0000683 
99.78% 
1 
Nearest matching 
Mean before 
Mean after 
% Balance improvement 
0.0210 
0.0000831 
99.57 
0.029059 
0.00009970 
99.67% 
1 
Optimal matching 
Mean before 
Mean after 
% Balance improvement 
0.0210 
-0.0000346 
99.81 
0.029059 
0.00000453 
99.89% 
2 
Full matching 
Mean before 
Mean after 
% Balance improvement 
0.0797 
0.000897 
99.15% 
0.2299 
0.0026094 
98.92% 
2 
Nearest matching 
Mean before 
Mean after 
% Balance improvement 
0.0797 
0.0308 
61.45 
0.229933 
0.101947 
55.70% 
2 
Optimal matching 
Mean before 
Mean after 
% Balance improvement 
0.0797 
0.0307 
61.47 
0.229933 
0.1019414 
55.70% 
3 
Full matching 
Mean before 
Mean after 
% Balance improvement 
0.190 
0.000703 
99.68 
0.3066 
0.002358 
99.27% 
3 
Nearest matching 
Mean before 
Mean after 
% Balance improvement 
0.190 
0.0139 
92.84 
0.30666 
0.12546 
59.11% 
3 
Optimal matching 
Mean before 
Mean after 
% Balance improvement 
0.190 
0.0115 
94.16 
0.30659 
0.125443 
59.11% 
 
This was investigated further by analysing treatment effect. The type I error rates are 
displayed in Table 8-6 .  
 167 
Table 8-6: Type I error rate for each method and model being evaluated. 
Outcomes analysed are mRS day 90 and ordinal NIHSS day 90. Case and 
control groups sampled from different populations. Results are given for 
initial inclusion criteria and after further restriction were applied. 
Type I error rates 
Covariate model  
and matching method 
Scale used for  
outcome assessment 
Initial inclusion  
criteria applied 
Further inclusion  
criteria applied 
1 
Full matching 
mRS 90 
NIH 90 
89.6% 
0.1%% 
8.4% 
0% 
1 
Nearest matching 
mRS 90 
NIH 90 
65.3% 
0.3% 
28% 
0.4% 
1 
Optimal matching 
mRS 90 
NIH 90 
50.7% 
0.1% 
2.6% 
0.4% 
2 
Full matching 
mRS 90 
NIH 90 
85.3% 
0% 
0% 
0% 
2 
Nearest matching 
mRS 90 
NIH 90 
23.8% 
1.9% 
0% 
13.2% 
2 
Optimal matching 
mRS 90 
NIH 90 
20.6% 
0.8% 
0% 
10.8% 
3 
Full matching 
mRS 90 
NIH 90 
93.0% 
0% 
13% 
0% 
3 
Nearest matching 
mRS 90 
NIH 90 
72.5% 
0.2% 
0.2% 
1.5% 
3 
Optimal matching 
mRS 90 
NIH 90 
 67.1% 
0.2% 
0.2% 
2.2% 
 
With the initial inclusion criteria applied the type I error rates are very high when 
analysing outcome as mRS day 90. When further restriction is applied to OTT these error 
rates reduce dramatically.  
The plots in Figure 8-5 illustrate the odds ratios for treatment effect with initial restriction 
(top) and further restriction (bottom). Further restriction results in odds ratios closer to 1 
than initial restriction but in both cases there is substantial deviation from 1. 
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Figure 8-5: Forest plot illustrating the odds ratio for treatment effect 
measured by full scale mRS day 90. Mean OR and 95% CI given for each model 
with each matching method. Case and control groups sampled from different 
populations. Plots are given for initial inclusion criteria (top) and after further 
restriction were applied (bottom). 
 
8.3.2.3. Matching controls to a treatment population 
The aim of these simulations was to investigate the variability that occurs when sampling 
non-randomised subjects treated with thrombolysis as the case group and generating a 
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matched control group. The difference in propensity score between the two groups 
before and after matching is given in Table 8-7. 
Table 8-7: Difference in propensity score between groups before and after 
matching along with percentage balance improvement between groups after 
matching. Control subjects matched to a group treated as standard of care. 
Distance information for each model 
Covariate 
model 
Difference in propensity score 
 between groups 
Full matching Nearest matching Optimal matching 
1 Mean before 
Mean after 
% Balance improvement 
0.035921 
0.00000765 
99.90% 
0.035921 
0.0003426 
99.07% 
0.035921 
0.0001357 
99.61% 
2 Mean before 
Mean after 
% Balance improvement 
0.519092 
0.0002227 
99.96% 
0.519092 
0.313179 
39.71% 
0.519092 
0.313791 
39.71% 
3 Mean before 
Mean after 
% Balance improvement 
0.587363 
0.000440 
99.93% 
0.587363 
0.401051 
31.76% 
0.587363 
0.4010522 
31.76% 
 
When more variables are added to the model the difference in propensity score between 
the two groups becomes substantially higher.   For these simulations the full matching 
method has reduced the mean difference in propensity score to a larger extent than any 
other method for all covariate models.  Treatment effect was analysed and the type II 
error rates are given in Table 8-8.  
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Table 8-8: Type II error rates for each method and model being evaluated. 
Outcomes analysed are mRS day 90 and ordinal NIHSS day 90. Untreated 
subjects matched to nonrandomised subjects treated as standard of care. 
Type II error rates 
Covariate 
model 
Scale used for  
outcome assessment 
Full 
matching 
Nearest 
matching 
Optimal 
matching 
1 mRS 90 
NIH 90 
0% 
0% 
0% 
0.7% 
0% 
0.4% 
2 mRS 90 
NIH 90 
23.4 
31.8 
73.0% 
80.4% 
73.4% 
80.4% 
3 mRS 90 
NIH 90 
56.6% 
58.1% 
88.4% 
92.9% 
88.0% 
92.9% 
 
Adding more covariates into the model substantially increases the type II error rates. The 
full matching method has the lowest error rates in comparison to other matching 
methods. Figure 8-6 illustrates the odds ratios for treatment effect for all methods of 
matching with each covariate model used.  
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Figure 8-6: Forest plot illustrating the odds ratio for treatment effect 
measured by full scale mRS day 90. Mean OR and 95% CI given for each model 
with each matching method. Untreated subjects matched to nonrandomised 
subjects treated as standard of care. 
8.4. Discussion 
The analysis presented here provides a within-VISTA investigation of propensity score 
matching using the MatchIt package in R. Different covariate models have been 
considered for the matching process. These models include the variables most often 
associated with outcome, age, baseline NIHSS and onset time to treatment171 178.  
It is important to note that matching based on propensity score attempts to balance on 
all observed covariates added into the matching model. This is in contrast to an RCT 
which should balance on all variables both observed and unobserved. Thus propensity 
score matching may not necessarily eliminate all systematic differences between the 
groups as it does not balance the unobserved variables326. This imbalance can ultimately 
result in a biased estimate of the treatment effect266.  
Forest plot control to treatment matching
1 2
Optimal 1.17 (1.16, 1.17)
Nearest 1.16 (1.16, 1.17)
Full 1.27 (1.26, 1.27)
Optimal 1.22 (1.22, 1.23)
Nearest 1.22 (1.21, 1.23)
Full 1.35 (1.35, 1.36)
Optimal 1.67 (1.66, 1.68)
Nearest 1.68 (1.67, 1.69)
Full 1.64 (1.63, 1.65)
 
Model 1
Model 2
Model 3
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From the initial simulations it appears that matching based on all covariate models across 
all methods substantially reduces the mean difference in propensity score (Table 8-3). 
With the exception of the full matching method the type I error rates are reassuringly 
low, falling below 5% (Table 8-4). Similarly the mean odds ratios for treatment effect all 
centre around 1 with the exception of full matching. These results suggest that very little 
error occurs by chance by matching alone, regardless of covariate model used. The 
deviation of the full matching method from other methods could possibly be due to the 
nature of the full matching method. This method allows for a larger matched group than 
the other methods which have a fixed case to control ratio.   
When matching subjects originating from two different trial populations, the error rates 
decrease substantially when further restrictions were applied to the data before matching 
(Table 8-6). This illustrates the importance of placing restrictions upon the data before 
matching to ensure similarity of the two populations.  
The large type II error rates generated when matching untreated subjects to treated 
subjects (Table 8-8) from neuroprotectant trials may be due to the conditional 
independence assumption (also known as ignorability) being violated.  This assumption 
states, given a set of observable covariates which are not affected by treatment, potential 
outcomes are independent of treatment assignment327.  In this case because treatment 
was given as standard of care the exact timing of the other covariates is uncertain. It may 
be the case that baseline NIHSS and blood pressure measurements etc. were taken after 
thrombolytic therapy was administered. This could result in the baseline covariates being 
misrepresented.  
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The methods used for analysis of treatment effect within a matched study are a subject of 
much debate throughout the literature266 328-330. It is often the case that matched pairs 
analysis is used in order to account for the matching itself266 331.  However, if ignorability 
holds and matching creates adequate balance between groups there is evidence to 
support using techniques similar to those in an RCT setting328-329 332-333.  The use of 
matched pair methods such as conditional logistic regression may result in loss of power, 
particularly when matching on the estimated liner propensity score has not created close 
pairwise matches328. This could be investigated further by repeating the simulations and 
analysing treatment effect allowing for the matched pairs design using methods such as 
generalised estimating equations. 
There are several limitations to this study making it difficult to draw any definitive 
conclusions about matching in RCTs. Many of the results generated are spurious, in 
particular the incredibly low type I error rates given when matching control subjects 
within the same population (Table 8-4) in comparison to the large type I error rates 
obtained from matching different populations (Table 8-6). As mentioned above, this could 
partly be due to the matching model used. Employing unnecessary variables in the 
matching process may lead to inefficiency in the analysis rather than benefit from 
matching. However the large degree of inconsistency is more likely to be a result of the 
analytical method employed.  
As previously discussed there is a great deal of debate in the literature regarding the 
correct method of analysis of matched data. The aim of this study was to assess the 
success of matching by evaluating if matching increases the power or precision of the 
analysis. The analytical method employed assumes that matching has created an 
adequate balance between groups, if unbalanced this method may be sub-optimal. For 
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this analysis, methods that account for matched pairs design such as logistic regression 
with GEE methods may have been more appropriate, leading to more consistent results. 
These methods would account for the lack of independence in the data and allow us to 
observe the true conditional treatment effect in the matched sample.  This would be 
expected to generate more accurate estimates of the type I and type II error rates for 
assessing the success of matching.  
We obtained our data from a single non-randomised data source. Further investigation is 
needed matching a historical control population to an external RCT control population 
and matching non-randomised subjects treated with thrombolysis to a true RCT 
thrombolysis group. The matched trial population can then be analysed and the results 
compared to those from the true population. 
In summary, the high error rates observed coupled with high percentage balance 
improvement suggest substantial further work is needed to assess the applicability of 
historical controls for use as a matched control group in future studies. Considerations 
need to be made into the model used for matching, the efficiency of the matching 
method used, the comparability of the two populations being matched and the analytical 
approach to investigate treatment effect.  
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Chapter 9  
Cluster Trials and Reliability 
of Multicentre Stroke Trials 
within VISTA 
9.1. Background 
While randomised control trials are the ‘gold standard’ in stroke research, cluster 
randomised trials, which randomise patients by groups, are becoming a more widely used 
approach. When evaluating strategies to promote the transfer of research findings into 
clinical practice, i.e. in "Implementation Research", a cluster randomised trial design is of 
advantage.  
However, compared to standard randomised control trials, cluster randomised trials 
decrease statistical efficiency requiring more patients to obtain equivalent statistical 
power228. Observations on individuals in the same cluster tend to be correlated and this 
reduces the effective sample size334.  
Cluster trials have to be inflated by a factor called the design effect which depends on the 
average cluster size and the degree of correlation within clusters (intracluster correlation 
coefficient or ICC). ICCs are calculated as the between-cluster variance divided by the sum 
of the within-cluster and between-cluster variance. Thus, they refer to the proportion of 
variance that can be attributed to the cluster-level.335  
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Knowledge of the ICCs of specific outcome measures within specific trial settings is 
essential to compute the desired sample size for cluster trials. Up to now there is limited 
information on the ICCs in stroke trials and quality of reporting of those few cluster trials 
in the literature has been poor336. 
A literature search was performed by a colleague Dr Benedikt Frank and only four articles 
presenting the results of a cluster randomised trial in secondary (i.e. hospital) stroke care 
including outcome variables could be identified337-340. Three of the trials missed their 
primary endpoint. Two of the latter underestimated their ICC in the planning phase and 
thereby underpowered their study337 339. 
Within the Virtual International Stroke Trials Archive (VISTA)204, we have access to 
datasets from numerous randomised multicentre stroke trials that made careful 
recordings of relevant baseline variables and of outcome measures at 90 days after stroke 
onset.  
This gives us the opportunity to compute in our data the ICCs for specific baseline and 
outcome measures and thereby to support the planning of future cluster trials in the field 
of stroke research. With reliable estimations of ICCs, the risk of under- or over-powering 
of studies should be reduced. In addition, we report the ICCs of different levels of 
clustering within VISTA (trial, continent, and year of enrolment) to provide a measure for 
the reliability of this trial archive. 
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9.2. Methods 
9.2.1. Data source and patients 
We gathered demographics, clinical data and functional outcome measures from trials in 
ischaemic stroke conducted in the period from 1992 to 2006. We obtained our data, 
anonymised in relation to patients, study-centres and trials, from VISTA. We included 
placebo patients from thrombolysis trials as well as all patients from neuroprotectant 
trials involving any drug now known not to influence outcome after stroke. We excluded 
patients for whom we lacked information about age, baseline NIHSS, and thrombolysis 
administration as standard of care. 
9.2.2. Statistical Analysis 
For a cluster trial to achieve the equivalent power of a randomised control trial, the 
standard sample size estimate has to be inflated by the design effect,          
where   is the estimated ICC and   is the average number of observations in each cluster. 
This estimated ICC is the total variation in the outcome attributed to the difference 
between clusters334: 
  
  
 
  
     
  
Where   
  is the between cluster variance and   
  is the within cluster variance. 
To estimate ICCs, we analysed the data using a linear mixed model (SAS PROC MIXED) for 
metric variables, respectively a generalised linear mixed model (SAS PROC GLIMMIX) for 
binary and ordinal variables, and hereby obtained the maximum likelihood estimates for 
the components of variance. Detailed justification for selection of this method has 
previously been published341-342. 
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For the purposes of this analysis ICCs are reported as unadjusted and adjusted estimates. 
We adjusted for age, baseline NIHSS and treatment with thrombolysis as confounders, as 
previously justified in detail241 284. For analytical purposes the NIHSS was converted to an 
ordinal measure, as discussed in previous chapters. Analyses were undertaken using SAS 
9.2. 
9.2.3. Cluster levels  
The reported levels of clustering were study-centres within each trial, as well as trial, 
continent, and year of enrolment within VISTA. Continents were defined as North 
America, South America, Europe, Africa, Asia, and Australia/Oceania. In 657/11841 
patients the information on the exact year of enrolment was missing and the respective 
start year of the trial was used.  
9.3. Results 
We computed the ICCs of every trial separately, using centre as the level of clustering and 
present the median, minimum and maximum ICC for specified baseline and follow-up 
data in Table 9-1 with n representing the total number and   the average number. The 
ICCs for mRS and NIHSS at different time points using centre as the level of clustering are 
reported in Table 9-2. We restricted this sub-analysis to patients with outcomes recorded 
at every time point. The ICCs across VISTA using trial, continent and year of enrolment as 
the level of clustering are presented in Table 9-3 to Table 9-5.  
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Table 9-1: ICC’s with centre as level of clustering. Presented as the median ICC 
for centre across all trials within the VISTA dataset (n) containing the 
measurement. 
 Trials 
(n) 
Cluster 
( ) 
Patients 
( ) 
Cluster 
Size 
( ) 
Unadjusted ICC 
Median (Min-Max) 
Adjusted ICC 
Median (Min-Max) 
Baseline Data 
Age 9 102.2 731.4 8.6 0.040 (<.001-0.106) 0.038 (<.001-0.102) 
thrombolysis 3 112.7 1003.0 8.9 0.554 (0.251-0.615) 0.592 (0.244-0.604) 
Baseline NIHSS 9 102.2 731.4 8.6 0.106 (<.001-0.136) 0.104 (<.001-0.146) 
Glucose 6 88.0 529.2 8.3 0.008 (<.001-0.071) 0.006 (<.001-0.060) 
Diastolic BP 7 109.0 831.7 9.6 0.061 (<.001-0.089) 0.062 (<.001-0.083) 
Systolic BP 7 109.0 832.0 9.7 0.031 (<.001-0.059) 0.026 (<.001-0.053) 
Outcome Data 
mRS day 90 
(ordinal) 8 112.4 753.0 6.5 0.025 (<.001-0.057) 0.007 (<.001-0.039) 
mRS day 90 0-1 
(Dichotomised) 8 112.4 753.0 6.5 0.058 (0.013-0.113) 0.031 (0.015-0.123) 
mRS day 90 0-2 
(Dichotomised) 8 112.4 753.0 6.5 0.054 (<.001-0.085) 0.019 (<.001-0.179) 
NIHSS day 90 
(Ordinal) 8 112.4 753.0 6.5 0.023 (<.001-0.074) 0.029 (0.008-0.085) 
NIHSS day 90 0-1 
(Dichotomised) 8 112.4 753.0 6.5 0.015 (<.001-0.061) 0.012 (<.001-0.078) 
BI day 90 >95 
(Dichotomised) 8 112.4 753.0 6.5 <.001 (<.001-0.051) 0.008 (<.001-0.062) 
Mortality day 90 8 102.8 687.0 8.3 0.014 (<.001-0.082) 0.010 (<.001-0.024) 
Glucose 24-48h 8 102.8 687.0 8.3 0.013 (<.001-0.097) 0.007 (<.001-0.058) 
Diastolic BP  
4-7 days 9 101.4 711.8 8.5 0.027 (<.001-0.112) 0.030 (<.001-0.110) 
Systolic BP 
4-7 days 9 101.4 711.8 8.5 0.013 (<.001-0.056) 0.015 (<.001-0.069) 
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Table 9-2: ICC’s for outcomes at other time-points with centre as level of 
clustering. Presented as the median ICC for centre across all trials within the 
VISTA dataset (n) containing the measurement. Data for each outcome is 
restricted to patients with recordings for all time-points of each outcome 
measure. 
 Trials 
(n) 
Cluster 
( ) 
Patients 
( ) 
Cluster 
Size 
( ) 
Unadjusted ICC 
Median (Min-Max) 
Adjusted ICC 
Median (Min-Max) 
mRS day 90 
(ordinal) 5 117.4 826.6 6.5 0.027 (<.001-0.084) 0.015 (0.004-0.030) 
mRS day 30 
(ordinal) 5 117.4 826.6 6.5 0.017 (<.001-0.058) 0.016 (<.001-0.037) 
NIHSS baseline 
(Ordinal) 6 103.0 711.0 9.0 0.080 (<.001-0.163) 0.079 (<.001-0.161) 
NIHSS day 30 
(Ordinal) 6 103.0 711.0 9.0 0.007 (<.001-0.064) 0.013 (<.001-0.032) 
NIHSS day 90 
(Ordinal) 6 103.0 711.0 9.0 0.006 (<.001-0.044) 0.007 (<.001-0.041) 
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Table 9-3: ICC's treating each anonymised trial as a cluster.  
 
Cluster 
(n) Patients (n) 
Cluster Size 
( ) 
unadjusted 
ICC 
Adjusted  
ICC 
Baseline data 
Age 11 11841 1076.5 0.036 0.043 
thrombolysis 4 7955 1988.8 0.123 0.112 
Baseline NIHSS 11 11841 1076.5 0.044 0.051 
Glucose 7 7888 1126.9 <.001 0.001 
Diastolic BP 9 11060 1228.9 0.023 0.019 
Systolic BP 9 11062 1229.1 0.006 0.004 
Outcome Data 
mRS day 90 
(ordinal) 10 11154 1115.4 0.018 0.006 
mRS day 90 0-1 
(Dichotomised) 10 11154 1115.4 0.014 0.008 
mRS day 90 0-2 
(Dichotomised) 10 11154 1115.4 0.018 0.002 
NIHSS day 90 
(Ordinal) 10 10554 1055.4 0.022 0.003 
NIHSS day 90 0-1 
(Dichotomised) 10 10554 1055.4 0.027 0.005 
BI day 90 >95 
(Dichotomised) 11 11533 1048.5 0.021 0.003 
Mortality day 90 11 11841 1076.5 0.020 0.006 
Glucose 24-48h 3 5698 1899.3 0.002 <.001 
Diastolic BP  
4-7 days 4 5470 1367.5 0.018 0.012 
Systolic BP 
4-7 days 4 5470 1367.5 <.001 <.001 
 
 
 182 
Table 9-4: ICC's treating each continent as a cluster. 
 
Cluster 
(n) Patients (n) 
Cluster Size 
( ) 
unadjusted 
ICC 
Adjusted  
ICC 
Baseline data 
Age 6 11633 1938.8 0.041 0.041 
thrombolysis 6 7955 1325.8 0.173 0.188 
Baseline NIHSS 6 11633 1938.8 0.013 0.009 
Glucose 6 7857 1309.5 0.007 0.009 
Diastolic BP 6 10875 1812.5 0.021 0.017 
Systolic BP 6 10877 1812.8 0.014 0.006 
Outcome Data 
mRS day 90 
(ordinal) 10947 1824.5 0.004 <.001 10947 
mRS day 90 0-1 
(Dichotomised) 10947 1824.5 0.007 0.001 10947 
mRS day 90 0-2 
(Dichotomised) 10947 1824.5 0.004 <.001 10947 
NIHSS day 90 
(Ordinal) 6 10349 1724.8 0.005 <.001 
NIHSS day 90 0-1 
(Dichotomised) 6 10349 1724.8 0.004 <.001 
BI day 90 >95 
(Dichotomised) 6 11326 1887.7 0.002 0.007 
Mortality day 90 6 11633 1938.8 0.007 0.004 
Glucose 24-48h 6 5698 949.7 0.009 0.009 
Diastolic BP  
4-7 days 6 5470 911.7 0.024 0.020 
Systolic BP 
4-7 days 6 5470 911.7 0.015 0.011 
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Table 9-5: ICC's treating year of enrolment as a cluster. 
 
Cluster 
(n) Patients (n) 
Cluster Size 
( ) 
unadjusted 
ICC 
Adjusted  
ICC 
Baseline data 
Age 11841 740.1 0.046 0.059 11841 
thrombolysis 7955 994.4 0.196 0.196 7955 
Baseline NIHSS 11841 740.1 0.026 0.026 11841 
Glucose 7888 563.4 <.001 0.001 7888 
Diastolic BP 11060 850.8 0.008 0.004 11060 
Systolic BP 11062 850.9 0.003 0.001 11062 
Outcome Data 
mRS day 90 
(ordinal) 15 11154 743.6 0.012 0.004 
mRS day 90 0-1 
(Dichotomised) 15 11154 743.6 0.007 0.005 
mRS day 90 0-2 
(Dichotomised) 15 11154 743.6 0.007 0.001 
NIHSS day 90 
(Ordinal) 16 10554 659.6 0.018 0.003 
NIHSS day 90 0-1 
(Dichotomised) 16 10554 659.6 0.012 0.004 
BI day 90 >95 
(Dichotomised) 16 11533 720.8 0.013 0.001 
Mortality day 90 16 11841 740.1 0.021 0.007 
Glucose 24-48h 9 5698 633.1 0.001 <.001 
Diastolic BP  
4-7 days 12 5470 455.8 0.014 0.010 
Systolic BP 
4-7 days 12 5470 455.8 <.001 <.001 
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9.4. Discussion 
The analysis presented here provides a collection of ICCs for various baseline and 
outcome measures used in contemporary stroke trials, including the three most prevalent 
scales, being mRS, NIHSS, and Barthel Index343.   
ICCs are known to be strongly influenced by event rate changes, underlining the 
importance of the knowledge of ICCs for specific outcome measures344. The use of 
incorrect ICC estimates in the planning phase of a trial can lead to an underpowered study 
and unreliable results.  
Alongside unadjusted ICCs, we present estimates adjusted for relevant covariates (age, 
thrombolysis and baseline NIHSS). Typically this will render smaller ICCs, as we confirmed 
in our sample, as some of the between cluster variation may be explained by the cluster 
level factor345. This should reduce sample size requirements but it is crucial that any 
subsequent analysis is also adjusted for these covariates. For example, a study with an 
average cluster size of 150 patients should be inflated by a design effect of 4.7 when 
using our median unadjusted ICC of 0.025 for ordinal mRS and only 2.0 when using the 
adjusted ICC estimation of 0.007. Additionally, the selection of outcome measures has a 
significant impact on required sample size: the choice of mRS as a binary measure, 
dichotomised between 1 and 2, would result in a design effect of 9.6 (unadjusted ICC of 
0.058), respectively 5.6 (adjusted ICC of 0.031) for an assumed average cluster size of 150 
patients. 
We obtained our data for the analysis from trials randomising at patient level. This 
contrasts with prior cluster randomised trials in secondary stroke care, as our average 
cluster size was smaller and number of clusters larger. However a previous simulation 
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study, evaluating the impact of different factors on ICC estimates, showed that cluster 
size had only a minimal effect on the ICC and its upper 95% confidence limit344. The same 
study observed a negligible change on the ICC estimate when increasing the number of 
clusters, but a significant impact on confidence intervals: as the number of clusters 
increases, the 95% confidence intervals become tighter. Both findings support the 
reliability of our ICC estimates. Additionally, our estimates largely track with the ICCs from 
a recently published, cluster randomised trial, reporting the same binary outcomes. Their 
adjusted ICC for mRS at 90 days dichotomised between 2 and 3 was reported to be 0.018, 
versus a median of 0.019 in our analysis. The ICCs for Barthel Index at 90 days 
dichotomised between 90 and 95 were lower in the recently published cluster 
randomised trial with 0.015 versus our finding of 0.030. 
By calculating the ICCs for various levels of clustering within VISTA, we analysed the 
reliability of this trials archive. The adjusted ICCs for the most commonly used outcome 
measures (mRS, NIHSS, and Barthel Index) were all below 0.01. Thus, trial, continent, and 
year of enrolment explained less than 1% of the variability of follow-up data within VISTA. 
In contrast, the majority of median adjusted ICCs calculated within each trial using centre 
as level of clustering were above 0.01.  
In summary, the low contribution of trials, year or continent of enrolment to overall 
variation in outcome offers reassurance that analyses using pooled data from multiple 
trials in VISTA are unlikely to suffer from bias from these sources. We present potentially 
valuable and reliable estimates of ICCs for specific baseline and follow-up data to support 
future sample size calculations for cluster randomised trials. 
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Chapter 10  
Discussion and conclusions 
This thesis describes a compendium of projects assessing the impact of applying different 
methods of design, inclusion and outcome measurement to limit sample size and 
strengthen analysis in clinical trials in acute stroke. 
First some simple inclusion criteria were investigated (Chapter 3).  When considering 
subjects for inclusion into a trial several factors need to be taken into consideration. It is 
important to exclude those in whom, given treatment, potential harm could outweigh any 
benefit gained.  Inclusion criteria considered here were the combined effect of age and 
onset time to treatment (OTT) and history of atrial Fibrillation (AF) after treatment with 
thrombolysis.     
The relationship between OTT and age could be investigated by assessing how the effect 
of thrombolysis changes over onset time to treatment (OTT). By looking across the entire 
range of OTT and assessing the interaction between the two covariates this provided 
complementary data to a previous VISTA analysis conducted by Mishra et al63. In a non-
randomised VISTA comparison, it was found that across the full range of OTT, up to 3.5h, 
the treatment effect of thrombolysis in very elderly stroke patients (>80 years old) was 
comparable to that of their younger counterparts. 
AF has been considered a risk factor for poor outcome from acute stroke and may 
influence response to thrombolytic therapy. Due to the potential confounding with age 
and stroke severity, supporting evidence for this is limited.  The association of AF and 
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modified Rankin Scale (mRS) at day 90 was assessed in a non-randomised VISTA analysis.  
Multiple logistic regression analysis adjusted for age and baseline National Institutes of 
Health Stroke Scale (NIHSS) showed that history of AF had no independent impact on 
stroke outcome. Compared to untreated comparators, the magnitude of the outcome 
following thrombolytic therapy was comparatively equal whether in presence or absence 
of AF.  
These data lend support to the use of thrombolysis across all age groups of stroke 
patients with and without history of AF within approximately 3.5h of stroke onset. AF 
appears to be a marker for high age and baseline NIHSS rather than an independent risk 
factor for poor outcome post stroke. 
For therapies such as thrombolysis, treatment must be initiated in the hyperacute period 
post stroke. The large sample size required for such trials may result from natural 
population heterogeneity and variation in baseline NIHSS collected when patients are 
unstable. For neurorestorative treatments that may be initiated later after stroke onset, 
e.g. at 24h, a more homogeneous population with more predictable outcome may be 
available. In Chapter 4 it was postulated that deferred selection would permit more 
powerful and thus smaller trials. 
The relationship between hyperacute vs. 24h NIHSS recordings and 90 day mRS was 
examined in subjects from VISTA.  A simulation study was then performed to model the 
sample size required to detect a ‘shift’ in mRS outcome equivalent to a 5% absolute 
difference in proportion achieving mRS 0-2 versus 3-6, setting power at 80% and 
assuming adjustment for entry age and NIHSS. Two restrictions of NIHSS were 
investigated 4-20 and 7-20. 
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It was found that extending the time window for patient selection provides a 
measurement which has a stronger more predictive relationship with outcome. This 
subsequently allows a larger population to benefit from treatment. Such extension of the 
time window must be balanced against any anticipated decay in biological effect of the 
treatment with increasing delay from stroke onset. However, with recent interest in 
neurorestorative treatments, as discussed by Steven Cramer288, any strategy that can 
limit the cost of proof of concept trials is desirable.   
Due to the simulated nature of the treatment effect no definitive conclusions can be 
made, only recommendations. Validation of these results on a randomised control trial 
would be desirable however no applicable data are available from current stroke trials. 
Trial inclusion was explored further in Chapter 5 by investigating selection for delayed 
treatment with thrombolysis based on a prognostic score. Pooled analysis of RCT suggests 
that additional patients could benefit but others may be harmed with initiation of 
thrombolysis beyond 4.5 hours after stroke onset.  Prognostic scoring methods were 
proposed to identify a strategy for patient selection to be applied first to an existing trial 
dataset and then validated in the pooled RCT 4.5-6h data.  
500 patients treated with thrombolysis and 500 controls from VISTA were selected, 
matching Rankin (mRS) outcomes to those from pooled RCT 4.5-6h data. We ranked 
patients by prognostic score (from age and NIHSS). Prognostic score limits were chosen to 
optimise the sample for a net treatment benefit significant at p=0.01 by Cochran Mantel 
Haenszel test and by ordinal logistic regression. More inclusive limits were also defined 
based on p=0.05 criteria. We iteratively chose lower and upper score limits to exclude 
patients with extreme predicted outcomes.  After finalising prognostic score limits, for 
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validation they were applied by an independent statistician to the pooled RCT data for 
4.5-6h. All analyses were adjusted for age and NIHSS.  
While the validation analysis based on ordinal outcomes failed to deliver a population in 
whom treatment >4.5h was safe and effective, analysis based on net benefit (mRS 0-1) 
showed significance. The analysis of trial data according to net benefit has proponents 
and opponents, the latter arguing that it may conceal useful treatment effects among 
subpopulations.  Unless we can prospectively select patients for these sub-populations, 
the ordinal approach to interpretation may remain optimal as it better reflects the true 
outcome of clinical practice. 
Clinical trials for acute ischaemic stroke treatment require large numbers of participants 
and are expensive to conduct. Methods that enhance statistical power are therefore 
desirable. In the past some trialists have investigated the use of earlier endpoints on 
single trial datasets230 and taken advantage of the fact that numerous outcome scales are 
available to measure various domains of neurological and functional recovery96 200. 
Clinical trials in stroke typically measure outcome after 90 days. Chapter 6 provides an 
exploration and validation analysis investigating the effect on power when using earlier 
outcome assessment.  
First a within-VISTA exploration study was conducted to compare the sensitivity of four 
outcome measures (mRS at 30 and 90 days, and NIHSS at 7 and 90 days, analysed as 
ordinal measures) to the established treatment effect of thrombolysis.  This was a non-
randomised comparison using a multiple re-sampling approach, day 7 NIHSS was found to 
be the most sensitive endpoint. Dichotomised analyses supported these results. However 
this needed validation in a randomised trial dataset for use in exploratory stroke trials. 
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The validation stage included data from patients who had been enrolled and treated 
within 270 minutes of stroke onset, in any of 8 published randomised trials171. A 
simulation approach was performed following a predefined analysis plan and was 
conducted by an independent statistician.   
The validation study reinforced the results from the non-randomised VISTA study. Both 
found day 7 NIHSS score offers statistical advantages as an endpoint for the early, 
exploratory testing of novel agents. Detecting an early signal of treatment benefit or 
futility in acute stroke trials is economically, scientifically and ethically desirable.  
In Chapter 7 it was hypothesised that the apparent treatment effect of the proven 
therapy thrombolysis would be detected more strongly if the outcome measure uses a 
combination of early and late measures (e.g. 7 day NIHSS combined with 90-day mRS) 
than either early or late measure alone. 
Global outcome measures were generated using combinations of typical outcome scales 
at different time-points. A simulation approach was undertaken to assess relations 
between sample size and power for ordinal scales and corresponding global outcomes. A 
simple incremental ranking method was also investigated for the combination of 
endpoints.  
The global test combination of NIHSS90 with NIHSS7 appears to offer incremental 
sensitivity to treatment effect compared to the ordinal forms of these scales alone. The 
combination of mRS90 with NIHSS7 did not increase the sensitivity to treatment effect 
when compared to NIHSS alone, but offers a broader clinical measure without loss of 
statistical power.  The use of a more simple incremental approach combining the scales 
using a ranking method offered no benefit in comparison to the ordinal scales. 
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When data concerning both early and late outcomes are combined into a global measure 
there is an increased sensitivity to treatment effect compared to solitary ordinal scales. 
This delivers a 20% reduction in required sample size at 80% power. Combining early with 
late outcomes merits further consideration and requires validation on external RCT data. 
If a placebo control is deemed impractical, researchers consider comparisons against 
historical controls. Abandoning the rigour of the blinded RCT carries substantial penalty in 
loss of reliability and should not be undertaken lightly. However, there may be strategies 
that can strengthen these compromises when considered unavoidable. In Chapter 8 a 
within-VISTA exploration of case-control matching is presented.   
The results indicate that caution must be taken when using historical controls to generate 
a matched control group. Looking at the equivalence of two trial populations highlights 
the importance of model selection and the application of inclusion criteria before 
matching. Substantial further work matching to external data and validation to RCT data 
is needed. 
Chapter 9 considers some elements in the design of cluster randomised trials. Reliable 
estimates of intracluster correlation coefficients (ICCs) for specific outcome measures are 
crucial for sample size calculations of future cluster randomised trials. ICCs indicate the 
proportion of data variability that is explained by defined levels of clustering.  
ICCs were estimated from linear and generalised linear mixed models using maximum 
likelihood estimation for common measures used in stroke research, including modified 
Rankin Skale (mRs), National Institutes of Health Stroke Scale (NIHSS) and Barthel Index 
(BI). 
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These estimates of relevant ICCs should assist trial planning. For example the sample size 
for a cluster trial with 150 patients per centre using ordinal analysis of mRS should be 
inflated by 2.0 due to the ICC of 0.007; whereas the ICC of 0.031 using mRS dichotomised 
above mRS 0-1, requires inflation by 5.6. The low contribution of trials, year or continent 
of enrolment to overall variation in outcome offers reassurance that analyses using 
pooled data from multiple trials in VISTA are unlikely to suffer from bias from these 
sources. 
While this thesis has concentrated on clinical trials in the area of acute stroke, some 
methods are applicable across different areas of medical research. The use of a global test 
statistic discussed in Chapter 7 is not unique to stroke research. Similar to the work 
presented in this thesis, a global test was used in the re-analysis of clinical trials in 
Parkinson’s disease346 and found to be a more powerful and clinically advantageous 
alternative to analysis of multiple individual outcomes, each assessing a single dimension 
of recovery. A similar study was performed evaluating the use of the global test in 
rheumatoid arthritis trials347. The global test statistic has also been utilised in other areas 
of medical research such as rehabilitation348, environmental health306, multiple 
sclerosis349, asthma350  and genetics351-353. 
Similarly, cluster randomised trials are becoming increasingly popular in medical research, 
particularly for non-pharmaceutical interventions354-355 and primary care356-358. Cluster 
randomised trials are an attractive alternative when an RCT is not practical. For example 
when assessing organisational changes359,  implementing an educational programme360-
361 or assessing screening methods362 it would be impractical to randomise at the 
individual patient level. The ICC’s presented in this thesis are only applicable to a similar 
population of stroke patients. However, the development and expansion of databases 
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such as the General Practitioners Research Database363 (GPRD) and the Safe Haven 
database364 present the opportunity to calculate ICC’s for future UK based cluster trials 
investigating certain aspects of primary care. This could be expanded further into medical 
interventions by using medical databases for ICC calculation such as: the Society of 
Thoracic Surgeons (STS) national database for cardiothoracic surgery, the Stanford Cancer 
Centre Research Database (SCCRD)365,  the UK based National Cancer Research Institute 
(NRCI) cancer research database366 and the Virtual International Cardiovascular and 
Cognitive Trials archive (VICCTA) currently under development.   
In conclusion, this research has shown that there are several areas in the design of clinical 
trials of acute stroke that merit further investigation. Several strategies have been 
highlighted that could potentially reduce sample size whilst retaining optimal levels of 
statistical power. Most analyses presented were performed retrospectively using non-
randomised historical data. Without validation within a prospective cohort the 
applicability of some of the results to current clinical practice may be limited. For 
example, when validated on external RCT data, the prognostic score limits found in 
Chapter 5 failed to find a safe treatment population. Without access to quality imaging 
data any further investigation would likely be futile. Similarly, substantial work is needed 
into the investigation of the use of a matched control group using historical controls. The 
use of historical controls also brings into question the applicability of historical data in 
current practice.  Prospective controls would likely be a better, more reliable matched 
population. 
The baseline severity measurement most commonly used in acute stroke trials was found 
to be sub-optimal in comparison to a later measure. Substantial decreases in required 
sample size were observed by changing the time-point for baseline severity measurement 
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from hyperacute (<6h) to 24h. Lack of validation would make this difficult to implement in 
a new RCT. However there is a clinical premise for the use of later baseline measurements 
if the nature of the drug under study allows it.  It has been shown that systolic BP, 
diastolic BP and serum glucose level fall within the first 24h post stroke. This decrease is 
greater when thrombolysis treatment has been given as standard of care367. Similarly it 
was shown in Chapter 4 that 24h NIHSS is more predictive of outcome making it a better 
measurement for inclusion. 
Translational development of treatments for acute stroke is both costly and challenging. 
The results shown here have important implications for the design of future trials in acute 
stroke. Some methods presented here could be implemented into a new RCT without 
additional cost.  The most common outcome scale used, mRS day 90127,  lacked statistical 
power when compared to NIHSS day 7. This suggests implementing an earlier endpoint 
may be more optimal to detect futility in a trial with the conventional 90 day mRS 
retained as the primary efficacy endpoint, at least for reperfusion strategies. 
Alternatively, a global endpoint could be used incorporating both mRS day 90 and NIHSS 
day 7 as the primary efficacy endpoint. This could potentially reduce the cost of a trial by 
decreasing required sample size for an equivalent level of statistical power. When 
considering a cluster randomised trial as an alternative to an RCT, reliable estimates of 
ICC’s for sample size calculation could increase statistical efficiency. However other 
aspects such as patient selection and the nature of the intervention under study can 
affect trial cost and statistical power and need to be taken under consideration. 
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Appendix A  
Appendix for Chapter 3 
Table 10-1: Details of the fitted model for all data looking at full scale mRS day 
90.  Coefficient and standard errors given for each reported interaction. 
All data 
 
Outcome 
mRS90 
Interaction 
OTT and  
thrombolysis 
Interaction 
OTT and  
age 
Interaction 
age and  
thrombolysis 
Interaction OTT and 
thrombolysis after 
removing all other 
non-significant 
interactions 
Interaction OTT, age 
and thrombolysis 
after removing all 
non-significant 
interactions 
Coefficient 0.3011 -0.00178 -0.0107 0.3076 0.000877 
S.E 
coefficient 
0.1288 0.00479 0.0060 0.1276 0.00139 
Table 10-2: Details of the fitted model for those ≤ 80 looking at full scale mRS 
day 90.  Coefficient and standard errors given for each reported interaction. 
≤80 
 
Outcome 
mRS90 
Interaction 
OTT and  
thrombolysis 
Interaction 
OTT and  
age 
Interaction 
age and  
thrombolysis 
Interaction OTT and 
thrombolysis after 
removing all other 
non-significant 
interactions 
Coefficient 0.3803 0.00889 -0.00477 0.3505 
S.E 
coefficient 
0.1425 0.00599 0.00747 0.1412 
Table 10-3: Details of the fitted model for those > 80 looking at full scale mRS 
day 90.  Coefficient and standard errors given for each reported interaction. 
> 80 
 
Outcome 
mRS90 
Interaction 
OTT and  
thrombolysis 
Interaction 
OTT and  
age 
Interaction 
age and  
thrombolysis 
Interaction OTT and 
thrombolysis after 
removing all other 
non-significant 
interactions 
Coefficient 0.3011 0.0164 0.0859 0.2348 
S.E 
coefficient 
0.3118 0.0408 0.0499 0.3107 
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Table 10-4: Details of the fitted model for all data looking at mortality day 90.  
Coefficient and standard errors given for each reported interaction. 
All data 
 
Outcome 
mortality 
90 
Interaction 
OTT and  
thrombolysis 
Interaction 
OTT and  
age 
Interaction 
age and  
thrombolysis 
Interaction OTT and 
thrombolysis after 
removing all other 
non-significant 
interactions 
Interaction OTT, age 
and thrombolysis 
after removing all 
non-significant 
interactions 
Coefficient 0.5597 -0.00235 -0.0118 0.5644 0.00399 
S.E 
coefficient 
0.2076 0.00925 0.0115 0.2054 0.00230 
Table 10-5: Details of the fitted model for those ≤ 80 looking at mortality day 
90.  Coefficient and standard errors given for each reported interaction. 
≤80 
 
Outcome 
mortality 
90 
Interaction 
OTT and  
thrombolysis 
Interaction 
OTT and  
age 
Interaction 
age and  
thrombolysis 
Interaction OTT and 
thrombolysis after 
removing all other 
non-significant 
interactions 
Coefficient 0.7107 0.0179 -0.00028 0.6737 
S.E 
coefficient 
0.2526 0.0123 0.0155 0.2509 
Table 10-6: Details of the fitted model for those > 80 looking at mortality day 
90.  Coefficient and standard errors given for each reported interaction. 
> 80 
 
Outcome 
mortality 
90 
Interaction 
OTT and  
thrombolysis 
Interaction 
OTT and  
age 
Interaction 
age and  
thrombolysis 
Interaction OTT and 
thrombolysis after 
removing all other 
non-significant 
interactions 
Coefficient 0.4773 0.0159 0.0888 0.4230 
S.E 
coefficient 
0.3822 0.0492 0.0618 0.3817 
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Table 10-7: Details of the fitted model for all data, adjusting for dichotomised 
age, looking at mRS day 90.  Coefficient and standard errors given for each 
reported interaction. 
All data 
 
Outcome 
mRS 90 
Interaction OTT and 
thrombolysis after 
removing all other 
non-significant 
interactions 
Interaction OTT, 
dichotomised age 
and thrombolysis 
after removing all 
non-significant 
interactions 
Coefficient 0.3871 -0.0709 
S.E 
coefficient 
0.1283 0.0666 
Table 10-8: Details of the fitted model for all data adjusting for dichotomised 
age, looking at mortality day 90.  Coefficient and standard errors given for 
each reported interaction. 
All data 
 
Outcome 
mortality 
90 
Interaction OTT and 
thrombolysis after 
removing all other 
non-significant 
interactions 
Interaction OTT, age 
and thrombolysis 
after removing all 
non-significant 
interactions 
Coefficient 0.6785 -0.1065 
S.E 
coefficient 
0.2083 0.0913 
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Appendix B  
Appendix for Chapter 8 
Table 10-9: Difference in propensity score between groups before and after 
matching along with percentage balance improvement between groups after 
matching. Case and control groups sampled from the same population of 
treated subjects. 
Distance information for each model 
Covariate 
model 
Difference in propensity 
score between groups 
Full 
matching 
Nearest 
matching 
Optimal 
matching 
Genetic 
matching 
1 Mean before 
Mean after 
% Balance improvement 
0.00194 
0.00000573 
98.71 
0.00312 
0.0000950 
96.95 
0.00181 
0.00000235 
98.59 
0.00138 
0.0000144 
99.56 
2 Mean before 
Mean after 
% Balance improvement 
0.00221 
0.00000817 
98.79 
0.00342 
0.000124 
96.52 
0.00210 
0.0000206 
97.10 
0.00169 
0.0000144 
99.18 
3 Mean before 
Mean after 
% Balance improvement 
0.00392 
-0.0000227 
98.62 
0.00617 
0.000576 
91.64 
0.00304 
0.000224 
95.28 
0.00239 
0.0000811 
94.62 
Table 10-10: Type I error rate for each method and model being evaluated. 
Outcomes analysed are mRS day 90 and ordinal NIHSS day 90.   Case and 
control groups sampled from the same population of treated subjects. 
Type I error rates 
Covariate 
model 
Scale used for  
outcome assessment 
Full 
matching 
Nearest 
matching 
Optimal 
matching 
Genetic 
matching 
1 mRS 90 
NIH 90 
0.8% 
0.2% 
0.4% 
5.7% 
52.9% 
21.2% 
0.5% 
0.3% 
2 mRS 90 
NIH 90 
0.8% 
0.2% 
1.2% 
4.7% 
43.5% 
12.5% 
0.8% 
0.5% 
3 mRS 90 
NIH 90 
1.2% 
0.2% 
1.3% 
8.0% 
34.5% 
6.2% 
1.0% 
0.7% 
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Figure 10-1: Forest plot illustrating the odds ratio for treatment effect 
measured by full scale mRS day 90. Mean OR and 95% CI given for each model 
with each matching method. Case and control groups sampled from the same 
population of treated subjects. 
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